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The goal of this research work was to understand the clinical-pharmacology based 
treatment approaches for sorafenib. Treatment with sorafenib is associated with high 
inter-patient variability in pharmacokinetic exposures, efficacy and toxicity.  
We explored the demographic, laboratory, clinical and pharmacogenetic factors to 
elucidate the sources of variability. In addition, we examined the impact of 
pharmacogenetic variation in VEGFR2, an important mediator of the VEGF pathway, on 
risk of prostate cancer.  
 xxxiv 
 
 
  
To support these investigations, (mainly single-dose) pharmacokinetic, pharmacogenetic, 
efficacy and toxicity information were collected from patients with solid tumors, enrolled 
in five phase I / II clinical trials at National Cancer Institute. Non-compartmental 
analysis-general linear modeling (NCA-GLM), population pharmacokinetic analysis and 
several correlative studies were performed to characterize the sources of variability in 
pharmacokinetics and response. The role of prostate specific antigen (PSA) and ex-vivo 
anti-angiogenic activity as efficacy markers was evaluated, respectively, for patients with 
prostate cancer treated with sorafenib and patients with solid tumors treated with 
combination of sorafenib and bevacizumab. Sweat concentrations of sorafenib were 
measured to study its association with development of hand-foot skin reaction (HFSR). 
Only body weight was a significant covariate for volume of distribution by population 
pharmacokinetic analysis, while BSA, albumin and UGT1A9*3 appeared to be 
significant by NCA-GLM. However, the contribution of these covariates in overall 
exposure variability was very small; hence, these were considered clinically irrelevant. 
The association of sorafenib exposure with efficacy in patients with prostate cancer, 
colorectal cancer and combined solid tumors were not significant; exposure-efficacy 
relationship for lung cancer patients requires further evaluation. Sorafenib exposures 
appeared to be associated with incidences of rash in single agent trials and with HFSR in 
trials involving treatment with sorafenib and bevacizumab combination. In-vitro cell-line 
experiments determined that prostate specific antigen (PSA) is not a suitable marker of 
efficacy in patients with prostate cancer treated with sorafenib. The ex-vivo anti-
angiogenic activity, measured by rat-aortic ring assay using patient serum samples, 
 xxxv 
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appeared to be not associated with clinical response. Sorafenib concentration in sweat, 
upto ≥5 ng/mL, apparently was not associated with HFSR. The VEGFR2 H472Q 
polymorphism was associated with progression-free survival (PFS) (with an apparent 
heterozygous advantage for survival) and toxicities in patients treated with drugs against 
the VEGF pathway. Patients who developed hypertension and HFSR on bevacizumab 
and sorafenib therapy, respectively, appeared to have longer PFS. Therefore, these side 
effects should be effectively managed to avoid/delay the treatment discontinuation. The 
VEGFR2 H472Q and V297I genotype were not predictive of risk of prostate cancer in 
Caucasian subjects. 
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CHAPTER ONE 
INTRODUCTION AND BACKGROUND 
 
 
1-1 Introduction 
Advances in our understanding of molecular mechanism underlying malignant 
transformation of cell growth has shifted the focus of cancer drug discovery from 
development of conventional non-specific cytotoxic drugs towards rationally designed, 
targeted therapies with activity against cancer-specific pathways. In the last century, the 
only treatment modalities available to a patient with cancer were surgery, radiation and 
(mostly) cytotoxic chemotherapies. While surgery is not curative in advanced metastatic 
diseases, the use of radiation and cytotoxic chemotherapies is limited by severe, dose-
limiting toxicities and inability to discriminate between normal and malignant growing 
cells (1).  
 
In the 1980s, the scientists started deciphering the key elements involved in cancer cell 
regulation or relay in of signals in cellular signal transduction pathways. The discovery of 
cancer oncogenes and tumor suppressor genes, which keep check on tumor development 
and growth, and identification of epigenetic events such as promoter hyper-methylation, 
which describes the impact of environmental factors on genes governing the cancer cell 
growth (2, 3) were few of the pioneering milestones. In the following years, key signal 
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transduction pathways were identified, further studies on oncogene functions and 
oncoproteins were conducted, and pathological consequences of their dysregulation were 
studied. It was established that malfunctioning or over-expression of 
oncogenes/oncoproteins transforms healthy cells into malignant ones. Consequently, 
these biomolecules were explored as targets for new cancer therapies, later to be called 
‘molecularly targeted anticancer therapies’. In subsequent years, several new targeted 
therapies were approved in the U.S.A. for clinical use, as summarized in Table 1-1. 
Toxicity profiles for these treatments differ from traditional cytotoxic therapies with 
negligible haemotological toxicities (e.g., bone-marrow suppression). Majority of these 
drugs are better tolerated with predictable and manageable side effect profiles.  
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 Table 1-1 U.S. FDA-approved, molecularly targeted anticancer therapies 
Generic name Category Biological Target Oncological Indication 
Trastuzumab MAb HER2 protein Breast cancer 
Bevacizumab MAb VEGF protein Breast cancer, Colorectal cancer, NSCLC 
Cetuximab MAb EGF Receptor Colorectal cancer, Head and neck cancer 
Panitumumab MAb EGF protein Colorectal cancer 
Imatinib TKI bcr-abl fusion protein Chronic myeloid leukemia,  
Gastrointestinal stromal tumor 
Erlotinib TKI EGF Receptor NSCLC 
Gefitinib† TKI EGF Receptor NSCLC 
Sunitinib TKI PDGF Receptor, VEGF Receptor 2,  
RET, CSF-1R and flt3 
Renal cell carcinoma,  
Gastrointestinal stromal tumor 
Sorafenib TKI VEGF Receptor 2, 
Ras and Raf kinases 
Renal cell carcinoma,  
Hepatocellular carcinoma 
Lapatnib TKI EGFR and HER2/neu proteins Breast cancer 
       †Only used for patients who were benefiting with the drug before FDA relabeling.  
HER2: Human epidermal growth factor receptor 2, VEGF: Vascular endothelial growth factor, EGF: Endothelial growth factor, 
PDGF: Platelet derived growth factor, RET: Rearranged during transfection proto-oncogene, CSF-1R: Colony stimulating factor-1 
receptor, flt3: FMS-like tyrosine kinase 3, MAb: Monoclonal antibodies, NSCLC: Non-small cell lung cancer, TKI: Tyrosine 
kinase inhibitor 
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1-2 Background 
1-2.1 The Ras/ Raf/MEK/ERK pathway 
The Ras/Raf/MEK/ERK pathway (Fig 1-1) is at the heart of the signaling networks for 
cell growth; ubiquitously present, it governs cell proliferation, differentiation and 
survival. The steps involved in relaying of signals through this pathway are as follows: 
 
Binding of ligands, such as endothelial growth factor (EGF), vascular endothelial growth 
factor (VEGF) and platelet derived growth factor (PDGFβ), to respective cell surface 
receptors or receptor tyrosine kinases (RTKs) (e.g., EGFR, VEGFR and PDGFR) 
initiates receptor dimerization and autophosphorylation on tyrosine residues. Ligand 
stimulated RTKs relay signals to MAPK cascade (composed of three sequential kinases 
Raf/MEK/ERK) via activation of Ras, a small G-protein. Activated Ras recruits Raf from 
cytosol to cell membrane and causes its activation, which in turn activates several 
downstream effectors including MEK, ERK, various substrates in cytoplasm (membrane 
proteins, phospholipase A2, RTKs) and nucleus (transcription factors), and regulates cell 
proliferation, differentiation, survival and apoptosis (4). 
 
Over-expression of ligands for RTKs (e.g., EGF, VEGF, and PDGF) that relay signals 
through the MAPK pathway or constitutive activation of components of 
Ras/Raf/MEK/ERK cascade (e.g., Ras oncogenes, K-ras, H-ras and N-ras; and mutant B-
rafV599E) results in uncontrolled cell growth, leading to tumor formation. Approximately 
30% of human tumors contain mutations in one of the three Ras genes; K-ras, H-ras and 
N-ras (5). Mutations in K-ras protein are most common with frequencies of 70-90% in 
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pancreatic adenocarcinomas, approximately 50% in colon carcinomas and 20-50% in 
lung adenocarcinomas (5, 6). Mutations in B-raf gene are also very common with 
frequencies of approximately 70% in human malignant melanomas and 15% in colon 
cancers. Most frequent among B-raf mutations is the V599E amino acid change within 
the kinase activation domain, which makes it constitutively active (5, 7). Several anti-
cancer drugs have been designed against these targets in the Ras/Raf pathway; Table 1-1 
lists drugs that are currently approved or under clinical development.   
 
 
Fig 1-1. Schematic representation of the multiple pathways activated by Raf-kinases.    
    (Adapted from Caraglia M et al, (8)) 
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1-2.2 Sorafenib 
Sorafenib (BAY 43-9006; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino] 
phenoxy]-N-methyl-pyridine-2-carboxamide; Fig 1-2), a novel bis-aryl urea, is approved 
in more than 70 countries for the treatment of patients with advanced kidney cancer, and 
in more than 60 countries for treatment of patients with advanced liver cancer (9). It is 
currently under clinical evaluation for a number of solid tumors, including the non-small 
cell lung cancer (NSCLC) and breast cancer.    
 
Fig 1-2 Molecular structure of sorafenib (IUPAC name: 4-[4-[[4-chloro-3 
(trifluoromethyl) phenyl] carbamoylamino] phenoxy]-N-methyl-pyridine-2-carboxamide) 
 
1-2.2.1 Mechanism of Action 
Sorafenib targets both the tumor cells as well as tumor vasculature, and inhibits tumor 
cell proliferation and angiogenesis. Key targets for sorafenib are outlined in Fig 1-3. In 
tumor cells, sorafenib inhibits the intracellular B-raf (wild type, IC50 = 22 nM; and 
mutant, IC50 = 38 nM) and C-raf (wild type, IC50 = 6 nM) serine/threonine kinases in 
Ras/Raf pathway (10). Raf protein acts as an intermediate signaling molecule for multiple 
pathways (Fig 1-1) (8). Thus, inhibition of Raf proteins by sorafenib effectively blocks 
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the external or constitutive activation of the Ras/Raf pathway, which helps in restricting 
the aberrant cell proliferation. 
 
Sorafenib also blocks the cell surface receptors (i.e., RTKs) on endothelial cell surfaces 
of tumor vasculature, which directly inhibits their autophosphorylation following binding 
of extra-cellular ligands. Specifically, sorafenib blocks the activation of VEGFR2 by 
VEGF (IC50=90 nM) and PDGFR by PDGFβ (IC50 = 38 nM) (10). While VEGF is a key 
molecular modulator of angiogenesis, PDGFβ plays an important role in maturation of 
newly formed tubular structures by recruitment of mural cells like pericytes. Inhibition of 
VEGFR, PDGFR along with c-Kit, c-Ret, Flt-3 slows down the process of angiogenesis. 
 
Additionally, Yu and colleagues (11) demonstrated in-vitro pro-apoptotic activity for 
sorafenib, mediated by reduction in levels of anti-apoptotic protein Mcl-1 (Myeloid cell 
leukemia 1) by destabilization and down-regulation in a time- and dose- dependent 
manner without affecting the other Bcl-2 family members. 
 
As a tumor grows, the lack of sufficient blood supply creates an hypoxic environment, 
stimulating the release of factors like HIF-1α, which induces angiogenesis by activating 
the transcription of VEGF (12). Fig 1-3 shows that these growth factors act in an 
autocrine manner on tumor cells or by the paracrine pathway on surrounding endothelial 
cells. Autocrine action on tumor cells increases their sensitivity towards growth factors, 
and paracrine action on endothelial cells stimulates the process of angiogenesis, which 
helps in increasing the blood supply to tumor from existing host blood vessels to relieve 
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tumor hypoxia. Sorafenib blocks both of these processes by its action on downstream 
targets, as shown in Fig 1-3. 
 
 
Fig 1-3 Key targets of sorafenib  
 
1-2.2.2 Preclinical studies 
In molecular biology assays, sorafenib inhibited various components of the 
Ras/Raf/MEK/ERK pathway. In cellular assays, sorafenib inhibited the MAPK pathway 
in colon (HCT-116, HT 29), pancreatic (Mia PaCa 2) and breast (MDA-MB-231) cancer 
cell lines expressing mutant K-ras or wild type or mutant B-raf, but did not show similar 
inhibitory effects in non small cell lung cancer cell lines (NCI-H460, A549) also 
expressing mutant K-ras (10). In-vivo, sorafenib demonstrated dose-dependent inhibition 
of tumor growth in mice tumor xenograft models of human colon (HT-29, Colo-205, both 
are B-rafV599E positive; DLD-1, K-ras positive), lung (NCI-H460, A549), breast (MDA-
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MB-231, containing G463V b-raf and K-ras oncogenes), ovarian (SK-OV-3, over-
expresses EGFR and HER2/neu), pancreatic (Mia PaCa 2, K-ras positive), melanoma 
(LOX, UACC 903 and 1205 Lu containing B-rafV599E) and thyroid (containing oncogenic 
RET) cancer cell lines (1, 10). No toxicity was observed in these models when measured 
as weight loss relative to control animals or drug-related lethality. Additionally, sorafenib 
reduced microvessel area and microvessel density in these models, confirming its anti-
angiogenic activity (10). 
 
1-2.2.3 Clinical studies 
Sorafenib has undergone or is undergoing multiple clinical trials both as a single agent 
and in combination with other chemotherapeutic agents. Results from phase I, phase II, 
phase III clinical trials along with clinical drug-drug interaction studies are summarized 
in appendix 1-1 to 1-4.  
 
Five phase I/II clinical trials at NCI are currently evaluating the effectiveness or safe dose 
of sorafenib, as a single agent or in combination therapy, in metastatic castrate resistant 
prostate cancer (mCRPC), NSCLC, colorectal cancer (CRC), Kaposi’s sarcoma (KS) and 
other solid tumors (ST). The rationales for use of sorafenib in these cancers are discussed 
below: 
 
Rationale: Sorafenib in metastatic castrate resistant prostate cancer (mCRPC) 
Prostate cancer is the leading non-cutaneous cancer among American men. A total of 
192,280 cases are expected in the U.S. in year 2009, and 27360 will succumb to this 
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disease (13). Both androgen-independent or androgen-dependent prostate cancer cells 
require Ras protein for growth and survival (14). Inhibition of Ras by S-trans, trans 
fernesyl thiosalicylic acid (FTS) resulted in growth arrest and cell death of LNCaP and 
PC-3 prostate cancer cell lines (14). The Ras/Raf/MEK/ERK pathway is at the 
convergence of various signaling inputs, which could mediate the progression of prostate 
cancer from being androgen-dependent to becoming androgen-independent, hence 
inhibition of this pathway by sorafenib can be viewed as a potentially useful target for 
therapeutic intervention (15). 
 
Levels of angiogenesis factors VEGF, PDGF and bFGF were found to be higher in  
prostate cancer tissue relative to normal tissue (16). Siegel et al (17) demonstrated that 
microvessel density (MVD) was higher in prostate cancer tissue than the adjacent 
hypoplastic or benign tissue, which increased the chances of metastasis. In pre-clinical 
settings, anti-angiogenic drugs have been shown to inhibit the growth of prostate cancer 
(18), and, clinically, improvement in the overall survival and progression free survival 
was seen following inclusion of anti-angiogenic drugs in clinical trials for patients with 
mCRPC (19). Sorafenib is thought to be effective in patients with prostate cancer because 
of its activity on Ras/Raf and VEGF pathway. 
 
Rationale: Sorafenib in solid tumors (ST) in combination with bevacizumab 
As mentioned in 1-3.1, sorafenib acts by a dual mechanism, namely inhibition of Raf 
kinase in the Ras/Raf/MEK/ERK pathway and inhibition of RTKs including VEGFR2 
and PDGFβ. Bevacizumab, a recombinant humanized anti-VEGF monoclonal antibody 
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(rhuMAb), blocks the binding of human VEGF to its receptors (i.e. VEGFR1, 2 and 3) 
(20). It is composed of human IgG1 framework regions and antigen-binding 
complementarity-determining regions from a murine monoclonal antibody (muMAb 
VEGF A.4.6.1). While both agents are effective as single agents, in selected tumors, 
simultaneous attenuation of the Ras/Raf and VEGF pathways by sorafenib and 
bevacizumab combinations is thought to provide synergistic antitumor activity. However, 
this combined effect might also result in increased toxicity compared to each agent alone.  
 
Rationale: Sorafenib in non-small cell lung cancer (NSCLC) 
The underlying cause for 20-40% of NSCLC is inappropriate activation of Ras/Raf 
pathway by a point mutation in K-ras (21). Somatic activation of K-ras by spontaneous 
recombination in mice has shown to predispose these animals to cancer, predominantly 
lung cancer (22). A causal relationship between smoking, K-ras mutation and occurrence 
of lung cancer has been reported earlier (23, 24). Sorafenib is a potent inhibitor of both 
wild type and mutant B-raf (B-rafV599E) and C-raf, which are downstream to the Ras 
protein in the Ras/Raf pathway; therefore, it inhibits the downstream signaling. Sorafenib 
has shown activity against NSCLC cell lines NCI-H460 and A549 with tumor growth 
inhibition of 27% to 68%, and has also shown regression of tumor growth in NCI-H460 
NSCLC tumor xenograft model (25). Based on these mechanistic and pre-clinical 
evidences, sorafenib was thought to be effective in the treatment of human NSCLC. 
 
Rationale: Sorafenib in metastatic colorectal cancer (CRC) in combination with 
Cetuximab 
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Cetuximab is approved by FDA for treatment of EGFR expressing CRC. It is a 
recombinant monoclonal antibody which binds specifically to the extracellular domain of 
epidermal growth factor receptor (EGFR, also known as HER1 or c-ErbB) in normal and 
tumor cells and competitively inhibits the binding of EGF and other ligands such as TGF-
α to these receptor sites (26). Cetuximab binding to EGFR limits the downstream 
signaling by inhibiting the phosphorylation and activation of RTKs. However, the clinical 
response rate for cetuximab is only 10% (27), possibly because of drug resistance caused 
by mutations in the downstream Ras protein. The frequency of mutation in the K-ras 
protein in patients with CRC was reported to be approximately 50% (5, 6).  
 
Sorafenib acts on B-raf and C-raf proteins which are further downstream to the Ras 
protein; hence, its combination with cetuximab may help in improving the overall 
response rate. Additionally, both VEGF and EGFR are validated targets for treatment in 
CRC. Clinically, the response rate for combination of bevacizumab (anti-VEGF agent) 
and cetuximab was 23%, and the median time to progression of disease was 4 months in 
patients with CRC (28, 29). Hence, simultaneous inhibition of EGFR, VEGFR2 and 
Ras/Raf pathway by combination of sorafenib and cetuximab is thought to provide better 
efficacy in patients with CRC than either agent alone. 
 
Rationale: Sorafenib in patients with Kaposi’s sarcoma (KS) 
KS is a tumor caused by human herpesvirus 8 (HHV), which is associated with HIV 
infection, i.e., AIDS in some cases. Typically, it spreads on the skin but may also involve 
the mouth, GI tract and respiratory tract. Changes in skin lesions for patients with KS 
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may accompany with changes in the amount of blood vessels and/or blood flow to the 
lesions. The VEGFR2, VEGFR3, PDGF and c-kit are known to play a role in 
pathogenesis of KS (30, 31). Sorafenib is shown to inhibit the functioning of these 
molecules; thus, it may help in restricting the tumor growth/progression in patients with 
KS. Patients with HIV associated KS also receive ritonavir, the HIV protease inhibitor 
commonly used to treat patients with AIDS. Ritonavir is known to be a potent inhibitor of 
CYP3A4 (32), an important metabolic enzyme for sorafenib. Therefore, co-
administration of ritonavir with sorafenib may affect sorafenib’s plasma exposures; hence, 
in this dose escalation trial, the first cohort of patients on ritonavir was to be administered 
a lower than approved doses of sorafenib (i.e., 200 mg QD rather than clinically approved 
dose of 400 mg BID). The objectives of this trial were to investigate the pharmacokinetic 
interactions of sorafenib and ritonavir, and safety and efficacy of sorafenib, when 
administered with or without ritonavir, in patients with KS.  
 
1-2.2.4 Biopharmaceutics and pharmacokinetics of sorafenib 
Sorafenib is poorly soluble in water and has high lipophilicity, with solubility values for 
the tosylate salt ranging from 0.034 mg/100 mL at pH 1.0 to 0.013 mg/100 mL at pH 4.5 
(33) and experimental hydrophobicity (log P) value of approximate 3.8 (34). Its 
calculated pKa values, 1.6 and 12.91, are outside the physiological pH range; hence, it 
largely remains neutral under physiological conditions.  
 
1-2.2.4.1 Absorption and Bioavailability 
                                                 
1 pKa predictions are based on ACD/labs software 
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In preclinical studies, sorafenib was almost completely absorbed in bile-duct cannulated 
female CD-1 mice (oral bioavailability (Foral), 78.6%) and male Wistar rats (Foral, 79.2%), 
and moderately absorbed in dogs (Foral, 67.6%) following oral administration with time to 
maximum plasma concentrations (Tmax) ranging between 1.5-2 hr (33).  
 
In humans, sorafenib has never been administered intravenously; therefore its Foral is 
unknown. Mean relative bioavailability (Frel) of orally administered sorafenib tablet 
against polysorbate-80 based oral solution ranged from 38 to 49% (35), reflecting the 
importance of GI dissolution. Oral administration with a moderate fat-content meal did 
not affect the Frel, but administration with high-fat meal reduced Frel by 29%, compared to 
fasting state (35).  Tmax in patients ranged between 0-24 hr (approximate median 3 hr), 
with secondary peaks observed at 8-12 hr and 24 hr post-dose, indicating entero-hepatic 
recirculation (EHR), which was also seen pre-clinically with biliary-excretion of 
sorafenib in bile-duct cannulated rats. In Caco-2 cell line experiments, sorafenib was 
found to be highly permeable based on a comparison with 22 reference compounds. 
However, in vivo preclinical data indicated that the extent of absorption in bile cannulated 
rats was approximately 80%, and the absolute oral bioavailability in dogs was ~59.9%. In 
an in vivo mass balance study in humans it was determined that approximate 77% of the 
administered dose was excreted in feces (51% as parent drug) (33). The unchanged drug 
excreted in feces could have come from unabsorbed parent drug in GI tract and EHR. 
Their exact contribution is not known, but approximately 10% of the dose (5-8% as 
unchanged drug) was recovered in the first fecal sample (0-48 h) (33), suggesting that the 
fraction of unabsorbed drug in GI would be only approximately 10%. The extent of 
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absorption and gastrointestinal solubility could also vary between subjects. Based on the 
definition of solubility and permeability in BCS classification (36), sorafenib may be 
classified as a BCS class II or IV drug because of its low gastrointestinal solubility and 
medium to high gastrointestinal permeability. In P-gp-expressing L-MDR1 cell line 
experiments, sorafenib was found to be a weak to moderate substrate of the P-gp efflux 
transporters (33), consistent with medium to high gastrointestinal permeability; however, 
the actual contribution of P-gp-mediated efflux, if any, in therapeutically relevant 
gastrointestinal concentrations is unknown. 
 
1-2.2.4.2 Distribution 
Sorafenib is highly plasma protein bound (PPB) with 99.5% of sorafenib bound primarily 
to serum albumin, and to a lesser extent to α- and β- globulins and low density 
lipoproteins (LDLs). The plasma-to-blood ratio for sorafenib was 1.33, suggesting no 
significant accumulation in RBC’s or platelets (33).  
 
In preclinical quantitative organ and tissue distribution studies with radio-labeled drug, 
sorafenib and its metabolites were found to be homogenously distributed throughout the 
body, with the exception of the brain, seminal vesicles and solid bones. The highest 
exposure of sorafenib was found to be in the liver. Sorafenib was rapidly eliminated from 
all organs and tissues (with t1/2~20-36 hr) with exception of skin for which t1/2 was 72.8 
hr (33). In a mass balance study in healthy male volunteers, with administration of 100 
mg sorafenib as a solution formulation, 96% of the dose was recovered within 14 days, 
77% of which was excreted in feces (51% as unchanged drug and 19% as N-
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demethylated metabolite, M6) and 19% was excreted in urine as the glucuronide 
metabolites (37). About 5-8% of unchanged drug was recovered in the first fecal sample 
(0-48 hr), and larger fractions of 19-25% were found in the second (48-72 hr) and third 
(72-96 hr) samples (33). Neither the N-oxide metabolite nor the glucuronide metabolite 
was detected in feces, and no unchanged drug was found in urine (37). The excretion of a 
large proportion of unchanged drug in feces may be caused by, 1) unabsorbed drug 
because of low GI solubility and/or 2) EHR of sorafenib (see section 1-3.4.1). The EHR 
for sorafenib may be described by two processes, 1) biliary excretion of unchanged drug , 
2) glucurodination of drug, biliary excretion of glucuronide metabolite into the gut, 
deconjugation and subsequent reabsorption into the systemic circulation and/or fecal 
elimination, 3) oxidation of drug to N-oxide metabolite, biliary excretion of N-oxide 
metabolite into the gut, reduction by colonic bacteria to the parent drug and subsequent 
reabsorption in systemic circulation and/or fecal elimination (33). Following oral 
administration, sorafenib (parent drug) accounts for 70-85% of circulating moieties in 
human plasma while approximately 17% remain in the form of N-oxide metabolite (33). 
 
1-2.2.4.3 Metabolism 
Sorafenib is metabolized by two parallel pathways, namely phase I oxidative metabolism 
by CYP3A4 enzymes and glucuronidation by UGT1A9 enzymes (37). A total of eight 
metabolites have been identified in humans (Fig 1-4), of which five were present in 
plasma (35). The metabolites M2, M4 and M5 were active against similar targets as 
sorafenib in in-vitro pharmacological assays, but their plasma levels were much lower 
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than sorafenib (33). The most predominant human metabolite, M2, was both less potent 
and less active than sorafenib (33). 
 
 
Fig 1-4 Metabolic profile for sorafenib  
 
1-2.2.4.4 Elimination 
In cancer patients, the mean terminal plasma half-life for sorafenib ranged between 25-48 
hr. As mentioned in 1-3.4.2, sorafenib is primarily excreted unchanged in feces and only 
a small proportion is eliminated in urine as metabolites. 
 
1-2.2.5 Dose proportionality studies 
In phase I clinical studies with sorafenib, the main exposure parameters estimated were 
AUC0-12 or 0-24, Cmax, tmax, t1/2 and steady-state accumulation ratio (i.e., AUCτSS/AUCτSD). 
Considerable inter-patient variability was observed for sorafenib pharmacokinetics in 
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these trials, as shown in Table 1-2. Variability in pharmacokinetic parameters after 
administration of multiple doses was greater than the variability on day 1 (Table 1-2). In 
these studies, a less-than-proportional increase in AUC and Cmax was observed with 
escalating doses of sorafenib, and plateau in AUC and Cmax was reached at doses of 600 
mg BID (35), most likely due to its limited GI solubility (solubility-limited absorption). 
Steady-state for sorafenib was reached after approximately seven days, with little 
additional drug accumulation thereafter (38). This indicates that sorafenib follows time-
independent pharmacokinetics; suggesting that drug levels after multiple doses can be 
predicted from first/single dose pharmacokinetics. Throughout the dose range of 50 to 
800 mg BID, the ratio of AUC and Cmax of N-oxide metabolite to sorafenib were similar, 
suggesting constant (first-order, non-saturable) CYP3A4 metabolism at or above 
therapeutic doses (37). 
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Table 1-2. Summary of exposure parameters from phase I clinical trials 
GM, Geometric mean, CV, Coefficient of variation, NC, Not calculated 
AUC0-12 (mg.h/L) Cmax (mg/L) t1/2 (hr) Dosing schedule 
(reference) 
Dose 
(BID) Day 1 Last day Day 1 Last day Last day 
  N GM %CV N GM %CV N GM %CV N GM %CV N GM %CV 
7 on/7off (39) 100 1 6.8 NC 3 24.4 76 3 1.0 32 3 3.5 74 3 38.1 48 
 200 1 6.1 NC 3 19.1 17 3 0.8 86 3 2.6 9 3 20.1 13 
 400 2 18.0 5 4 56.6 91 4 2.3 37 4 6.2 107 3 20.0 22 
 600 3 21.0 81 6 64.8 77 6 2.7 61 6 6.6 71 6 24.3 21 
21 on/7 off (38) 100 4 4.8 105 4 30.2 37 4 0.7 100 4 4.4 11 4 25.2 40 
 200 3 24.9 34 3 50.5 13 3 3.6 24 3 6.3 50 2 29.8 13 
 400 9 24.0 43 5 76.5 25 10 3.0 71 6 10.0 24 3 23.8 39 
 600 12 30.4 56 6 77.0 46 12 4.6 56 8 9.2 45 6 38.6 38 
28 on/7 off (40) 100 3 10.1 97 5 38.1 37 7 2.0 72 5 4.7 29 4 26.3 27 
 200 4 10.9 38 5 34.7 44 6 1.3 34 5 4.0 52 4 31.8 10 
 400 4 21.8 59 3 47.8 24 4 2.9 68 3 5.4 41 3 27.4 24 
 600 3 10.1 97 5 38.1 37 7 2.0 72 5 4.7 29 4 26.3 27 
Continuous (35) 100 3 23.8 43 NC NC NC 4 2.3 54 NC NC NC NC NC NC 
 200 3 16.1 83 NC NC NC 4 2.8 88 NC NC NC NC NC NC 
 400 5 71.7 43 NC NC NC 5 9.4 44 NC NC NC NC NC NC 
 600 8 79.0 52 NC NC NC 12 9.8 51 NC NC NC NC NC NC 
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1-2.2.6 Clinical drug-drug / drug-disease interaction studies 
Results from different drug-drug interaction (DDI) studies for sorafenib are summarized 
in appendix 1-4, and the important findings are summarized below: 
a) When a single 50 mg dose of sorafenib was co-administered with a potent CYP3A4 
inhibitor ketoconazole (400 mg QD, started three days prior to co-administration with 
sorafenib) no significant change in sorafenib plasma exposures was observed; 
however, the plasma concentrations of the nN-oxide metabolite were significantly 
decreased (37). This may be explained by compensatory elimination of sorafenib by 
parallel glucuronidation pathways, assumed to be not substantially affected by 
ketoconazole. Glucuronidation may be a high capacity pathway under normal 
physiological conditions, i.e., not saturated. However, in in-vitro studies with human 
liver microsomes and c-DNA expressed UGT1A isoforms, ketoconazole has also 
been shown to inhibit UGT1A9 enzyme with Ki value of 31.9±3.3 μmol/L (41). It is 
possible that the ketoconazole dose was not sufficient to inhibit both the CYP3A4 and 
UGT1A9 pathways; therefore, we do not observe any significant changes in sorafenib 
exposures. 
b) In a probe substrate clinical trial studying the effect of sorafenib on CYP3A4, co-
administration of sorafenib with CYP3A4 substrate midazolam showed no significant 
changes in midazolam exposure, which suggests that sorafenib is neither an inhibitor 
nor an inducer of CYP3A4 (35).  
c) Following co-administration with another CYP3A4 substrate, gefitinib, in patients 
with NSCLC, no changes in systemic exposures of sorafenib was observed, but AUC 
for gefitinib decreased by 38%. The exact mechanisms for this reduction in gefitinib 
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exposure is not known but is thought to be mediated by mechanisms other than 
enzyme induction, e.g., PPB displacement (42). 
d) Sorafenib inhibited the glucuronidation of irinotecan, which is known to be 
metabolized by UGT1A1 and UGT1A9 pathways. When sorafenib (400 mg BID) was 
administered in continuous dosing cycle with irinotecan 125 mg/m2 (administered on 
days 1, 8, 15 and 22 of each cycle), mean AUC0-10 and Cmax of sorafenib increased by 
68% and 78%, respectively, but the reduced 140 mg fixed dose of irinotecan had no 
effect on exposures of sorafenib (43). In-vitro experiments demonstrated that the 
inhibitory rate constants (Ki) for inhibition of glucuronidation by UGT1A1 and 
UGT1A9 pathways by sorafenib were 1 μM and 2 μM (35), consistent with the in-
vivo effect of sorafenib on irinotecan. 
e) To assess the effects of chronic hepatic impairment on the pharmacokinetics of 
sorafenib, sorafenib systemic exposures were compared between patients with Child-
Pugh A and B hepatocellular carcinoma (44). Patients with Child-Pugh B had higher 
mean values for both AUC0-8 hr and Cmax, although these differences were not 
statistically significant (44). Plasma exposures of metabolite M5 (see Fig 1-4) were 
slightly lower in Child-Pugh B patients, while levels of M2 and M4 were not different 
between two groups (44). 
 
Overall, these results indicate that alterations in sorafenib metabolism via the UGT1A9 
pathway may be more important than the CYP3A4 pathway. However, there are no 
clinical studies showing that the inhibition of CYP3A4 has no effect on sorafenib 
exposures when it is administered in a clinically relevant dosing regimen, i.e., 400 mg 
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BID. This suggests the need for further exploration of both the CYP3A4 and UGT1A9 
metabolic pathways. 
 
Except P-gp, for which sorafenib is a weak to moderate substrate, no other transporters 
systems are known to be involved in the GI absorption of sorafenib. However, based on 
its known disposition profile, i.e., hepatobiliary elimination, it may interfere with 
disposition of (drug) substrates of MRP2 and BCRP transporters. Co-administration of 
sorafenib with docetaxel and doxorubicin, both of which are partly excreted by 
hepatobiliary elimination and are substrates for P-gp and MRP2 transporters (45-48), 
increased their respective systemic exposures by 21-80% (Appendix 1-4) (49, 50).  
 
1-2.3 Population pharmacokinetic analysis 
At the annual meeting of the American Association of Pharmaceutical Sciences (AAPS) 
in 2007, Rajagopalan et al (51) from Bayer Health Care presented the population 
pharmacokinetic analysis for sorafenib in cancer patients (n=229) with additional single 
dose pharmacokinetic data in healthy subjects (n=69). Population pharmacokinetic 
analysis was performed with NONMEM using the first-order conditional estimation 
(FOCE) method with η-ε interaction. The base pharmacokinetic model was a two-
compartmental model with first order absorption (ka), absorption lag time and relative 
oral bioavailability modeled as a function of dose to incorporate the observed infra-
proportional increase in sorafenib exposure with increasing single doses. Covariates 
examined included, age, body weight, creatinine clearance, gender, ethnicity (Japanese 
vs. non-Japanese), disease (cancer patient vs. healthy subject), and baseline laboratory 
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markers (both as continuous variables and categorical variables i.e., less than upper 
normal limits (ULN) vs. greater than ULN). Laboratory values for SGOT, SGPT, total 
bilirubin, alkaline phosphatase, and total protein were examined.  
 
The absorption rate constant and the relative bioavailability were found to be influenced 
by ethnicity. The final model population (mean) values were: clearance (CL/F) =3.31 
L/hr (inter-patient variability, 25%), volume of distribution for central compartment 
(Vc/F) =85.2 L (inter-patient variability, 10%), volume of distribution for peripheral 
compartment (Vp/F) =24.6 L (inter-patient variability, 45%), inter-compartmental 
clearance (Q)=1.29 L/hr, first-order absorption rate constant (ka)=0.229 hr-1 (inter-patient 
variability, 104%), and tlag=0.214 hr. The CL/F of 3.31 L/hr suggests a low hepatic 
extraction ratio when compared with hepatic blood flow of 90 L/hr, even though true in-
vivo CLtotal is not known. The population mean of ka for Japanese patients was 0.106 hr-1, 
and relative oral bioavailability was 28.9%, lower compared to non-Japanese patients 
(51). 
 
1-2.4  Efficacy of sorafenib in various solid tumors 
Sorafenib has been investigated in several solid tumors as a single agent or in 
combination therapy, including the renal cell carcinoma, hepatocellular carcinoma, 
melanoma, head and neck carcinoma, nasopharyngeal carcinoma, breast cancer and 
NSCLC etc.  Its response rate varies widely among patients with different tumors (see 
Table 1-3), which may be attributed to differences in underlying tumor biology, variation 
in sorafenib exposures among patients and physiological or genetic differences. The 
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tumor response in these trials was measured by RECIST (response evaluation criteria in 
solid tumors). RECIST is a set of published guidelines which evaluate the changes in 
measurable lesions from their baseline size in order to classify drug response in following 
categories: complete response (CR), disappearance of all target lesions; partial response 
(PR), 30% decrease in the sum of the longest diameter (LD) of target lesions; stable 
disease (SD), < 30% decrease and < 20% increase in sum of LD of target lesions; and  
progressive disease (PD), ≥ 20% increase in sum of LD of target lesions (52). 
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Table 1-3 Summary of treatment outcomes with sorafenib in selected Phase II/III trials 
Trial CR† 
(%) 
PR† 
(%) 
SD† 
(%) 
PD† 
(%) 
Not evaluable 
(%) 
PFS 
(months) 
OS 
(months)
Current status
for tumor type
Phase III, RCC (53) <1 10 74 12 4 5.5 NR Approved 
Phase III, HCC (54)  0 2 71 NR NR 4.1 10.7 Approved 
Phase II, HCC (44)  0 2 34 35 23 4.2 9.2 Approved 
Phase II, Melanoma (55) 0 3 16 73 NR 2.5 NR Not Approved 
Phase II, mCRPC (56) 0 20 14 66 NR 3.9 14.6 Not Approved 
Phase II, Head and Neck Cancer (57) 0 4 37 37 4 1.8 4.2 Not Approved 
CR, Complete response, PR, Partial response, SD, Stable disease, PD, Progressive disease, PFS, Duration of progression free survival, 
OS, Duration of overall survival, RCC, Renal cell carcinoma, HCC, Heaptocellular carcinoma, mCRPC, Metastatic castrate resistant 
prostate cancer, NR, Not reported 
† Response evaluation was based on RECIST criteria  
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1-2.5 Toxicities and their plausible mechanisms 
Sorafenib treatment-related adverse events observed in selected phase I/II/III clinical 
trials are summarized in Table 1-4. The most common treatment-related toxicities for 
sorafenib are hand-foot reaction syndrome (HFSR), diarrhea, skin rash / desquamation, 
hypertension and fatigue (58). Clinically, sorafenib is administered in continuous dosing 
cycles, and, being a cytostatic agent, long-term administration is required to 
achieve/maintain therapeutic benefit; hence, even lower incidences/grades of toxicities 
may have an adverse impact on patients’ quality of life. As described in Table 1-5, 
several patients had to reduce doses or to discontinue sorafenib treatment because of 
these treatment-related toxicities. The possible mechanistic causes for these toxicities are 
discussed below: 
 
(A) Dermatological toxicities 
The dermatological toxicities may be caused by slow removal of sorafenib from the skin, 
compared to other organs as observed in preclinical animal studies (t1/2skin~72.8 hr versus 
t1/2other organs~20-36 hr) (49). Other hypotheses regarding sorafenib-induced dermatological 
toxicities are, (a) accumulation of potentially toxic concentrations in eccrine sweat glands 
that are present in greatest density in the palms and soles, (b) inhibitory effects of 
sorafenib on MAP-kinase pathway in keratinocytes (59) and (c) damaged vascular 
integrity due to the dual VEGFR2 and PDGFR inhibition by sorafenib (60). 
 
(B) Cardiovascular toxicities 
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Hypertension is a common side effect of most anti-angiogenic therapies. It may be caused 
by vascular stiffness resulting from inhibition of replication of endothelial cells or by 
reduction in number of arterioles and capillaries, leading to reduction in vascular surface 
area and an increase in peripheral vascular resistance (59). Sorafenib may also alter the 
angiotensin-II regulated control of blood pressure in renin-angiotensin system, which is 
mediated by protein kinases such as EGFR, PDGFR etc (59).  Veronese et al (61) 
conducted a pharmacodynamic study on 20 patients to help understand the mechanism of 
sorafenib-associated hypertension. Factors considered for the analysis were known 
mediators of vascular tone and hypertension (i.e., aldosterone, catecholamines, 
endothelin, urotensin II, serum VEGF and von Willebrand factor), which were measured 
at baseline and after three weeks of therapy. Results indicated that sorafenib-induced 
hypertension may be associated with changes in catecholamines and indices of vascular 
stiffness.  
 
(C) GI toxicities 
One possible cause for diarrhea may be the persistent contact of sorafenib and/or 
metabolites with GI lumen because of its low solubility, which may cause irritation of GI 
lumen. Both VEGF and MAP-kinase pathways are involved in mucosal defense and 
repair; inhibition of these pathways by sorafenib may increase the sensitivity of GI lumen 
to these drugs (59). Sorafenib is also recycled via EHR, which may further worsen the 
diarrhea by re-circulating the drug to GI lumen.  
 
(D) Constitutional toxicities 
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The exact reason for treatment-associated fatigue is not known, but it may be caused by 
natural progression of disease, independent of administered treatment. Other possible 
reasons are decrease in ATP (62) with cytostatic treatments or hypothyroidism associated 
with anticancer treatments.  
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Table 1-4 Summary of the most frequent sorafenib-related adverse events from selected phase I/III trials. 
 
Toxicities 
Combined phase I trials,      
ref† (63), % (n) 
Phase III RCC, ref 
(53),  % (n) 
Phase III HCC,        
ref (54), % (n) 
Phase II Melanoma,   
ref (55), % (n) 
 All grades gr ≥ 3 All grades gr ≥ 3 All grades gr ≥ 3 gr ≥ 3 
Fatigue 40 (70) 6 (11) 37 (165) 5 (22) 22 4 16 (21) 
Anorexia 35 (60) 1 (2) 16 (73) <1 (3) 14 <1 NR 
Diarrhea 34 (59) 4 (7) 43 (195) 2 (11) 39 8 8 (11) 
Rash:desquamation 27 (46) 2 (4) 40 (180) 1 (4) 16 1 7 (10) 
HFSR 25 (44) 8 (13) 30 (134) 6 (25) 21 8 7 (9) 
Hypertension NR NR 17 (76) 4 (16) 5 2 NR 
Nausea 11 (2) 0 (0) 23 (102) <1 (3) 11 <1 NR 
†ref = reference number 
RCC, Renal cell carcinoma, HCC, Hepatocellular carcinoma, NR, Not reported, HFSR, Hand-foot skin reaction 
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Table 1-5 Summary of treatment discontinuations/interruptions/dose reductions due to treatment associated side effects from selected 
sorafenib trials 
Trial Dose reductions Dose interruptions Treatment discontinuation
 (%) (%) (%) 
Phase III, RCC (53) 13 21 10 
Phase III, HCC (54)  26 44 38 
Phase II, HCC (44) NR NR 20 
Phase II, Melanoma (55) 16 27 0 
Phase II, mCRPC (56) NR NR 6 
Phase II, Head and Neck Cancer (57) 57 50 4 
RCC, Renal cell carcinoma, HCC, Hepatocellular carcinoma,  
mCRPC, Metastatic castrate resistant prostate cancer, NR, Not reported
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1-3 Relevance of pharmacogenetic evaluation 
Considerable inter-patient variability in sorafenib exposures (Table 1-2), possible 
ethnicity-dependent differences in oral absorption rate and bioavailability observed in the 
population pharmacokinetic analysis, and large inter-patient variability in response rates 
and incidences/grades of toxicities (Tables 1-3 and 1-4) are characteristic for sorafenib. 
Several factors may contribute to this variability: intrinsic patient factors (e.g., age, 
gender, race, extent of EHR, PPB and genetics), extrinsic factors (e.g., concomitant 
medications or concomitant illnesses) or factors limiting the performance of dosage form 
(e.g., poor solubility and high lipophilicity).  These factors may also include genetic 
differences in pharmacokinetics or pharmacodynamics. Identification of genetic markers 
and their subsequent inclusion in FDA approved labels, such as dihydropyrimidine 
dehydrogenase (DPD) for capecitabine, G6PD for primaquine, Her2/neu for 
trastuzumab, UGT1A1 for irinotecan, TPMT variants for azathioprine, Philadelphia 
(Ph1) chromosome deficiency for busulfan, is a result of pharmacogenomic explorations, 
and suggests that a significant portion of inter-individual variability in tumor response, in 
incidence and severity of adverse effects and in drug and/or metabolite exposures may be 
explained by differences in the genetic makeup of patients (7). FDA has identified 
pharmacogenomics as a key opportunity in their “Critical Path” recommendations for the 
development of new medicinal compounds (40). The observed ethnic differences in 
bioavailability and absorption rate for sorafenib, reported in population pharmacokinetic 
analysis, also suggest possible underlying genetic differences in expression of drug 
metabolizing enzymes or transporters. 
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The process of identifying these genetic variations and understanding the clinical 
significance are still evolving; however, several methods have been suggested: The 
traditional method has been the candidate gene approach, in which a single gene or a 
small number of genes (pre-identified based on existing knowledge) are evaluated in their 
ability to explain the differences in the pharmacokinetics/pharmacodynamics of the drug. 
The pathways-based (polygenic) approach, involving the evaluation of multiple single 
nucleotide polymorphisms (SNP) in components of a ‘biological’ or ‘pharmacological’ 
pathway, is thought to be a better predictor of therapeutic responses compared to the 
single gene variant approach (64, 65). Another evolving method is the whole-genome 
analysis, in which the entire genome is taken into consideration without bias towards a 
particular gene or pathway, using techniques like the SNP chip and gene expression 
platforms. A major advantage of this approach is identification of previously unknown 
genetic variants, but the disadvantages are enormous amount of information, high rate of 
false positive findings and huge expenses.  
 
For the current exploratory studies using sorafenib, the polygenic pathway approach has 
been used to investigate the effect of known genetic polymorphism in drug metabolizing 
enzyme and drug targets on drug exposure (pharmacokinetics) and drug responses 
(pharmacodynamics, tumor response and incidences and severity of adverse events). 
 
Genetic variants 
The underlying hypothesis behind genotype-phenotype-exposure-response associations is 
that drug exposures, drug responses and toxic effects can be predicted by the 
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identification of patients’ genotype or phenotype before the start of chronic treatment 
(66). The functional consequences of genetic variations range from no effect to altered 
expression of the encoded protein to changes in cellular function/location (66). The 
genetic variations in metabolic enzymes and drug targets that were studied for sorafenib 
are described below: 
 
1-3.1 Metabolic Enzymes 
1-3.1.1 CYP3A4 and CYP3A5 
Cytochrome P450 enzymes are primarily expressed in the liver and intestine; they are 
responsible for the oxidative metabolism of endogenous steroids, hormones as well as 
many drugs (67). CYP3A5 is expressed in similar levels at all developmental stages, but 
CYP3A4 is an enzyme specific for adults (68); expression levels for both of these 
enzymes vary based on ethnicity. Considerable inter-individual variability has been 
observed in the expression and metabolic activity of CYP3A enzymes, of which 70-90% 
is thought to be attributable to genetic control (69). It is important to consider these 
genetic differences to avoid possible DDIs. 
 
Until today, 20 CYP3A4 alleles, consisting of 38 SNPs have been reported (66). Most 
occur at low frequency or are prevalent in specific populations. For example, the 
frequency of CYP3A4*1B (-392 A>G) SNP located in 5’-regulatory region is 3.6-9.6% 
in Caucasians and 53-67% in African-Americans (70). This SNP is reported to be 
epidemiologically associated with a number of disease states, including prostate cancer, 
leukemias caused by treatment with epipodophyllotoxins, and early puberty (69). So far 
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no association has been reported between the CYP3A4*1B genotype and the 
pharmacokinetics of its known substrates (70). Shimanda et al (71) compared the 
expression and activity of various cytochrome P-450 enzymes in liver microsomes from 
Japanese and Caucasians patients (N=30 each group). They reported no race-related 
differences in CYP3A4 expressions, but observed differences in activity, where 
metabolic activation by CYP3A4 was found to be higher in Caucasians than in Japanese 
patients. The CYP3A4*1B SNP was absent in the Japanese population (72). However, 
this SNP appears to not explain the lower relative bioavailability for patients’ with 
Japanese ethnicity compared to Caucasians, as observed in population pharmacokinetic 
analysis (51). 
 
CYP3A5 is polymorphically expressed in adults with detectable expression of 10-20% in 
Caucasians, 33% in Japanese and 55% in African-Americans (70, 72). CYP3A5*3 SNP 
is associated with low expression of CYP3A5 protein (70). CYP3A5*3 SNP causes 
splice site defect, which results in incorporation of intronic sequences in mature mRNA, 
leading to premature truncation of translation and production of truncated protein. The 
frequency of this polymorphic variant varies from approximately 90% in Caucasians, 
75% in Japanese to 50% in African-Americans.  CYP3A4 and CYP3A5 are considered to 
have overlapping substrate specificity. No SNP in the CYP3A5 gene has been described 
which can explain the variability in metabolism of its substrates.  
 
1-3.1.2 UGT1A9 
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The UGT enzyme system is divided into two superfamilies, UGT1 and UGT2, which are 
further subdivided into three subfamilies, i.e., UGT1A, UGT2A and UGT2B. Several 
genetic polymorphisms are described in the UGT1A gene which includes UGT1A1, 
UGT1A6, UGT1A7, UGT1A9, UGT1A10 etc. 
 
UGT1A9 is expressed in the liver as well as in a number of extra-hepatic tissues, 
including the GI tract, kidney, ovary, prostate and breast (73). Due to its large substrate 
spectrum and abundance in these tissues, UGT1A9 plays a central role in the 
detoxification of a substantial number of molecules. Girard et al. identified a number of 
polymorphisms within the promoter region and exon 1 of the gene, which were related to 
protein expression and the glucuronidation activity (74). Expression of UGT1A9 in 
human liver samples were higher for patients with promoter region variations at positions 
-275 (p=0.006), -331/-440 (p=0.046), -665 (p=0.042) and -2152 (p=0.0004). UGT1A9*2 
(C3Y), UGT1A9*3 (M33T), UGT1A9*4 (Y242X) and UGT1A9*5 (D256N) SNPs in the 
coding region have shown to result in complete or partial inactivation of glucuronidation 
activity for substrates such as SN-38, the active metabolite of irinotecan (74). UGT1A9*3 
dramatically reduced the SN-38 glucuronide formation, with only 3.8% activity 
compared to UGT1A9*1 allele (75). The UGT1A9*1/*3 genotype was present in about 
4% of Caucasians but was absent in African-Americans (75). The UGT1A9*5 SNP was 
identified in Japanese subjects and the variants were found to have less than 5% catalytic 
activity towards SN38 glucuronidation when compared to wild type carriers (76). 
Recently, Girard et. al. reported a novel I399 C>T SNP in the intronic region of UGT1A9 
gene, which resulted in increased glucuronidation of UGT1A1 and UGT1A9 substrates in 
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in- vitro human liver microsomes studies (77); the frequency of this SNP was 44% in 
Caucasians liver samples. The homozygous UGT1A9 I399TT genotype was associated 
with 1.7-fold higher expression of UGT1A1 protein and 2.5- and 1.8-fold higher capacity 
to glucuronidate SN-38 and bilirubin respectively, in the liver microsomal samples that 
harbored the reference UGT1A1 -53(TA)6/6 repeats. Sandanaraj et al (78) tested the 
findings of Girard et al (77) in Asian cancer patients, and confirmed 2.3 fold higher 
expression of UGT1A9 mRNA in liver tissues of subjects restricted to harboring only the 
(TA)6/6 polymorphic repeats in the TATA box region of the UGT1A1 gene; they also 
showed the SNP to be associated with increased glucuronidation activity and 
significantly low systemic exposure to SN-38 (78). 
 
1-3.2 Drug targets 
Sorafenib targets the VEGFR-2 and Ras/Raf pathways. Functional polymorphisms in 
these targets may alter receptor-sensitivity and/or drug-activity. Characterization of such 
polymorphism is important to understand the inter-individual differences in drug effect or 
toxicities. 
 
1-3.2.1 Kinase Domain Receptor (KDR) or Vascular Endothelial Growth Factor 
Receptor2 (VEGFR2) 
VEGF is important for initiation and regulation of angiogenesis. Although the biological 
effects of VEGF are mediated by two receptors (VEGF receptor1 or Flt1 and VEGF 
receptor 2 or Flk1/KDR). The interaction between VEGF and VEGFR2 is believed to be 
more important for angiogenesis during tumor development. Försti et al. reported 8 SNPs 
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in VEGFR2 gene region (79). Two of them, rs2305948 (Val297Ile) and rs1870377 
(Gln472His) have a higher incidence and result in more important functional effects. 
They are located within the immunoglobulin-like (Ig like) domains 3 and 5, respectively. 
Ig-like domain 3 has been shown to be critical for VEGF binding. Ig-like domains 4–7, 
on the other hand, have been shown to contain structural features that inhibit receptor 
signaling in the absence of VEGF (79). The frequencies of variant allele for these SNPs 
in Swedish and Polish patients with breast cancer were 27% and 50%, respectively (79). 
Exploration of these polymorphisms is important to understand the differences in efficacy 
or toxicity of sorafenib. 
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CHAPTER TWO 
RESEARCH HYPOTHESES 
 
 
Overview 
This research project is designed to explore the clinical pharmacology-based treatment 
approaches for sorafenib in patients with mCRPC, CRC, NSCLC, KS and other solid 
refractory tumors, following administration as single agent or in combination therapy.  
Sorafenib is associated with high inter-individual variability in plasma exposures 
(pharmacokinetics), clinical efficacy and incidences of treatment-related toxicities 
(Tables 1-2, 1-3 and 1-4): For example, the coefficient of variation (%CV) on AUCτSD 
for 400 mg BID dose is reported to vary between 24-91%, the rate of partial response and 
stable disease (from selected phase II/III clinical trials) varied between 2-20% and 14-
74%, respectively. Several patients refused further treatment or were administered 
reduced, possibly sub-therapeutic, doses of sorafenib because of treatment-related 
toxicities (Table 1-5). Markers for prediction of sorafenib-associated variability in 
exposure, effect and toxicity are not known, but need to be elucidated to maximize the 
treatment effectiveness and to minimize the treatment-related side effects and treatment 
discontinuations. 
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This project specifically aims to identify possible demographic, clinical or 
pharmacogenetic covariates that may influence the plasma exposures (pharmacokinetic 
profiles) of sorafenib, and to evaluate the impact of variable exposures on treatment 
efficacy and incidences of treatment-associated toxicities. In addition, a few other 
laboratory and pharmacogenetic markers for clinical efficacy and toxicity, and 
pharmacogenetic markers for prostate cancer risk are to be explored. 
The research hypotheses that will be tested are as follows (Fig 2-1): 
1. Demographic variables such as body weight, body surface area (BSA), age, 
gender and ethnicity have quantifiable effects on sorafenib exposures. 
2. Abnormal liver function, characterized by lower than normal levels of albumin 
and total protein, and above normal levels of ALT, AST, alkaline phosphatase and 
total bilirubin, have quantifiable effects on sorafenib exposures. 
3. Pharmacogenetic variations in metabolic enzymes for sorafenib, i.e., 
CYP3A4*1B, CYP3A5*3C, UGT1A9*3 and UGT1A9*5, have quantifiable 
effects on sorafenib exposures. 
4. Variability in exposures of sorafenib among patients is associated with variable 
clinical efficacy of sorafenib in patients with various solid tumors, after adjusting 
for differences in tumor types. 
5. Pharmacogenetic variations in VEGFR2, a drug target for sorafenib is associated 
with differences in clinical efficacy among patients with solid tumors. 
6. Variability in sorafenib exposures among patients is associated with variable 
incidences and severity of treatment-associated toxicities. 
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7. Pharmacogenetic variations in VEGFR2, a drug target for sorafenib are associated 
with incidences of hypertension, a treatment-associated side effect. 
8. Sorafenib induces the production of prostate specific antigen (PSA) by the 
prostate gland; therefore, PSA is not a suitable surrogate marker for clinical 
efficacy in patients with prostate cancer treated with sorafenib. 
9. Clinical responses for patients with solid tumor treated with sorafenib in 
combination with bevacizumab are predicted by the extent of ex-vivo anti-anti-
angiogenic activity in steady-state serum samples from these patients. 
10. The occurrence of sorafenib-induced hand-foot skin reaction (HFSR), a cutaneous 
side effect involving the palms and soles of hand and foot, is related to excretion 
of sorafenib in sweat by eccrine glands. 
11. Subjects with genetic variations in VEGFR2, an important mediator for VEGF 
angiogenesis pathway, are at increased risk of prostate cancer relative to patients 
with wild-type genotype. 
12. Toxicities induced by anti-VEGF (i.e., bevacizumab)/ VEGFR2 inhibitor (i.e., 
sorafenib) therapies serve as phenotypic markers for efficacy of these agents in 
patients with solid tumors.  
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Fig 2-1 Schematic illustration of various components for exploration of clinical and 
pharmacogenetic markers for exposure, efficacy and toxicity of sorafenib treatments in 
cancer patients with solid tumors 
 
To test these hypotheses, 24-hr sorafenib plasma concentration-time profiles on day 1 and 
at steady-state (for selected patients) were measured from five phase I/II clinical trials at 
the National Cancer Institute (NCI), evaluating the efficacy or safe dose of sorafenib in 
patients with mCRPC, CRC, NSCLC, KS and ST. In addition, patients were genotyped 
for CYP3A4*1B, CYP3A5*3C, UGT1A9*3, UGT1A9*5, VEGFR2 H472Q and 
VEGFR2 V297I SNPs, and demographic and clinical covariates information were 
collected at baseline. Information such as clinical response, progression-free survival 
(PFS) as well as toxicities (nature and grades) was collected over the course of sorafenib 
treatment in these studies. Characterization of pharmacokinetics and covariate analysis 
for sorafenib exposures were performed by non-compartmental analysis (NCA)-general 
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linear modeling (GLM) and population pharmacokinetics approach. Correlative studies 
by one-way ANOVA, Chi-square tests and Kaplan Meier survival analysis were used to 
evaluate other pharmacokinetic/pharmacodynamic/pharmacogenetic associations. 
 
In-vitro cell line experiments were performed to study the impact of sorafenib treatment 
on release of PSA (measured using ELISA) from prostate cancer LNCaP cells. Excretion 
of sorafenib in sweat was measured by liquid chromatography-mass spectrometry to 
investigate its association with development of HFSR. 
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CHAPTER THREE 
BIOANALYTICAL METHOD FOR QUANTITATION OF 
SORAFENIB IN HUMAN PLASMA 
 
 
3-1 Introduction 
Only few bioanalytical methods have been described for quantification of sorafenib in 
human plasma. An HPLC-UV method was described to quantify sorafenib in mouse 
serum matrix, but was limited by poor sensitivity (lower limits of quantification (LOQ), 
80 ng/mL) and long run time of 35 min(80). Recently another HPLC-UV method was 
reported for human plasma as biological matrix with shorter run time of 14 min but 
poorer quantification limits of 500 ng/mL (81). Two LC/MS/MS methods were also 
described (37, 82). One of them was based on a complex liquid-liquid extraction with 
quantifiability upto 10 ng/mL, while the other method was based on a simple protein 
precipitation with LOQ of 7.3 ng/mL and run time of 6 min. Both of these methods 
required plasma volumes of 100 μL or higher.  
 
Published analytical methods were limited by complex extraction procedure, long run-
time, poor sensitivity and requirement of large plasma volume; hence, it was considered 
essential to improve the currently available procedures. Therefore, a simple, selective, 
rapid and sensitive LC-MS/MS method was developed which also used a less volume of 
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plasma (83) compared to other published methods (37, 82). The procedures used in 
development and validation of this novel bioanalytical method for quantification of 
sorafenib in human plasma, using liquid chromatography with electrospray ionization-
tandem mass spectrometric detection, are described in this chapter. 
 
3-2 Physicochemical characteristics of sorafenib 
Sorafenib (Fig 3-1) is a bis-aryl urea which remains unionized at physiological pH. The 
pKa values for sorafenib predicted using ACD/labs (software from Advanced Chemistry 
Development, Inc) were 1.6±0.3 and 12.9±0.7, respectively for Pyridine Nitrogen and 
terminal Caboxamide Nitrogen (Fig 3-1). The prediction of pKa for pyridine nitrogen is 
lower than its normal value, i.e. 5.14, possibly because of resonance between the pyridine 
and carboxamide group resulting in transfer of proton from Caboxamide Nitrogen to 
Pyridine Nirogen. Sorafenib is highly lipophilic and has very low solubility in aqueous 
solvents.  
 
3-3 Experimental procedures 
3-3.1 Materials and reagents 
Sorafenib and the internal standard ([
2
H
3
, 
15
N] sorafenib) were provided by Bayer Health 
Care (New Haven, CT, USA). Acetonitrile (Optima grade) and formic acid (purity ≥ 98 
%) were purchased from Fisher Scientific and Sigma-Aldrich, respectively. Deionized 
water was generated with a Hydro-Reverse osmosis system (Durham, NC, USA) 
connected to a Milli-Q UV Plus purifying system (Millipore, Billerica, MA, USA). Drug-
free heparinized human plasma was obtained from the National Institutes of Health (NIH) 
 44 
 
 
Bioanalytical Method   Chapter 3 
Clinical Center Blood Bank (Bethesda, MD, USA). Initially these experiments were 
performed in eppendroff tubes, but most recently all the experiments were being 
performed in Kimbel® glass tubes purchased from VWR Scientific (Westchester, PA). 
 
 
Molecular weight: 637 g/mol (tosylate salt), 464.9 g/mol (free base) 
Solubility (tosylate salt): 0.034 mg/100mL at pH 1.0, to 0.013 mg/100mL at pH 4.5 
Predicted* pKa: 1.6±0.3, 12.9±0.7 
Lipophilicity (experimental logP) (34): 3.8 
Fig 3-1 Structure and physicochemical properties of sorafenib. *pKa predictions are 
based on ACD/labs software (version 9.0, Advanced Chemistry Development, Inc., used 
in April 2006) (84). 
 
3-3.2 Stock solutions and standards 
3-3.2.1 Preparation of sorafenib standard dilutions 
Stock solutions of sorafenib were prepared by dissolving the drug in acetonitrile/water: 
90/10 (v/v) mixture at a concentration of 1 mg/mL, which was stored in glass tubes at -20 
ºC. Serial (working) dilutions were prepared from this stock solution for the preparation 
of calibration and quality control (QC) samples, as shown in Table 3-1. 
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Table 3-1 Calculations for preparation of serial dilutions using sorafenib master stock of 
1 mg/mL concentration. 
  
Stock 
Secondary stock 
Concentration (ng/ml)
Add
(µL) of stock 
+ µL of  
ACN:water - 90:10 (v/v) 
A 20000 20 Master (1 mg / mL) 980 
B 10000 500 A 500 
C 5000 500 B 500 
D 1000 200 C 800 
E 250 250 D 750 
F 100 400 E 600 
G 50 500 F 500 
 
 
3-3.2.2 Preparation of dilutions for internal standard ([2H3, 15N] sorafenib) 
The internal standard (IS) master stock and working stock were prepared respectively at 
concentrations of 1 mg/mL and 50 µg/mL in acetonitrile/water: 90/10 (v/v) mixture. Both 
the master and working internal standard stocks were stored at -20 ºC. Working stock was 
directly added to the precipitation solvent (100 µL of 50 µg/mL stock in 200 mL of 
ACN) to get the dilution of approximately 2000 times resulting in final concentration of 
25 ng/mL. 
 
3-3.2.3 Preparation of Quality Control (QC) samples 
QC samples were prepared in batch, by addition of standard solutions to plasma in 
volumetric flasks as shown in Table 3-2, to obtain three different final concentrations of 
8 ng/mL, 160 ng/mL and 1600 ng/mL. These were divided into 300 µL aliquots, which 
were stored in glass tubes at -20 ºC. 
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Table 3-2 Calculations for preparation of QC samples 
QC concentration Volume/concentration of master stock Volume of plasma 
8 ng/ml 8 µL of 5000 ng/ml q.s. 5 ml 
160 ng/ml 8 µL of 100,000 ng/ml q.s. 5 ml 
1600 ng/ml 8 µL of 1000,000 ng/ml q.s. 5 ml 
 
3-3.3 Sample preparation 
3-3.3.1 Preparation of standards 
Two sets of standard curves were prepared everyday by adding 5 µL of specific stock to 
45 µL of blank human plasma as shown in Table 3-3 in clean, labeled glass tubes. These 
samples were processed using the optimized extraction procedure as mentioned in 
section 3-3.4 below. 
 
Table 3-3 Calculations for preparation of standard calibrators  
Sample name 
for HPLC 
Plasma 
volume  
(µL) 
Stock 
from 
Table 3-1 
Amount of 
stock solution 
(µL) 
Final 
concentration 
(ng/mL) 
Blank 50 - - Blank 
IS only 50 - - IS only 
5 ng/ml 45 G 5 5 
10 ng/ml 45 F 5 10 
25 ng/ml 45 E 5 25 
100 ng/ml 45 D 5 100 
500 ng/ml 45 C 5 500 
1000 ng/ml 45 B 5 1000 
2000 ng/ml 45 A 5 2000 
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3-3.3.2 Preparation of QC samples 
On the day of the assay runs, for each QC strength, one 300 µL aliquot was defrosted and 
divided into 5 aliquotes of 50 μL volume each, in glass tubes. These samples were treated 
in the same way as standard calibrators using the extraction procedure mentioned in 
section 3-3.4 below. 
 
3-3.3.3 Preparation of patient samples 
Similar to QCs, patient samples were thawed and 50 μL aliquot was transferred to clean 
glass tubes, which was extracted by procedure mentioned in section 3-3.4 below. 
 
3-3.4 Extraction procedure 
Total 100 µL of 50 µg/mL internal standard stock was added to 200 mL of ACN, which 
was then used as a precipitation solvent. The scheme for the extraction procedure is 
shown in Fig 3-2. Fifty microliters (50 µL) of standard calibrator / QC sample / patient 
plasma sample was subjected to protein precipitation with 500 µL of ACN containing 
internal standard. This mixture was vortex mixed and centrifuged at 3700 g for 10 min. 
Supernatant was transferred to Waters®  clear glass microvials, of which 25 µL was 
injected onto the column. 
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500 μL of ACN (precipitation solvent) containing IS 
Centrifuge at 3700 g for 10 min 
Vortex 45 sec
Vortex 45 sec
QCs or Patient samples (50μL) 
5 μL of secondary sorafenib stock (Table 3-3) 
45 μL of blank plasma 
 
 
 
Transfer 160 μL of supernatant in clean labeled Waters®  LC-MS vials 
Fig 3-2 Extraction procedure for sorafenib   
 
3-4 Equipment and chromatographic conditions 
Optimized experimental conditions for HPLC and MS system are listed below: 
3-4.1 HPLC: Waters
® 
2695 Alliance separation module  
3-4.1.1  Pump 
   Mobile phase A: Acetonitrile 
   Mobile phase B: 0.1 % formic acid 
   Isocratic method: A/B - 65/35 (v/v) 
   Total run time: 4 minutes 
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  Retention time: Approx. 1.5 minutes both for sorafenib and sorafenib internal 
standard  
3-4.1.2 Injector 
   Injection volume: 25 µL 
3-4.1.3 Column 
 Waters SymmetryShield RP8 (2.1×50 mm, 3.5 μm)  
 Column compartment temperature: 35 ˚C 
3-4.1.4. Wash solutions 
 Needle wash: Acetonitrile with 0.1% formic acid 
 Seal wash: Acetonitrile: Water- 20: 80 (v/v) 
 
3-4.2 Mass spectrometer: Micromass Quattro micro API mass spectrometer  
3-4.2.1. Ionization: Electrospray Positive 
   Multiple Reaction Monitoring (MRM) mode: 
  Sorafenib; parent ion (M+H+): 464.9 (m/z)  
              product ion (M+H+): 252.0 (m/z)  
  Sorafenib internal standard; parent ion (M+H+): 469.0 (m/z)  
            product ion (M+H+): 256.0 (m/z)  
3-4.2.2 Source Conditions 
   Cone voltage: 45 V 
  Collision energy: 33 eV 
 Capillary voltage: 3.50 kV 
 Desolvation temperature: 410
◦
C 
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 Desolvation gas flow: 610 L/h 
 Source temperature: 130º C 
 IE1: 1.0; IE2: 1.0 
 Exit: 10 
 
3-5 Data evaluation 
QuanLynx, a component of MassLynx, was used for generation of each calibration curve. 
The output was based on a least-squares linear regression analysis, with the appropriate 
weighting factor, of the peak area ratio of sorafenib and the internal standard against the 
nominal drug concentration. The least-squares regression line was not forced through the 
origin (0, 0), and blank (zero concentration) samples were not included in the calibration 
curve. The concentrations of the QC and unknown samples were determined by back-
calculation (interpolation) using the standard calibration curve. 
 
3-6 Validation procedures 
Validation was carried out on six different days, following the lab standard operating 
procedure (SOP), which was written based on guidelines for Bioanalytical Method 
Validation published by FDA. On each day of analysis, calibration standards were 
prepared in duplicate at 5, 10, 25, 100, 500, 1000 and 2000 ng/mL (concentration range 
5-2000 ng/mL). Five QC samples at each concentration were also thawed and analyzed 
with standard calibrators. Each validation run included two blank (zero concentration) 
samples and one sample containing only internal standard, along with the calibrators and 
 51 
 
 
Bioanalytical Method   Chapter 3 
QC samples. The validation parameters were calculated by using the methods described 
below. 
 
3-6.1 Selectivity 
The intent of the selectivity study is to ensure that there is no interference or matrix effect 
by endogenous matrix constituents in elution of sorafenib and internal standard. To 
examine the interference, blank plasma samples from six different sources were analyzed 
using the LC-MS/MS method. The obtained chromatograms were then visually examined 
for interfering peaks across the retention window for sorafenib and internal standard. The 
peak area of blank sample should be less than 5% of the area for the lower limit of 
quantification (LOQ) to be considered as non-interfering (i.e., not statistically different 
from zero). The method used to evaluate the matrix effect is described in section 3-6.2. 
 
3-6.2 Recovery, Matrix Effect and Process Efficiency 
Recovery, matrix effect and process efficiency were estimated at a low (10 ng/mL) and a 
high concentration (2000 ng/mL). Sorafenib stock solution aliquots were added either 
pre-extraction or post-extraction, and the internal standard was added post-extraction in 
all the samples. Recovery was calculated as the response ratio (sorafenib peak area/ 
internal standard peak area) measured in pre-extraction sorafenib spiked samples (n=5), 
as a percentage of that measured from post-extraction sorafenib spiked samples (n=5). 
The matrix effect was determined by comparison of the absolute sorafenib response area 
in post-extraction sorafenib spiked samples (n=5) with that of response ratio observed in 
mobile phase, i.e., acetonitrile/water:90/10 mixture (n=3). The response ratios for the 
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post-extraction spiked samples and mobile phase were compared to calculate the internal 
standard adjusted matrix effect. The process efficiency, defined as the overall 
extractability (i.e., recovery in presence of any matrix effect) of the assay method, was 
estimated as the sorafenib response ratio observed after extraction relative to the 
sorafenib response ratio observed in pure solvent. The calculation of these parameters is 
further shown in Table 3-7. 
 
3-6.3 Limits of Detection and Quantification (LOD and LOQ) 
The LOD is defined as the smallest concentration that can be distinguished from the 
blank. It is also the concentration having a signal of three times the noise in blank plasma 
samples across the retention window of sorafenib. It was determined by calculating the 
S/N ratio for a low concentration i.e. 1 ng/mL. 
 
The lower limit of quantitation (LLOQ) was determined as the lowest concentration for 
which sorafenib spiked in six different sources of plasma resulted in reliable and 
reproducible measurements with acceptable accuracy and precision (<20% bias and 
imprecision). It is also the concentration for which signal to noise (S/N) ratio is at least 
6:1. 
 
3-6.4 Accuracy and Precision 
The calibrator predicted concentration values for QC samples, run in quintuplicate at 
each concentration level on six different days, were used to assess the accuracy and 
precision of the assay.  
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Inaccuracy / bias / percent deviation from actual value was defined as the percent 
difference between the mean calibrator predicted concentration and nominal 
concentrations for each QC. 
   %100
]nominal[
]observed[]nominal[DEV % ×⎟⎟⎠
⎞⎜⎜⎝
⎛ −=  
The imprecision was calculated by performing the one way analysis of variance 
(ANOVA) on calibrator predicted concentrations for each QC using run day as a factor. 
The between-runs mean square variance (MSbet), the within-run mean square variance 
(MSwit), and the grand mean of observed concentrations across all the runs were obtained 
from ANOVA and were used in formulas below to calculate the between and within run 
imprecisions (BRIP and WRIP). 
%100
GM
/)(
BRIP ×−= nMSMS witbet  
%100
GM
WRIP ×= witMS   
where n = number of replicates within each validation run, GM = grand mean 
 
3-6.5 Stability 
3-6.5.1 Freeze-thaw stability 
QC samples at nominal concentrations of 8, 160 and 1600 ng/mL were subjected to three 
freeze-and-thaw cycles, in quintuplicate for each cycle, with each freeze cycle lasting for 
at least 12 h. All these samples were analyzed using LC-MS/MS method on the same day 
and the results were compared with the mean calibrator predicted concentrations (which 
were also used for calculation of accuracy in section 3-6.3). 
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3-6.5.2 Auto-sampler stability 
An entire set of samples (two calibration curves and QC samples in quintuplicate) were 
left in the auto-sampler at 4 °C after the initial run. Analysis was repeated after 7 h and 
then again after 24 h. Predicted concentrations for 7th and 24th h were then compared with 
those obtained for 0th h samples. 
 
3-6.5.3 Short term (bench-top) stability 
A set of sorafenib working stocks prepared in ACN/water: 90/10 solvent mixture at 
concentrations of 10 and 2000 ng/mL were left at work bench (room temperature) for 6 h. 
Another set of identical samples were stored at -20 °C. After 6 h these samples were 
analyzed together and concentrations were compared.  
 
3-6.5.4 Dilution Analysis 
Sample dilution was validated for samples for which plasma concentrations were found 
to be above the upper limit of quantification (ULOQ) in initial analysis. QC samples of 
concentration 10,000 ng/mL were prepared and a 5µL volume was diluted ten-fold with 
45 µL of human blank plasma; these samples were then processed as normal samples. 
Predicted concentrations from these samples were used to calculate the accuracy and 
precision of dilution analysis.  
 
3-7 Results and Discussion 
3-7.1 Selectivity 
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Fig 3-3 Typical chromatogram showing 464.9 →252.0 m/z (sorafenib) and  
469.0 →269.0 m/z (internal standard) transitions for; (a) blank human plasma 
with internal standard; (b) a calibrator sample spiked with 5 ng/mL sorafenib 
(LLOQ) with internal standard. 
 
The peak area of the blank sample, observed across the retention window of sorafenib 
and internal standard for six blank samples, was less than 5% of the peak area for LOQ, 
suggesting that the method can distinguish the peak for analyte of interest from all other 
chemical peaks. Typical chromatograms for blank plasma and plasma spiked with 5 
ng/mL of sorafenib are shown in Fig 3-3.  
 
3-7.2 Calibration Curve 
The lowest bias over the concentration range of 5-2000 ng/mL was obtained following 
regression analysis of the data to a quadratic fit with a weighting factor of 1/x (x being 
the nominal concentration) for the ratio of the peak area of sorafenib and the internal 
standard against the nominal concentration. The mean correlation coefficient for 
regression equations, generated for six different days, was 0.9995 (SD, ± 0.0005; range 
0.9988-0.9998).  
 
The percentage deviations from nominal (% DEV) were calculated for each calibrator 
concentration using the calibration curve predicted concentrations (Tables 3-4 (a) and 
(b)). The %DEV ranged from -4.33 to 3.08, which suggested a good fit of the data to the 
weighted quadratic regression.  
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3-7.3 Limits of Detection and Quantification 
Plasma samples with a final concentration of sorafenib of 1 ng/mL were analyzed to 
determine the lower limit of detection (LOD) for sorafenib. The LOD was determined by 
estimating the signal to noise ratio using Quanlynx software, and was estimated to be 0.2 
ng/mL. The lower limit of quantitation (LLOQ) was determined to be 5 ng/mL with 
percent relative standard deviation (% RSD) of 7.45% and % DEV of -4.33 %, using 
calibration curve predictions (Table 3-4(b)). Five different lots of human plasma were 
spiked with sorafenib to the final concentration of 5 ng/mL and were analyzed. The % 
RSD and % DEV were found to be 4.80 % and 2.00 % respectively. This further 
confirmed that the analytical method was able to quantify the LLOQ in an accurate and 
reproducible manner. 
 
3-7.4 Accuracy and Precision 
The assay was adequately accurate with bias of less than 15% for all the individual 
measurements, on each validation day at all three concentrations. The between-run and 
within-run imprecision values were less than 5%, well within the acceptable limits. The 
results for accuracy, precision and dilution analysis are reported in Table 3-5. The bias 
and imprecision for dilution analysis samples were 3.82 % and 3.92 %, respectively. This 
established that the samples of concentrations above the calibration range can be diluted 
ten-fold with blank human plasma to reduce its concentration to the level that would be 
within the estimation range for analysis.  
 
3-7.5 Recovery, Matrix Effect and Process Efficiency 
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The results for recovery, matrix effect and process efficiency are shown in Tables 3-6 
(a), 3-6 (b) and 3-7. The recovery and process efficiency were 80-100% at both low (10 
ng/mL) and high (2000 ng/mL) concentrations, and the matrix effect was approximately 
20%. The observed variability (% RSD) for a set of observations at any concentration 
level was less than 8%, which was within the acceptable limits. 
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Table 3-4 (a) Calibrator predicted concentrations from six days of validation runs 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 
r2=0.9988 r2=0.9996 r2=0.9998 r2=0.9990 r2=0.9998 r2=0.9998 Nominal 
Concentration Rep 1 Rep 2 Rep 1 Rep 2 Rep 1 Rep 2 Rep 1 Rep 2 Rep 1 Rep 2 Rep 1 Rep 2 
5 4.8 5.3 4.6 5.4 4.4 4.8 4.5 4.8 4.2 4.9 4.6 5.1 
10 10.4 9.5 9.8 10.2 11.1 10 10.3 10.5 10 11.2 9.7 11 
25 24.6 25 24.7 24.6 23.9 28.3 26.1 24.6 24.5 25.7 24.5 25.2 
100 100 104.6 100.4 103.2 96.1 99.5 98.3 105.4 108 99.6 103.8 100.1 
500 451.7 501.5 509.5 500.9 507.4 496 507.1 510.4 488.8 502.7 487.3 488.2 
1000 1023.4 1036 1011.1 969.4 981.9 1016.3 1000.1 968.8 1002.1 996.4 1010.3 1016.2 
2000 1958.2 2024.5 2039.1 1967.2 2014.4 1985.8 2063.9 1945.1 1998.3 2003.8 2013.9 1979.5 
Table 3-4 (b) Summary of calibrator predicted concentrations from Table 3-4 (a) 
Nominal Concentration Mean SD RSD(%) DEV (%) N 
5 4.78 0.36 7.45 -4.33 12 
10 10.31 0.56 5.42 3.08 12 
25 25.14 1.15 4.59 0.57 12 
100 101.58 3.41 3.35 1.58 12 
500 495.96 16.22 3.27 -0.81 12 
1000 1002.67 20.82 2.08 0.27 12 
2000 1999.48 34.49 1.72 -0.03 12 
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Table 3-5 Intra-run and inter-run quality control accuracy and precision 
 Nominal sorafenib concentration (ng/mL) 
 8 160 1600 
10000 
(dilution 10x) 
N 30 30 30 20 
Grand mean (ng/mL) 7.99 159.46 1485.79 9618.00 
SD (ng/mL) 0.47 7.60 86.38 41.88 
RSD (%) 5.93 4.77 5.81 4.35 
DEV (%) -0.12 -0.34 -7.14 -3.82 
Deviation Range (%) (-10 to 15) (-7.44 to 13.75) (-14.99 to 3.90) (-13.13 to 1.83)
Imprecision      
Within-run (%) 4.53 2.64 1.19 3.98 
Between-run (%) 1.68 1.75 2.50 * 
*No additional variability 
SD: standard deviation, % relative standard deviation (RSD) = (SD/Grand mean)*100 
% Deviation (DEV) = (([nominal] – [observed])/[nominal])*100 
Deviation range: range of deviations for QC samples with same nominal concentrations  
Table 3-6 (a) Response ratios for samples with pre- and post-extraction addition of 
sorafenib, and pure drug solutions for low concentrations 
Nominal Response for Response for Response for  
Concentration (ng/mL) Pre-Extraction Post-Extraction Pure drug 
10 0.254 0.247 0.264 
10 0.267 0.259 0.267 
10 0.276 0.252 0.257 
10 0.257 0.264  
10 NA 0.273  
Mean 0.26 0.26 0.26 
SD 0.01 0.01 0.01 
%CV 3.80 3.93 1.95 
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Table 3-6 (b) Response ratios for samples with pre- and post-extraction addition of 
sorafenib, and pure drug solutions for high concentrations  
Nominal Response for Response for Response for  
Concentration (ng/mL) Pre-Extraction Post-Extraction Pure drug 
2000 54.425 51.413 52.442 
2000 54.840 51.791 51.198 
2000 54.763 52.472 51.948 
2000 55.876 52.765  
2000 55.759 51.163  
Mean 55.13 51.92 51.86 
SD 0.65 0.68 0.63 
%CV 1.17 1.32 1.21 
 
Table 3-6 (c) Absolute response for samples with pre- and post-extraction addition of 
sorafenib, and pure drug solutions for low concentrations 
Nominal Response for Response for Response for  
Concentration (ng/mL) Pre-Extraction Post-Extraction Pure drug 
10 1274.20 1198.67 1663.05 
10 1426.61 1287.96 1687.25 
10 1519.74 1315.42 1593.29 
10 1418.18 1369.95  
10  1450.91  
Mean 1409.68 1324.58 1647.86 
SD 101.37 93.93 48.79 
%CV 7.19 7.09 2.96 
 
 
 
 62
Bioanalytical Method   Chapter 3 
 63
Table 3-6 (d) Absolute response for samples with pre- and post-extraction addition of 
sorafenib, and pure drug solutions for high concentrations  
Nominal Response for Response for Response for  
Concentration (ng/mL) Pre-Extraction Post-Extraction Pure drug 
2000 246338.73 208855.33 304687.41 
2000 232021.20 232372.84 296021.41 
2000 230365.72 239895.36 298377.06 
2000 204823.20 240550.92  
2000 237468.59 234026.25  
Mean 230203.49 231140.14 299695.29 
SD 15496.91 12958.38 4480.87 
%CV 6.73 5.61 1.50 
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Table 3-7 Recovery, matrix effect and process efficiency 
  Based on absolute response Based on response ratio† 
  Sorafenib concentration (ng/mL) Sorafenib concentration (ng/mL) 
  10 2000 10 2000 
A Mean extracted response (n = 5) 1409.68 230203.49 0.2635 55.13 
 RSD (%) 7.19 6.73 3.80 1.17 
B Mean unextracted response (n = 5) 1324.58 231140.14 0.2590 51.92 
 RSD (%) 7.09 5.61 3.93 1.32 
C Mean response in pure solvent (n = 3) 1647.86 299695.29 0.2627 51.86 
 RSD (%) 2.96 1.50 1.95 1.21 
      
 Recovery, A/B*100, (%) 106.42 99.59 101.74 106.18 
 Matrix effect, (1-B/C)*100, (%)  19.62 22.87 1.41 -0.12 
 Process efficiency, A/C*100, (%) 85.55 76.81 100.30 106.31 
 †Response ratio = peak area for sorafenib/ peak area for internal standard 
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3-7.6 Stability 
3-7.6.1 Freeze-thaw Stability 
The results for freeze-thaw stability are shown in Table 3-8. After three freeze-thaw 
cycles, mean observed concentrations deviated less than 6% for each QC concentration. 
This indicates that repeated freeze-thaw cycles do not considerably affect the sample 
integrity of sorafenib in human plasma. 
Table 3-8 Freeze-thaw stability for sorafenib in plasma samples 
Back predicted mean concentration (%RSD) & 
Percentage of corresponding mean concentrations at Cycle 0* 
Sorafenib 
concentration 
(ng/mL) Cycle 0 Cycle 1  Cycle 2 Cycle 3 
8  7.99 7.74 (7.34%) 7.7 (7.40%) 7.58 (7.57%) 
  96.87% 96.37% 94.87% 
160 159.46 153 (4.55%) 153.82 (1.80%) 151.54 (2.88%) 
  95.95% 96.46% 95.03% 
1600 1485.79 1463.12 (1.21%) 1479.46 (0.71%) 1438.94 (1.17%) 
  98.47% 99.57% 96.85% 
*Cycle 0 indicates the mean back-calculated concentrations reported in Table 3-5 
 
3-7.6.2  Autosampler Stability 
The results for autosampler stability study are presented in Table 3-9. The percent 
change from the initial analysis was less than 1% at all three QC concentrations. This 
indicated that the processed sorafenib samples were stable at 4ºC after placing in the 
autosampler tray for at least 24 h. 
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            Table 3-9 Autosampler or re-injection stability for sorafenib 
Mean response (% RSD) & 
Percent change from mean response at zero hour 
Sorafenib QC 
concentration 
(ng/mL) 0th h 7th h 24th h 
8 8.44 (0.02%) 8.36 (0.02%) 8.36 (0.03%) 
  -0.95% -0.95% 
160 172.36 (0.03%) 171.80 (0.03%) 171.88 (0.03%) 
  -0.32% -0.28% 
1600 1650.46 (0.01%) 1652.90 (0.01%) 1645.06 (0.01%) 
  0.15% -0.33% 
 
3-7.6.3  Short-term (bench-top) Stability 
The percent concentration change for samples, which were left outside at room 
temperature for 6 h versus the samples stored at -20 ˚C was -8.82 % and -1.79 %, 
respectively for 10 and 2000 ng/mL solutions. These changes were within the acceptable 
limits; hence sorafenib was considered stable in ACN/water:90/10 mixture for at least 6 h 
at room temperature.  
 
3-7.6.4  Long-term Stability 
The long-term stability study was not performed with this newly developed LC-MS/MS 
method. However, the previously published LC-MS/MS method reported less than 10% 
change in sorafenib concentration following storage at -70 ºC for at least 179 days (82). 
 
3-8 Conclusions 
In conclusion, a rapid and sensitive method for determination of sorafenib in human 
plasma was developed and validated. This method requires only a small volume of 
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plasma (50 µL) and has a short run time of 4 minutes. This method was found to meet or 
exceed all FDA guidelines for bioanalytical method validation. The quadratic calibration 
curve fit was found to be appropriate, and the results for selectivity, accuracy and 
precision, freeze-thaw cycle stability and short-term stability were within the acceptable 
limits. The method was later used for analysis of plasma samples from patients treated 
with sorafenib at 400 mg/Q12h and at 200 mg/Q12h as single agent or in combination 
with other chemotherapeutic agent. 
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CHAPTER FOUR 
CHARACTERIZATION OF PHARMACOKINETICS AND 
EXPLORATION OF POTENTIAL COVARIATES BY NON-
COMPARTMENTAL ANALYSIS – GENERAL LINEAR 
MODELING AND POPULATION PHARMACOKINETIC 
MODELING APPROACH FOR PATIENTS WITH SOLID TUMORS 
 
 
4-1 Introduction 
Sorafenib is approved in more than 60 countries for treatment of advanced renal cell 
carcinoma and/or advanced hepatocellular carcinoma, and is being extensively used 
clinically. Several clinical trials have studied pharmacokinetics, efficacy, toxicity and 
pharmacodynamic biomarkers for sorafenib. These clinical trials are summarized in 
appendix 1-1, 1-2 and 1-3. The clinically approved dose for sorafenib is 400 mg BID 
(49); however, both 200 and 400 mg BID doses have been studied in combination with 
other chemotherapies.  
 
High inter-patient variability has been reported for sorafenib pharmacokinetics based on 
both non-compartmental and population pharmacokinetic analysis. Results of non-
compartmental analysis from selected clinical studies are summarized in Table 4-1 (a) 
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and (b). The %CV on sorafenib exposures (area under the curve, AUC) and peak plasma 
concentrations (Cmax) ranged from 5-83% and 33-88% for 200 or 400 mg BID doses. The 
median time to peak plasma concentration (tmax) varied between 2-9.5 h. The 
heterogeneity in studied patient population, with respect to type of cancer, disease stage, 
patient demographics, co-morbidities, and physiological differences are few possible 
reasons for variability between studies (single dose pharmacokinetics and patient 
characteristics for selected sorafenib trials are described in Table 4-1 (a) and (b)).  
 
The variability in exposure (pharmacokinetics) for anticancer drugs may explain the 
variability in treatment associated toxicities or efficacy. Calvert and Egorin demonstrated 
that thrombocytopenia caused by carboplatin was directly related to its systemic exposure 
(AUC), which in turn was dependent on the renal clearance of the parent drug. They 
devised a formula for the estimation of desired AUC, based on creatinine clearance of 
individual patients, and advocated its use for estimation of optimal, likely non-toxic doses 
for cisplatin (85). Relling and colleagues demonstrated that therapeutic success with 
methotrexate in pediatric acute lymphoblastic leukemia (ALL) was related to achieving 
desired concentrations in plasma. They showed that monitoring of steady-state 
concentrations for methotrexate and dose adjustments based on that, helped in improving 
the treatment outcome (86). Stewart and colleagues demonstrated that hematologic 
toxicities due to topotecan were related to its systemic exposure in children with different 
types of refractory tumors (87). 
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Similarly, the variability in sorafenib exposures may also predict the differences in its 
efficacy and toxicities among patients. Our group had found that the incidence rate of 
hand-foot skin reaction (HFSR) increases with increased cumulative sorafenib doses, 
following the co-administration with bevacizumab, an anti-VEGF monoclonal antibody 
(60).  However, to best of our knowledge, there is no published evidence of a significant 
exposure-toxicity or exposure-response relationship for sorafenib. Treatment-associated 
toxicities for some drugs in the same tyrosine kinase inhibitor category as sorafenib have 
shown to be associated with drug plasma levels, such as association of severity of rash 
with erlotinib steady-state systemic exposures (i.e., AUCτss) (88). 
 
Several studies explored the markers to explain the variability in 
exposure/efficacy/toxicity in order to identify patients who are likely to benefit from 
treatment and those at higher risk of toxicities. Population pharmacokinetic-
pharmacodynamic analysis, a powerful approach to identify such pharmacokinetic and 
pharmacodynamic markers, has increasingly been used in various stages of drug 
development and is expected by the FDA for most new submissions for drug approval. 
One example of its use is the dosing recommendation for a widely used anticancer drug, 
docetaxel: it is recommended that patients with liver function markers values of greater 
than 1.5-times of ULN, should not be administered docetaxel (US FDA label) or doses 
should be reduced (European summary of product characteristics) (89, 90). These 
recommendations were based on population pharmacokinetic analysis which showed that 
abnormal liver function predicted low clearance for docetaxel, which in turn was related 
with higher incidences of febrile neutropenia (90). Dose adjustment for anticancer drugs 
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based on body size metrics such as BSA and BW has been in use for a long time. 
Increasingly, pharmacogenetic and molecular markers are also being employed to select 
the right treatment and right dose. For example, polymorphisms in metabolic enzymes 
have been established as a determinant of plasma levels for anticancer drugs such as 
DHFR for methotrexate, UGT1A1 for irinotecan, and TMPT for 6-mercaptopurine; and 
genetic variation in drug targets have shown to describe the differences in response or 
toxicity, such as influence of polymorphism in TS on response and toxicity for 5-
fluorouracil. Similarly, molecular markers such as EGFR expression for erlotinib and 
cetuximab, and c-kit expression for imatinib are currently being clinically used for 
selection of right treatment.  
 
Identification of markers for efficacy and toxicity are not only important to increase the 
clinical utility of new drug regimens, but also to avoid the false-negative conclusions 
about inefficacy of these drugs in certain tumor types. The latter is critical to facilitate the 
availability of drugs with activity in a selected patient population. 
 
We performed an exploratory analysis to identify the sources of variability in sorafenib’s 
systemic exposures (pharmacokinetics), efficacy and toxicity profiles. The heterogeneity 
in the patient population under study, with respect to type of cancer, demographics, 
(patho-) physiological and pharmacogenetic differences was evaluated as potential 
contributing covariates. Sorafenib pharmacokinetics was characterized for patients with 
mCRPC, NSCLC, CRC, ST and KS, by both non-compartmental and population 
pharmacokinetic modeling approaches, and covariates for pharmacokinetics parameters 
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were screened by general linear modeling (GLM) and population pharmacokinetics 
covariate analysis. The advantages and limitations of these approaches are discussed in 
sections 4-2 and 4-3. The methodologies used for these analyses along with results are 
described in this chapter. 
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Table 4-1 (a) Summary of patient characteristics and results of single-dose pharmacokinetics for selected sorafenib trials with a 400 
mg BID dose  
 
Cmax 
(mg/L)  
AUC0-12 
(h*mg/L) 
Tmax (h) 
Study† N 
Age(mean/range)
(years) 
  Male/ 
Female (%)
PK Sampling  
Schedule (h) GM %CV GM %CV Median Range 
Clark (39) 2 53.7 58:42 0,0.5,1,2,6,10,12,24 2.3 37 18.0 5 9.2 2.0-12.0
Moore (40) 4 33-70 41:59 NR 2.9 68 21.8 59 2.9 1.0-12.3
Strumberg (91) 5 18-75 64:36 NR 9.4 44 71.7 43 3.0 0.0-12.0
Awada (38) 9 42-79 57:43 0,2,3,4,6,12,24 3.0 NR 24 NR NR 0.0-12.0
NR: Not reported 
 
 
Table 4-1 (b) Summary of single-dose pharmacokinetics for a 200 mg BID dose of sorafenib from literature. Age range, gender 
proportion, cancer type and pharmacokinetic sampling for these patients were same as mentioned in Table 4-1 (a) 
 
  Cmax (mg/L) AUC0-12 (h*mg/L) Tmax (h) 
Study† N GM %CV GM %CV Median Range 
Clark (39) 4 0.8 86 6.1 NR 6.0 2.0-6.0 
Moore (40) 4 1.3 34 10.9 38 5.0 2.0-12.0 
Strumberg (91) 3 2.8 88 16.1 83 2.0 0.0-4.0 
Awada (38) 10 3.6 NR 24.9 NR NR 0.0-12.0 
†
 Patients with different solid tumors were enrolled on these trials. PK: pharmacokinetics, Cmax: peak plasma concentration, AUC: area 
under the curve, Tmax: time to peak plasma concentration, GM: geometric mean, CV: coefficient of variation, NR: Not reported. 
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4-2 Non-compartmental pharmacokinetic analysis 
Non-compartmental pharmacokinetic analysis describes the plasma concentration-time 
profiles in terms of exposure metrics such as area under the curve (AUC), peak plasma 
concentration (Cmax) and time to peak plasma concentration (tmax) etc. The key parameter 
for non-compartmental analysis is the total systemic drug exposure or AUC, which is 
calculated by trapezoidal rule without assuming any specific compartmental model; 
however, estimates can be highly dependent on the blood sampling schedule.  
 
In non-compartmental analysis, estimation of pharmacokinetic parameters are based on a 
two-stage approach, where (i) exposure metrics are calculated separately for each 
individual (or each plasma concentration – time profile), and (ii) those are then pooled 
together to calculate the central tendency (e.g., mean) and dispersion (e.g., %CV) from 
their distributions. These parameters are calculated independently for each dose level on 
every occasion, after giving equal weight to each individual. Separate analysis for each 
dose level or occasion may result in smaller subgroup sample sizes, which may lead to 
poor precision in estimated mean parameters. 
 
The estimated individual pharmacokinetic parameters are then used to screen the 
covariates by general linear modeling approach, which is described later in this chapter. 
Advantages and limitations of non-compartmental analysis in context of data collected 
for sorafenib clinical trials are described below: 
 
4-2.1 Advantages of non-compartmental analysis 
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1. Non-compartmental analysis is computationally very simple. 
 
2. Estimation of pharmacokinetic parameters using non-compartmental analysis is 
generally based on observed plasma concentration-time profiles after a single dose, 
which is usually less variable than plasma concentration-time profiles after multiple 
doses. If we draw a parallel between non-compartmental analysis and probe substrate 
study, in non-compartmental analysis a single dose of sorafenib (probe substrate) is 
administered to understand the behavior or response of the system. Such responses (in 
this case pharmacokinetics of sorafenib) can then be compared among subjects to 
answer the questions of our interest, which are: how differently people behave to 
single dose of sorafenib and what patient specific factors can help in explaining that 
variability. However, more reliable estimates of AUCs are required to get the 
dependable answers to these questions. 
 
3. Non-compartmental analysis does not involve any compartmental pharmacokinetic 
assumptions. 
 
4-2.2 Limitations of non-compartmental analysis 
1. With sparse data, non-compartmental analysis is not possible. 
  
2. Data from multiple occasions collected for same patient cannot be used together to 
calculate the overall pharmacokinetic parameters. 
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3. For reliable estimation of AUCs, samples should be collected upto at least 2-3 half-
lives, which was not possible with current administered dosing schedule of sorafenib. 
Sorafenib’s half-life ranges between 25-48 h, and it was administered twice a day at 
200/400 mg dose level. Although, population pharmacokinetic analysis can be used 
with sparse samples, but we would need pharmacokinetic samples upto 2-3 half-lives 
to obtain the unbiased individual estimates of pharmacokinetic parameters. 
 
4. It is not possible to test various ‘what-if’ scenarios, because we can not perform 
simulations with non-compartmental analysis approach. 
 
5. In non-compartmental analysis, mean pharmacokinetic parameters are calculated by 
giving equal weight to data from all the individuals. It does not account for 
differences in uncertainty at each individual level and at each observation level. 
 
4-3 Population pharmacokinetic analysis 
This approach is suitable for both rich and sparse data, which can be combined together 
even if they represent different dose levels or different routes of administration.  
Population pharmacokinetic analysis uses a mixed effect modeling approach and requires 
an explicitly specified pharmacokinetic model prior to analysis. It is a one-stage analysis 
approach, in which complete study population, rather than individuals, are considered as 
a unit of analysis for estimation of pharmacokinetic parameters, their distributions and 
their relationship with covariates within the population. Mixed effect modeling refers to 
evaluation of variability in two forms, fixed effect (measurable or attributable variability) 
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and random effect (unobservable or non-attributable variability), examples of which are 
shown in Fig. 4-1.  
 
Most of the limitations of non-compartmental analysis can be overcome by population 
pharmacokinetic analysis. Specific advantages and limitations of this approach, in context 
of sorafenib data, are as below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4-1 Examples of sources of variability in population pharmacokinetic analysis 
 
4-3.1 Advantages 
1. This approach combines the data from different occasions (plasma concentration 
–time profiles after single dose and at steady-state), and from different dose levels 
(200 or 400 mg BID) simultaneously, for the estimation of population and 
individual pharmacokinetic parameters. Contrary to non-compartmental analysis, 
the estimated variability and precision on population pharmacokinetic parameter 
estimates are not biased by small sample size in population subgroups assuming 
Sources of 
variability 
Fixed effect or 
measurable variability 
Random effect or 
unobservable variability 
Demographic variables: Weight, 
gender, age etc; (Patho-) physiological 
variables: Liver and kidney function 
markers; Pharmacogenetic variables: 
Polymorphisms in metabolic enzymes 
and drug targets 
Biological variability 
Inter-individual variability: 
Residual error (model m
analytical method errors, intra-
individual variability and inter-occasio
variability)  
isspecification, 
n Statistical variability 
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random sampling. Also, the results are more generalized than the non-
compartmental analysis, because a larger number of subjects are evaluated. 
 
2. Population pharmacokinetics allows estimation of physiologically relevant 
parameters such as clearance (CL) and volume of distribution (Vd) for each 
subject, even if only a few samples are collected (i.e. sparse sampling). With 
current sorafenib data, even though terminal phase samples were not collected, 
parameters like CL and Vd could still be calculated because rich steady-state data 
were available for approx. 30% of patients. However, these estimates may be 
biased towards patients with steady-state observations. 
 
3. Population pharmacokinetic modeling gives us the flexibility to perform 
simulations, which helps in testing various ‘what-if’ scenarios. This property not 
only helps in clinical decision making but may also in optimizing the clinical trial 
design.  
 
4. Differences in uncertainty at each individual level (by estimation of inter-
individual variability) and at each observation level (by estimation of residual 
varability) are explicitly accounted for during population pharmacokinetic 
analysis. This technique gives more weight to subjects with rich (more precise) 
data than the subjects with sparse sampling (or data with poor precision).  
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5. It is a powerful approach to identify the individual-specific characteristics that 
influence the disposition of the drug. Both individual specific and population 
pharmacokinetics parameters are calculated.  
 
4-3.2 Limitations 
1. Population pharmacokinetic analysis is computationally intensive and performer 
requires specific training in technique and use of software. 
 
2. It is based on compartmental assumptions, and usually one model is used for all 
individuals within the study population. However, that may not always be true. 
Differences may exist in drug disposition between subjects, for example, one 
person can have a distinct entero-hepatic recycling phenomenon while others may 
have a limited or no entero-hepatic disposition for the same drug. Results may 
also be biased by non-random sampling or sampling at pre-specified time-points. 
 
4-4 Characterization of pharmacokinetics by non-compartmental analysis 
There were four objectives of non-compartmental analysis: 
1). Characterization of sorafenib exposures in mCRPC, NSCLC, CRC, ST and 
KS. 
2). Evaluation of impact of bevacizumab co-administration on sorafenib 
pharmacokinetics 
3). Evaluation of impact of ritonavir co-administration on sorafenib 
pharmacokinetics 
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4). Screening of potential covariates for exposure parameters of sorafenib by 
general linear modeling  
 
4-4.1 Methods 
4-4.1.1 Patients and study design 
Samples collected from 106 patients with solid tumors enrolled in 5 phase I/II sorafenib 
clinical trials at NCI were used for non-compartmental analysis. These trials evaluated 
the efficacy or safe dose of sorafenib, as a single agent or in combination therapy, for 
mCRPC, NSCLC, CRC, KS and other ST. These were single-arm, single-center, open-
label trials. The clinical protocols were approved by the Institutional Review Board, and 
all the patients provided informed consent before participation in these trials. Enrollment 
was restricted to patients with normal organ function and age 18 years and older. Patients 
with prostate caner and lung cancer received clinically approved dose of sorafenib, i.e., 
400 mg BID as single agent, and patients with CRC were treated with 400 mg BID 
sorafenib and cetuximab (400 mg/m2 loading dose in week 1, followed by 250 mg/m2 IV 
weekly) combination. Patients with solid tumors were treated with a combination of 200 
mg BID sorafenib and 5 mg/kg bevacizumab IV biweekly. The design of trial enrolling 
patients with solid tumor allowed the evaluation of impact of bevacizumab co-
administration on sorafenib pharmacokinetics, which is also described in results section 
4-4.2. Patients with KS were enrolled into a dose escalation trial where they received 
sorafenib as either single agent (at a starting dose of 200 mg BID) or in combination with 
ritonavir (starting dose for sorafenib was 200 mg QD). Because pharmacokinetics was 
drawn for patients receiving sorafenib with and without ritonavir, impact of ritonavir co-
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administration on sorafenib pharmacokinetics was also evaluated. Day 1 
pharmacokinetics for KS trial was not drawn; hence it was not included in covariate 
screening by non-compartmental analysis. 
 
4-4.1.2  Sample collection 
Samples for pharmacokinetic analysis for these patients were collected after initial doses 
and at steady –state. The dosing and sampling schedules for trials under consideration are 
shown in Table 4-2. Serial samples were drawn upto 12 hr after first dose and one 
sample was drawn 12 hr post-second dose. Blood samples were collected in heparinized 
tubes and were centrifuged at 2400 rpm for 5 minutes. Following that plasma was 
aliquoted and stored at -80 ◦C until the time of bio-analysis for sorafenib.    
 
4-4.1.3 Sample bio-analysis 
Samples were analyzed using a validated method based on liquid chromatography with 
tandem mass spectrometric detection, as described in chapter 3. 
 
4-4.1.4 Genotyping analysis 
Details of methods used for genotyping analysis are described in chapter 7. In brief, 
genomic DNA was extracted from serum or plasma or whole blood samples using 
QiaBlood extraction kit (Qiagen, Valencia, CA) and stored at 4 ◦C. Genotyping was 
performed via direct sequencing for CYP3A4*1B, CYP3A5*3, UGT1A9*3, UGT1A9*5, 
VEGFR2 H472Q and VEGFR2 V297I single nucleotide polymorphisms (SNPs). Single 
or nested PCR reactions were performed, which were followed by sequencing PCR using 
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Big Dye Terminator Cycle Sequencing kit. The PCR primers used for sequencing are 
shown in Table 4-3 Sequencing was performed on ABI Prism 3130 xl Genetic Analyzer 
(Applied BioSystems).  
 
4-4.1.5 Pharmacokinetic analysis 
Non-compartmental analysis was performed separately for plasma concentration – time 
profiles from day 1 and for steady-state. Plasma concentration – time profiles for only a 
single dosing duration (upto 12 h) can be used for estimation of exposure metrics by non-
compartmental analysis; therefore, concentrations at 12th h post-second-dose were not 
considered. The samples for which estimated concentrations were below the limits of 
quantification (5 ng/mL) were assigned half-of-the LOQ values (2.5 ng/mL). The time-
points for which samples were missing were not included in the analysis. 
Pharmacokinetic parameters, including area under the curve (AUC 0-12), peak plasma 
concentration (Cmax) and time to peak plasma concentration (tmax) for day 1 and at steady 
state (if applicable) were calculated by using the WinNonlin professional software 
version 5.0 (Pharsight Corporation, Mountain View, CA, USA). Accumulation ratios, if 
applicable, were calculated by comparison of the exposures for a dosing interval at 
steady-state (AUC0-12τSS) with exposures after first dose (AUC0-12τSD). 
 
4-4.1.6 Statistical analysis 
Distribution of these parameters across trials was compared by assessing the central 
tendency (mean, median) and dispersion (standard deviation and 95% confidence 
interval). The distribution of pharmacokinetic parameters was skewed; hence, log-
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transformation was performed to stabilize the variance and to make the distribution more 
normal. The calculated summary statistics were back-transformed to normal scale for 
description; the final reported parameters were geometric mean (GM), %CV and 95% CI. 
The statistical analyses were performed using JMP 8.0 (SAS Institute Inc., Cary, NC, 
USA) statistical software.   
 
4-4.2 Results and Discussion 
The plasma concentration – time profile after administration of initial doses and at 
steady-state are shown in Fig 4-2 (a), (b) and (c), and pharmacokinetic parameters and 
their distributions after administration of first dose and at steady-state are summarized in 
Table 4-4 (a) and (b).    
 
The geometric mean for Cmax for 400 mg BID sorafenib dose ranged from 1.8 to 2.7 
mg/L with %CV ranging from 46-87%, and the geometric mean for AUC0-12 varied 
between 13.9 to 19.6 mg/L*h with %CV of 45-79%. For the 200 mg BID dose, geometric 
means for Cmax and AUC0-12 were 1.3 mg/L and 10.2 mg/L*h, respectively with % CV of 
~65%. The Tmax ranged between 2-12 h, with median of 6 to 8 h. The high inter-subject 
variability in these pharmacokinetic parameters was in accordance with previously 
reported results (Table 4-1). Accumulation ratios for 200 and 400 mg doses were 4.14 
(range 1.09 – 27.97; Table 4-5 (a)) and 3.23 (range 0.74-16.83; Table 4-5 (b)), 
respectively, which was expected based on sorafenib’s half-life of 25-48 hr (49). The 
potential sources of variability in these pharmacokinetic parameters are explored in 
section 4-5, and effect of this variability on efficacy and toxicity are evaluated in chapters 
5 and 6.  
Non-compartmental & Population Pharmacokinetic Analysis                       Chapter 4 
Table 4-2. The dosing and pharmacokinetic sampling schedule for sorafenib trials 
 
Trial 
Name 
Tumor type Stage of 
clinical trial 
Sorafenib dosing schedule 
(Dose in mg) 
Sampling schedule 
Bay-mCRPC mCRPC Phase II 400 BID , 28 days CC* C1D1: 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24 h 
Bay-Bev various 
solid tumors 
Phase I 200 BID, 28 days CC* Arm A, C1D1, C2D1; Arm B, C2D1: 
0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24 h 
Bay-NSCLC NSCLC Phase II 400 BID , 28 days CC* C1D1, C1D15: 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24 h
Bay-KS KS Phase I 200 QD/200 BID/400 BID , 
28 days CC* 
C1D7: 0, 1, 2, 4, 6, 8, 12, 16, 24 h 
Bay-CRC CRC Phase II 400 BID , 28 days CC* C1D1: 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24 h 
*CC: Continuous cycle 
mCRPC, metastatic castrate resistant prostate cancer, NSCLC, non-small cell lung cancer, KS, Kaposi’s sarcoma, CRC, colorectal 
carcinoma, C1D1, cycle 1 day 1, C2D1, cycle 2 day 1, C1D15, cycle 1 day 15. One cycle was of four week duration. 
 
Schematic presentation of sampling schedule shown in Table 4-2 
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Table 4-3 List of PCR primers for CYP3A4*1B, CYP3A5*3C, UGT1A9*3, UGT1A9*5, VEGFR2 H472Q and VEGFR V297I SNPs 
Variant PCR 
Type 
Forward (F) Primer 
(5′-3′) 
Reverse (R) Primer 
(5′-3′) 
Annealing 
temperature
CYP3A4*1B Single F1:CTGTGTGAGGAGTTTGGTGAG 
F2:GTTCTGTCTGTCTGGGTTTGG 
R1:TGGAAGAGGCTTCTCCACCTTG 
R2:CACACCACTCACTGACCTCCT 
64º C 
CYP3A5*3C Nested F1:TCCTCAGAATCCACAGCTG 
F2:AGCACTTGATGATTTACCTGCC 
F3:AGTGGCATAGGAGATACCCAC 
R1:TAAACTTCACTAGCCCGATTCT 
R2:CCAGGAAGCCAGACTTTGATC 
R3:AGGTTCTAGTTCATTAGGGTG 
64º C 
UGT1A9*3 Nested F1:TTGATAACTGTGGCTTAATTGTTGCC 
F2: ATTTCTCCCTCCCCTCCGTG 
F3: AGAAATAGCCTCTGAAATTCTCC 
R1:CCAAAGGTGAAGTATTCTTAAGG 
R2:GTGCTAAAGGAGAGATAACTTAC 
R3:TCCCTGATGGCAGTTGATACCA 
64º C 
UGT1A9*5 Nested F1: TCCCTGATGGCAGTTGATACCA 
F2: TGATGGCTTGCACAGGGTGG 
F3: ACCAGCCCCCTTCCTCTATG 
R1:AGTGGCAAAGTATTCCCCTGG 
R2:CAAAAATGTCATTGTATGAACCCA
R3:GCATGACTACAACCACCTCATG 
64º C 
VEGFR2 
Val297Ile 
(rs2305948) 
Single/ 
Nested 
F1: GGTTTGAACCCAAGTTCCTG 
F2: TGGCCTCCCTAACAAGAAAA 
F3: CCCTGACAAATGTGCTGTTC 
R1: CACTTTCACCACGTGAGGTTT 
R2: TGGTGTCCCTGTTTTTAGCA 
R3: TGCTGTGCTTTGGAAGTTCA 
60º C 
VEGFR2 
Gln472His 
(rs1870377) 
Single/ 
Nested 
F1: CAGAATCACCCTACACAGATGC 
F2: TGGTACTGCTAAAAGTCAATGG 
F3: CCTGGAAGTCCTCCACACTT 
R1: TTCCCAGAATAGCTGCTTCC 
R2: GGCTGCGTTGGAAGTTATTT 
R3: AACCAAAGTCTGAATCTTTTCCTT 
60º C 
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Table 4-4 (a) Summary of non-compartmental pharmacokinetic parameters after single dose of sorafenib 
 
   Cmax (ng/mL) AUC0-12 (ng/mL*h) Tmax (h) 
Study Dose N GM (x103) %CV 95%CI (x103) GM (x103) %CV 95%CI (x103) Median Range 
Bay-mCRPC 400 mg BID 46 1.8 87 1.4-2.4 13.9 79 10.7-18.1 6.4 2-12.2 
Bay-Bev 200 mg BID 24 1.3 64 1-1.8 10.2 69 7.3-14.4 8.2 2-12.8 
Bay-NSCLC 400 mg BID 18 2.7 67 2-3.8 19.6 79 13.8-27.8 6 2-12.2 
Bay-KS 200 mg BID NC NC NC NC NC NC NC NC NC 
Bay-CRC 400 mg BID 18 2.1 46 1.6-2.7 14.4 45 10.9-19 8 2-12.2 
 
Table 4-4 (b) Summary of non-compartmental pharmacokinetic parameters at steady-state for sorafenib 
 
   Cmax (ng/mL) AUC0-12 (ng/mL*h) Tmax (h) 
Study Dose 
Cycle (C), 
Day (D) N GM(x103) %CV 95%CI (x103) GM(x103) %CV 95%CI (x103) Median Range 
Bay-mCRPC 400 mg BID NC NC NC NC NC NC NC NC NC NC 
Bay-Bev 200 mg BID C2, D1 9 4.1 64 2.6-6.3 35.1 59 22.6-54.5 4 0.4-8.1
Bay-NSCLC 400 mg BID C1, D15 17 8.4 54 6-11.8 67.2 50 49.6-91 4 0.3-12 
Bay-KS 200 mg BID C1, D7 2 7.4 47 NC 64.2 38 NC NC 1, 12.0
Bay-CRC 400 mg BID NC NC NC NC NC NC NC NC NC NC 
Bay-mCRPC: Phase II trial of sorafenib in metastatic castrate resistant prostate cancer, Bay-Bev: Phase I trial of sorafenib and 
bevacizumab combination in patients with solid tumors, Bay-NSCLC: Phase II trial of sorafenib in non-small cell lung cancer, Bay-
KS: Phase I trial of sorafenib in patients with Kaposi’s sarcoma, Bay-CRC: Phase II trial of sorafenib and cetuximab combination in 
patients with colorectal cancer, Cmax: Peak plasma concentration, AUC0-12: Area under the curve for 0 to 12 h duration, Tmax: Time to 
peak plasma concentration, GM: Geometric mean, CV: Coefficient of variation, CI: Confidence interval, NC: Not calculated 
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Fig 4-2 (a) Measured plasma concentration – time profiles (normal scale) for sorafenib after administration of initial doses in patients 
with (A) metastatic castrate resistant prostate cancer (mCRPC), (B) solid tumors (ST), (C) colorectal cancer (CRC) and (D) non-small 
cell lung cancer (NSCLC) 
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Fig 4-2 (b) Measured plasma concentration – time profiles (log scale) for sorafenib after administration of initial doses in patients with 
(A) metastatic castrate resistant prostate cancer (mCRPC), (B) solid tumors (ST), (C) colorectal cancer (CRC) and (D) non-small cell 
lung cancer (NSCLC) 
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Fig 4-2 (c) Measured plasma concentration – time profiles for sorafenib after administration of multiple doses in patients with solid 
tumors (ST) and non-small cell lung cancer (NSCLC) (A) in normal scale, (B) in log scale  
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Table 4-5 (a) Accumulation ratios for patients with solid tumors treated with sorafenib 
and bevacizumab combination 
Pt ID AUC0-12SS~day 30 AUC0-12SD AUC0-12SS/AUC0-12SD Ratio 
 (ng/mL*hr) (ng/mL*hr)  
1 88856.4 17431.7 5.1 
2 48308.9 17177.4 2.8 
3 24314.2 4491.8 5.4 
4 22788.3 21154.0 1.1 
6 24161.6 8208.9 2.9 
7 20249.3 7760.0 2.6 
8 35140.0 1256.9 28.0 
  Median 2.9 
  Range (1.1 – 28.0) 
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Table 4-5 (b) Accumulation ratios for patients with non-small cell lung cancer treated 
with sorafenib  
Pt ID AUC0-12SS~day 15 AUC0-12 SD AUC0-12ss/AUC0-12SD  
 (ng/mL*hr) (ng/mL*hr)  
1 92989.9 27989.1 3.3 
2 68471.9 15018.9 4.6 
3 70208.8 37238.8 1.9 
4 75951.9 17063.7 4.5 
5 103173.6 91943.2 1.1 
6 110654.2 41098.0 2.7 
7 81383.9 9633.6 8.4 
8 25165.9 30578.2 0.8 
9 118102.0 7016.6 16.8 
10 27549.4 37039.9 0.7 
11 105102.4 6468.6 16.2 
12 74349.5 35595.6 2.1 
13 175654.6 12531.3 14.0 
14 36481.0 15375.4 2.4 
15 31176.5 12440.3 2.5 
16 96662.3 24411.4 4.0 
17 29702.2 9199.1 3.2 
  Median 3.2 
  Range 0.7 – 16.8 
 
4-4.2.1 Effect of bevacizumab co-administration on sorafenib pharmacokinetics 
The design of this phase I trial conducted to establish the safe dose of sorafenib and 
bevacizumab combination in patients with solid tumors is shown in Fig 4-3. Patients 
were recruited in either arm A or arm B. Patients on arm A received sorafenib alone for 4 
weeks followed by treatment with sorafenib and bevacizumab combination, while 
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patients on arm B first received bevacizumab for 4 weeks followed by combination 
therapy. Thus, the effect of bevacizumab co-administration can be studied by comparing 
the sorafenib exposure parameters between arm A, cycle 1, day 1 and arm B, cycle 2, day 
1.  
 
The plasma concentration – time profiles for sorafenib from patients enrolled in these two 
arms are shown in Fig 4-4, with a mean plasma concentration (± SD) and time designated 
respectively on the ordinate and abscissa. The mean plasma concentrations (point 
estimates) were higher for patients on arm B than arm A; however, the differences were 
not statistically significant. The AUC0-12 and Cmax were also not statistically different 
between these two arms (p values 0.2391 and 0.3058, respectively). These results indicate 
that co-administration of bevacizumab may not influence sorafenib exposures. 
 
Fig 4-3 Schematic representation of phase I trial evaluating the maximum tolerable dose 
of sorafenib and bevacizumab combination in patients with solid tumors 
 
 
 
Patients 
Arm A 
Sorafenib 200 mg BID + 
Bevacizumab 5 mg/kg IV, 1st and 15th day 
28 days cycle of combined therapy 
Sorafenib 200 mg BID 
Continuous 28 days cycle 
Bevacizumab 5 mg/kg IV 
1st and 15th day
Cycle 
Arm B 
Cycle 2 & onwards 
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Fig 4-4  Comparison of plasma concentration – time profiles for sorafenib administered 
as single agent (Arm A) and in combination with bevacizumab (following prior 
administration of bevacizumab for 4 weeks) (Arm B). 
 
4-4.2.2 Effect of ritonavir co-administration on sorafenib exposures 
Another phase I trial included in current analysis evaluated the safe dose of sorafenib in 
patients with KS, when administered with or without ritonavir. The design of this is 
shown in Fig 4-5 below. Patients with AIDS-related KS received sorafenib in 
combination with ritonavir. Ritonavir is known to be a strong inhibitor of CYP3A4 
enzyme, which is also one of the metabolic enzymes for sorafenib. Because of the 
potential for drug interaction these patients were started at a lower dose of sorafenib, i.e., 
200 mg QD. Patients not receiving ritonavir started at 200 mg BID doses, half-of-the 
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clinically approved 400 mg BID dose. Sorafenib pharmacokinetics between these two 
groups was compared to evaluate the impact of ritonavir co-administration on disposition 
of sorafenib. Assuming that steady-state for sorafenib is reached by day 7 based on its 
half-life of 25-48 h; sorafenib exposures for a dosing interval at steady-state (AUC0-τ, SS) 
would be comparable in these two groups. In absence of any interaction, AUC0-12, SS for 
sorafenib 200 mg BID without ritonavir should not be significantly different from AUC0-
24, SS for sorafenib 200 mg QD with ritnovair. However, the limitation of this comparison 
was small sample size; so far only 8 subjects have been recruited in this trial.  
 
6 patients in each 
 
Fig 4-5 Schematic representation of phase I trial evaluating the maximum tolerable dose 
of sorafenib in patients with Kaposi’s sarcoma 
Patients 
HIV- related KS 
Receiving Ritonavir 
HIV- related or classic KS 
Not receiving Ritonavir 
200 mg QD 
200 mg BID 
400 mg BID 
200 mg BID 
400 mg BID 
Sorafenib + 
Ritonavir 
Only 
Sorafenib 
MTD: Dose preceding that at which 2 of 6 
patients experience DLT 
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Fig 4-6 (A) Comparison of plasma concentration-time profiles for sorafenib 200 mg BID 
administered as single agent versus sorafenib 200 mg QD administered with ritonavir.  
 
Fig 4-6 (B) Comparison of sorafenib exposures, AUC0-12, SS for sorafenib 200 mg BID 
administered as single agent versus AUC0-24, SS for sorafenib 200 mg QD administered 
with ritonavir.  
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Comparison of plasma concentration-time profiles for patients who received sorafenib 
with or without ritonavir demonstrated that concentrations for 200 mg BID dosing 
regimen are higher than 200 mg QD administration (Fig 4-6 (A)), which is as expected. 
Comparison of exposure metrics in these groups revealed that exposures after co-
administration with ritonavir (AUC0-24, SS) were not significantly different from exposures 
after administration as single agent (AUC0-12, SS) (Fig 4-6 (B)).  Ritonavir co-
administration appeared to have no significant effect on sorafenib exposures. These 
results were consistent with findings from another prospective DDI clinical trial, which 
demonstrated that sorafenib exposures were not significantly affected by co-
administration with ketoconazole, also a potent CYP3A4 inhibitor (37). 
 
4-5  Exploratory covariate screening by non-compartmental analysis-general 
linear modeling approach 
As shown in Table 4-1 (a) and (b), and Table 4-4, the pharmacokinetics for orally 
administered sorafenib was highly variable among patients with various types of solid 
tumors. An exploratory analysis was conducted to identify the clinically important 
covariates that may explain the inter-patient differences in systemic exposures and peak 
plasma-concentrations for sorafenib. The subsets of patients with full pharmacokinetic 
profiles from prostate cancer, colorectal cancer, lung cancer and solid tumor trials were 
used for this analysis. Patients from KS trial were not included in this analysis, because 
no samples were collected after administration of initial doses (only day 7 samples were 
collected) and also sorafenib was co-administered with ritonavir, which has a potential of 
drug-interaction with sorafenib. Although no interaction was observed with current small 
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sample size (section 4-4.2.1); but that needs to be confirmed with larger sample size. We 
used demographic (age, gender, weight, BSA and ethnicity), clinical or laboratory (AST, 
ALT, albumin, alkaline phosphatase, total protein, total bilirubin, serum creatinine and 
creatinine clearance) and pharmacogenetic (genetic variation in CYP3A4, CYP3A4, 
UGT1A9 and VEGFR2) variables as covariates in this exploratory analysis. The results 
of this non-compartmental covariate analysis were used as guidance for selection of 
covariates for population pharmacokinetic analysis.  
 
4-5.1 Methods 
4-5.1.1 Pharmacokinetic metrics 
Covariate analysis was performed for the pharmacokinetic metrics, AUC0-12 and Cmax, 
which are summarized in Table 4-4. Patients on these trials were administered either 200 
or 400 mg BID sorafenib doses. In order to correct for the different dose levels, the 
calculated pharmacokinetic metrics were normalized by the amount of administered dose, 
assuming linear pharmacokinetics as previously shown for dosage range of 50 to 400 mg 
BID (35). Both dose-normalized AUC0-12 (AUC/D) and Cmax (Cmax/D) distributions 
were skewed to the right, as shown in Fig 4-7. Hence, these metrics were ln-transformed 
to obtain a reasonably symmetric distribution, which also satisfied the assumptions for 
parametric statistical tests. Further analysis was performed with ln-transformed values.  
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Fig. 4-7 Distribution of dose normalized Cmax and AUC0-12. (A) and (B) – normal scale 
values, (C) and (D) – ln-transformed values. In right margins, box and whisker plots are 
shown, where center of the diamond represents mean, the solid horizontal line in the box 
represents median, edges of the box depict inter-quartile range and the flanking whiskers 
represents the data within the 1.5 times inter-quartile range. The points outside the 
whiskers are considered outliers. 
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4-5.1.2 Assessment of covariates 
The possible (expected) mechanistic impact of candidate covariates (which were screened 
to explain the inter-individual variability) on sorafenib pharmacokinetics are summarized 
in Table 4-6. The administered dose and trial were included as covariates to assess 
pharmacokinetic linearity and differences in pharmacokinetic parameters across clinical 
trials. Other covariates included in this analysis represented standard demographic 
information, hepatic and renal function markers, and genetic marker variations in studied 
population.  
BSA was calculated using the DuBois and DuBois formula: 
425.0725.0 )(*)(*20247.0 kgweightmheightBSA =  
where height and weight were measured in meter and kilogram units. 
Renal function was estimated as creatinine clearance (CLCr), which was calculated using 
the Cockroft-Gault equation: 
SCr
WeightAgeGenderCLCr *72
)*)140((* −=  
where weight was measured in kilogram units, age in years and SCr in g/dL. 
The gender variable took value of 1 for males and 0.85 for females. CLCr values above 
150 mL/min were right truncated, because values above 150 mL/min are physiologically 
unlikely. 
Hepatic and renal function markers were evaluated both as continuous (actual lab values) 
and nominal variables (High (H), Normal (N) and Low (L)). The classification as 
nominal variables was performed to differentiate the patients with ‘normal’ and 
‘abnormal’ organ function, and was considered to be more helpful in clinical decision 
making. 
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Genetic variation in the metabolic enzymes for sorafenib, namely CYP3A4, CYP3A5 and 
UGT1A9, were also evaluated as covariates. Genetic variability in the drug target for 
sorafenib, namely VEGFR2, was also evaluated as covariate for exposure metrics, 
although, no mechanistically plausible relationship was expected.  
 
Distributions of these covariates were assessed for any imbalances, skewness or 
collinearity. For nominal covariates, frequency distributions of subgroups were compared 
for imbalances. For continuous covariates, measures of central tendency (mean, median) 
and dispersion (standard deviations and range) were evaluated for skewness, uni-
modality and fold range. Collinearity was assessed by multivariate correlation (between 
continuous variables) or one-way ANOVA (between nominal and continuous variables). 
The statistical analysis was performed using JMP 8.0 (SAS Institute Inc., Cary, NC, 
USA) statistical software.
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Table 4-6 List of covariates and their expected (possible) effects on sorafenib pharmacokinetics/exposures. 
 
S.N. Category Covariate Name  Expected effect on sorafenib exposures 
1 Demographic Body weight (BW) Increase in BW may decrease AUC and Cmax, because of increase in metabolic 
clearance (CL) and volume of distribution (Vd). 
2  Body surface area 
(BSA) 
It is a composite matrix of BW and height. Effects on pharmacokinetics are 
expected to be similar to BW, i.e., decrease in AUC and Cmax with increase in 
BSA. 
3  Age Aging may cause reduction in liver mass, liver blood flow, plasma protein binding 
and activity of liver metabolic enzymes, which would affect the CL and/or Vd 
(66), and may increase the AUC and Cmax. 
4  Height Height does not change after reaching the adulthood. Variation in height among 
adult individuals would not have any additional effect in addition to what are 
expected based on changes in BW and BSA. 
5  Gender Generally, females have lower BW, lower Vd and were also found to have higher 
expression of CYP3A4 mRNA and CYP3A4 enzymes (66). These differences 
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may affect the metabolic CL and Vd of sorafenib, resulting in higher AUC and 
Cmax for females compared to males. 
6  Ethnicity Expression and activity of drug metabolic enzymes and drug transporters may 
vary among patients with different ethnicities, which may alter the AUC and/or 
Cmax. 
7 Liver function 
markers 
Albumin It is a marker of liver synthetic function. Lower than normal levels may suggest 
dysfunction in synthesis or elimination organs for albumin, such as liver or 
kidney. These dysfunctions may reduce the sorafenib CL, resulting in increased 
AUC. However, poor nutritional states leading to protein catabolism may also 
lower albumin levels. Sorafenib’s pharmacokinetics may also get affected because 
of its high affinity towards albumin, where increase in fraction of free drug 
(because of lower albumin levels) may increase its plasma clearance or 
distribution to peripheral tissues, resulting in decrease in AUC and Cmax. 
8  Total protein Total protein comprises of albumin (major proportion) and globulins (α,β,γ); 
hence change in its level may alter the proportion of free drug available for drug 
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effect or undergoing metabolism. Effects on AUC and Cmax will be similar to that 
described for albumin. 
9  ALT and AST These are leak enzymes which tell us about the integrity of liver cells. Higher than 
normal levels suggest damage in liver cells (92) may result in reduced metabolism 
of sorafenib by liver enzymes resulting in increased AUC and Cmax. 
10  Alkaline 
phosphatase 
It is an enzyme present in the cells lining the biliary ducts of the liver. Higher than 
normal levels suggest obstruction of bile duct. Sorafenib is predominantly cleared 
by hepato-biliary elimination; hence, obstruction of bile duct would affect its 
clearance and extent of recirculation, which may increase its systemic exposures. 
However, this effect should be interpreted with caution because levels of this 
enzyme also increases in bone metastasis associated with cancer. 
11  Total bilirubin Decrease in levels of total bilirubin may suggest prehepatic (i.e., RBC hemolysis), 
hepatic (i.e., deficiencies in bilirubin metabolism and biliary excretion) or post-
hepatic (i.e., obstruction in bilirubin excretion) changes in bilirubin pathway. 
Specifically, its levels would reflect not only the normal hepatic function but also 
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the hepatic UGT1A1 enzyme activity as well as canalicular transport function 
(e.g., mediated by MRP2); which may affect sorafenib’s disposition to liver and its 
metabolism influencing AUC and Cmax. 
12 Kidney function 
markers 
Serum creatinine 
and creatinine 
clearance 
These markers reflect the state of renal function. Values of CLCr in range of 40-59 
(both inclusive) suggest mild renal dysfunction, range 20-39 suggest moderate 
dysfunction and below 20 suggests severe dysfunction. Only sorafenib 
glucuronide metabolites equivalent to 19% of administered dose are eliminated by 
renal route; hence, effect of kidney function on sorafenib AUC and Cmax would be 
minimal. 
13 Pharmacogenetic 
markers 
CYP3A4*1B This polymorphism is located in the promoter region of CYP3A4 gene, and is 
usually reported to result in a gain of function (i.e., increased metabolic activity); 
however, there is a lack of consensus about functional impact of this 
polymorphism. This polymorphism may increase the metabolic clearance of 
sorafenib, resulting in decrease in AUC and Cmax. 
14  CYP3A5*3C This polymorphism is located in intron 3, and results in splicing defect in mRNA 
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for CYP3A5 protein, leading to reduced translation and lower protein (enzyme) 
expression. The CYP3A5*3 variant allele commonly exists in linkage with 
CYP3A4*1B wild type allele; in addition, these enzymes exhibit significant 
overlap in substrate specificity (93). This polymorphism may result in reduced 
metabolic clearance and increased AUC and Cmax of sorafenib 
15  UGT1A9*3 This polymorphism is located in the coding region (exon 1) of UGT1A9 gene. 
Carries of variant allele had significantly reduced glucuronidation activity (3.8% 
glucuronidation activity for SN-38 in comparison to wild type carriers) (75). This 
effect on glucuronidation activity may result in reduced metabolic clearance of 
sorafenib, resulting in increase in AUC and Cmax. 
16  UGT1A9*5 This polymorphism is also located in the coding region (exon 1) of UGT1A9 gene; 
and carriers of variant allele had significant reduction in glucuronidation activity 
(less than 5% catalytic activity for SN-38 glucuronidation in comparison to wild 
type allele carriers) (75). This polymorphism may also result in reduced metabolic 
clearance of sorafenib, resulting in increase in AUC and Cmax.  
 105
Non-compartmental & Population Pharmacokinetic Analysis                       Chapter 4 
 106
17  VEGFR2 H472Q This polymorphism exists in exon 11 of VEGFR2 gene, and is located in 
immunoglobulin-like (Ig-like) domain 5. Ig-like domains 4-7 have been shown to 
contain structural features that inhibit receptor signaling in absence of VEGF (79). 
Mechanistically, this polymorphism is not expected to affect the sorafenib 
pharmacokinetics, but because we had data available for variations in this 
genotype, we included it as a covariate. 
18  VEGFR2 V297I This polymorphism exists in exon 7 of VEGFR2 gene, and is located in Ig-like 
domain 3, which is shown to be critical for VEGF binding (79). Mechanistically, 
this polymorphism is also not expected to affect the sorafenib pharmacokinetics, 
but it was screened as covariate because data were available for variations in this 
genotype. 
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4-5.1.3 Covariate Screening 
To identify the important covariates, both ln-transformed exposure metrics were 
individually fit to each nominal and continuous covariate using a linear model (i.e., one-
way ANOVA or linear regression). The contribution of these covariates to the overall 
variability in the respective pharmacokinetic metrics and their statistical significance 
were respectively assessed by coefficient of determination (r2) and p-value. A priori cut-
off for r2 and p-value were set to 0.1 and <0.05, respectively; covariates which met either 
of the two criteria were further evaluated for mechanistic plausibility. In addition, 
intercept and effect size estimates (relative to intercept) or intercept and slope estimates 
were reported for ANOVA and linear regression, respectively. Because the exposure 
metrics were ln-transformed prior to analysis, the effect size and slope were multiplied 
with 100 to be interpreted as percent (%) change on normal scale. The statistical analysis 
was performed using JMP 8.0 (SAS Institute Inc., Cary, NC, USA) statistical software. 
 
4-5.1.4 Final Model 
A stepwise regression with forward selection and backward elimination was used for 
development of final model, individually for both exposure metrics. All candidate 
covariates were eligible for inclusion in the final model. The cut-off p-value of 0.25 was 
used for entering the covariates (forward selection) in the development of full model, 
followed by removal (backward elimination) of covariates from full model with a p-value 
of 0.10. These liberal p-values were chosen considering the exploratory nature of this 
analysis. 
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The statistical analysis was performed using JMP 8.0 (SAS Institute Inc., Cary, NC, 
USA) statistical software. 
 
4-5.2 Results and Discussion 
4-5.2.1 Pharmacokinetic metrics 
The distribution of each pharmacokinetic metrics and their ln-transformed values are 
shown in Table 4-7. As shown in Table 4-7 and Fig 4-7 , both dose-normalized AUC0-12 
and Cmax were right skewed, hence they were ln transformed which followed normal 
symmetric distribution. Both Cmax/D and AUC0-12/D were highly variable with %CV 
greater than 70%, and their values varied by more than 50 folds. Ln-transformation 
reduced the variance in these parameters to 20-50%, which although statistically reduced 
the chances of finding correlations with covariates, but was considered important to meet 
the assumptions of normality for statistical tests. 
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Table 4-7. Summary of pharmacokinetic parameters for sorafenib trials 
Dose normalized  PK metrics  N Mean  Median Min  LQ UQ Max %CV Fold range
Cmax/D [ng/mL/mg] 106 7.1 6.4 0.5 3.3 9.4 25.6 74 52 
AUC0-12/D [ng/mL*hr/mg] 104 52.1 41.6 2.7 22.2 72.4 229.9 77 84 
Ln(Cmax/D) 106 1.7 1.9 -0.7 1.2 2.2 3.2 46 4 
Ln(AUC0-12/D) 104 3.7 3.7 1.0 3.1 4.3 5.4 22 5 
 
  PK: pharmacokinetics, LQ: lower quartile, UQ: upper quartile, CV: coefficient of variation, Cmax, peak plasma concentration,  
  AUC0-12, area under the curve from 0-12 hr after administration of first dose of sorafenib 
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Both metrics were highly inter-related (r=0.95, p<0.0001). The AUC0-12/D and Cmax/D 
were reflective of CL/F and Vd/F, respectively. These exposure metrics can generally be 
described as function of the following underying pharmacokinetic properties: 
total
oral CL
FAUC 1,∝  
d
aoral V
kFC 1,,max ∝  
where Foral is absolute oral bioavailability, CLtotal is total systemic clearance and ka is the 
absorption rate constant. From these equations it is apparent that AUC/D and Cmax/D are 
functions of F/CLtotal and F/Vd.  
 
4-5.2.2 Assessment of covariates 
The screened covariates are summarized in Table 4-8 (a), (b) and (c). Patients from four 
different trials were included in covariate analysis, but the numbers of patients in these 
trials were not equal. Approximately 77% of the patients received 400 mg BID, and the 
remaining patients were administered 200 mg BID. The proportion of males was higher 
than females (70% vs. 30%), and more than 8 out of 10 patients were Caucasians. These 
imbalances may obscure or bias the true effect of trial, dose, gender and ethnicity on 
exposure metrics. Among liver function markers, ALT, total bilirubin and total protein 
values were outside the normal limits for only 7%, 8% and 13% patients, which increased 
the possibility of bias in the effect size estimation and false negative findings. A total of 
23%, 26% and 52% patients had abnormal values for AST, alkaline phosphatase and 
albumin. Thirty-nine percent (39%) patients had serum creatinine values outside the 
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normal limits, and only 13% patients had mild to moderate renal dysfunction based on 
the estimated creatinine clearance.  
 
Patients’ age varied from 30-85 years (approximately 3-fold variation with a median of 
64 years), and their weight ranged from 35-132 kg (approximately 4-fold variation with a 
median of 81 kg). Height varied from 144 to 191 cm with 1.3-fold variation and a median 
of 171 cm, and the variability in BSA was 2.5-fold with range of 1.2-2.5 m2 and q median 
of 1.9 m2. Creatinine clearance values ranged from 25-150 mL/min (approximately 6-fold 
variation with a median of 91 mL/min). ALT, AST, alkaline phosphatase and bilirubin 
total had wide range of distribution with approx. 7-17 fold variation (%CV 40-60). 
Albumin and total protein had only 2-fold variation (%CV 9-12), but as mentioned earlier 
more than 50% of patients had albumin levels lower than normal. 
 
Similar to the laboratory and demographic covariates, the genotype distributions for 
CYP3A4*1B, CYP3A5*3C, UGT1A9*3, UGT1A9*5, VEGFR2 H472Q and VEGFR2 
V297I polymorphisms were also imbalanced.  None of the patients in studied population 
carried the variant allele for UGT1A9*5 SNP; hence, it was not included in further 
analysis. Only 11% and 2% patients carried the variant allele for CYP3A4*1B and 
UGT1A9*3 SNPs, respectively, while the frequencies of variant allele for VEGFR2 
H472Q and VEGFR2 V297I SNPs were 20% and 15%, respectively. For CYP3A5*3C, 
the frequency of wild-type (wt) allele was smaller compared to the variant allele, i.e., 13 
%. Among these, CYP3A4*1B, CYP3A5*3 and both VEGFR2 polymorphisms were in 
Hardy-Weinberg equilibrium (Table 4-8 (c), p>0.05), when evaluated for only Caucasian 
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patients. The deviation of UGT1A9*3 from Hardy-Weinberg equilibrium may be 
attributed to the small sample size, leading to increase in selection bias for study subjects. 
 
Collinearity between these covariates was assessed by evaluating the multivariate 
correlations (Table 4-9). The relationship between nominal and continuous covariates or 
other nominal covariates were also assessed, a selected example of which is shown in Fig 
4-8. The effect of BSA, gender and CLCr were confounded by body weight (Table 4-9), 
which were not unexpected given that BSA and CLCr were calculated by DuBois and 
DuBois and Cockroft-Gault formula, respectively; and females had significantly lower 
body weight (mean=71 kg, SD=18.3) than males (mean=87 kg, SD=17) (p<0.0001) (Fig. 
4-8). Similarly, AST and ALT and SCr and CLCr were correlated (Table 4-9). 
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Table 4-8 (a) Summary of nominal, non-genetic covariates 
 
 Level 1 (%) No. Level 2 (%) No. Level 3 (%) No. Total 
Trial† mCRPC, (43) 46 / NSCLC, (17) 18 / CRC, (17) 18 and ST,(23) 24  
Dose [200/400 mg] 200 (23) 24 400 (77) 82   106 
Gender [F/M] F (30) 32 M (70) 74   106 
Ethnicity Cauc (81) 86 AA (9.5) 10 Asian/other (9.5) 10 106 
SCr [L/N/H] L (37) 39 N (60) 64 H (3) 3 106 
CLCrCG  Mild dysfunction (10) 11 Moderate dysfunction (3) 3 N (87) 92 106 
Albumin [L/N] L (52) 55 N (48) 51 H (0) 0 106 
Protein, Total [L/N/H] L (11) 12 N (87) 92 H (2) 2 106 
ALT [L/N] L (0) 0 N (92.5) 98 H (7.5) 8 106 
AST [L/N] L (0) 0 N (76.5) 81 H (23.5) 25 106 
Alk Phos [L/N/H] L (2) 2 N (73.5) 78 H (24.5) 26 106 
Bilirubin, Total [N/H] L (0) 0 N (92.5) 98 H (7.5) 8 106 
†mCRPC: Phase II trial of sorafenib in metastatic castrate resistant prostate cancer, ST: Phase I trial of sorafenib and bevacizumab 
combination in patients with solid tumors, NSCLC: Phase II trial of sorafenib in non-small cell lung cancer, Bay-CRC: Phase II trial 
of sorafenib and cetuximab combination in patients with colorectal cancer 
SCr: serum creatinine; CLCr: creatinine clearance; ALT: alanine transaminase or SGPT, AST: aspartate transaminase or SGOT, Alk 
Phos: alkaline phosphatase, L: lower than normal lab values, N: normal lab values, H: higher than normal lab values. 
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Table 4-8 (b) Summary of continuous covariates 
 
Covariate N Mean  Median Min LQ UQ Max CV% Fold range 
Age [years] 106 62.8 64.2 30.4 55.3 71.4 85.0 18 2.8 
Weight [kg] 106 82.7 81.3 35.2 69.0 97.7 132.5 23 3.8 
Height [cm] 106 170.2 171.3 144.3 164.2 176.9 191.5 6 1.3 
BSA [m2] 106 1.9 1.9 1.2 1.7 2.2 2.5 14 2.1 
SCr [g/dL] 106 0.95 0.9 0.4 0.8 1.05 1.9 25 4.8 
CLCrCG [mL/min] 106 92.3 90.6 25.5 74.4 109.7 150.0† 31 5.9 
Albumin [g/dL] 106 3.6 3.6 2.2 3.3 3.9 4.4 12 2 
Protein, Total [g/dL] 106 6.5 6.6 4.6 6.2 6.9 8.2 9 1.7 
ALT [U/L] 106 23.4 20.5 8.0 15.0 28.0 75.0 52 9.4 
AST [U/L] 106 28.4 26.0 13.0 21.0 34.0 90.0 39 7 
Alk Phos [U/L] 106 99.8 81.5 34.0 64.0 115.5 414.0 58 12.2 
Bilirubin, Total [mg/dL] 106 0.65 0.6 0.1 0.5 0.8 1.7 38 17 
†CLCrea values greater than 150 were truncated at 150. 
LQ: lower quartile, UQ: upper quartile, CV: coefficient of variation 
BSA: body surface area SCr: serum creatinine; CLCr: creatinine clearance; ALT: alanine transaminase or SGPT, AST: aspartate 
transaminase or SGOT, Alk Phos: alkaline phosphatase 
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   Table 4-8 (c) Summary of pharmacogenetic covariates 
 
 Genetic Variants N Genotype Frequenciesa Allele Frequenciesb  
   Wt Het Var p q p-valuec 
 CYP3A4*1B 104 88 (84.6) 9 (8.6) 7 (6.7) 0.88 0.12 0.19 
Metabolic CYP3A5*3C 104 5 (4.8) 18 (17.3) 81 (77.9) 0.14 0.86 0.65 
Enzymes UGT1A9*3 104 100 (96.1) 3 (2.9) 1 (1) 0.98 0.02 <0.01 
 UGT1A9*5 102 102 (100) 0 (0) 0 (0) 1 0 NA 
Sorafenib  VEGFR2 H472Q 103 66 (64.1) 32 (31.1) 5 (4.8) 0.8 0.2 0.76 
Target VEGFR2 V297I 102 74 (72.5) 25 (24.5) 3 (3) 0.85 0.15 0.99 
   NA: not accessible 
   Wt, wild type sequence; Het, heterozygous and Var, homozygous variant sequences; 
   p, q are standard Hardy-Weinberg nomenclature for allele frequencies 
   a. Number represents number of patients with percentages in parentheses 
   b. Data are given as relative frequency 
   c. p-value for evaluation of Hardy-Weinberg equilibrium for Caucasian subjects only 
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Table 4-9 Assessment of collinearity (correlation coefficient, r) between continuous covariates by evaluating the multivariate 
correlations 
 
BW Age BSA Alb Total 
Protein
Alk 
Phos 
Total 
Bili 
AST ALT SCr CLCr 
BW 1.00 
Age  -0.02 1.00 
BSA  0.75¶ 0.20 1.00 
Alb  0.04 -0.24 -0.01 1.00 
Total Protein  -0.06 -0.27 -0.19 0.53 1.00 
Alk Phos  0.01 0.03 0.03 -0.32 -0.09 1.00 
Total Bili  0.09 0.04 0.05 0.10 0.01 0.00 1.00 
AST 0.06 0.14 0.10 -0.02 0.08 0.32 0.02 1.00 
ALT 0.11 0.01 0.14 0.17 0.17 0.27 0.02 0.60 1.00 
SCr  0.13 0.13 0.16 0.14 0.07 -0.07 0.17 0.09 0.00 1.00 
CLCr  0.64 -0.46 0.39 0.05 0.02 0.03 -0.01 -0.04 0.08 -0.53 1.00 
 
 
¶The correlation coefficient above 0.5 are highlighted  
 
BW: body weight, BSA: body surface area, Alb: albumin, Alk Phos: alkaline phosphatase, Total Bili: total bilirubin, AST: aspartate 
transaminase or SGOT, ALT: alanine transaminase or SGPT, SCr: serum creatinine, CLCr: creatinine clearance 
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Fig 4-8 Comparison of body weight (continuous variable) between genders (nominal variable) 
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4-5.2.3 Covariate Screening 
4-5.2.3.1 Characterization of extreme values for AUC0-12/D and Cmax/D 
A Caucasian man of age 57 years with prostate cancer had the lowest values of AUC0-
12/D and Cmax/D. His weight and BSA were 101 kg and 2.2 m2, which were in the upper 
quartile of their respective distributions as shown in Table 4-8 (b). Except serum albumin, 
which was marginally low, his liver and renal function markers were within the normal 
limits. He carried wild-type genotype for CYP3A4*1B, UGT1A9*3, UGT1A9*5 and 
VEGFR2 H472Q; heterozygous genotype for VEGFR2 V297I and variant genotype for 
CYP3A5*3C. 
 
A 72 year old Caucasian woman with non-small cell lung cancer had the highest values 
of AUC0-12/D and Cmax/D.  Her body weight and BSA were in the lower quartile of their 
respective distributions (Table 4-8 (b)), with values of 55.8 kg and 1.56 m2, respectively. 
Her liver function markers were within the normal limits, but renal function markers, SCr 
and CLCr, were marginally lower than normal, 0.75 g/dL and 59.3 mL/min respectively. 
Her genetic makeup for metabolic enzymes was similar to the Caucasian man with lowest 
values of AUC0-12/D and Cmax/D, as discussed in previous paragraph.  
 
Overall, comparison of these extreme values suggests an inverse relation between body 
weight or BSA and AUC0-12/D and Cmax/D, which is mechanistically plausible. Liver and 
kidney function markers and genetic polymorphisms in studied metabolic enzymes did 
not appear to be important for variability in AUC0-12 or Cmax. 
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4-5.2.3.2 Covariate screening for ln (Cmax/D) using linear regression or ANOVA 
Results of covariate screening for ln (Cmax/D) are summarized in Table 4-10. Gender, 
weight, BSA, CLCr, albumin, ALT, and VEGFR2 H472Q had a significant univariate 
effect on ln (Cmax/D), but none of them had met the r2>0.1 criterion. No other covariates 
met either of the pre-specified criteria, i.e., r2>0.1 or p-value<0.05. 
 
Gender, weight, BSA and CLCr accounted for 7.4%, 6.6%, 5.6% and 5.3% of the 
variation in ln (Cmax/D). Among these, associations of ln (Cmax/D) with gender, BSA and 
CLCr were confounded by weight, as described earlier and shown in Table 4-9, Fig 4-8 
and section 4-5.2.2.  
 
The Cmax/D decreased by 10% per 10 kg increase in body weight, which is 
mechanistically understandable. An increase in body weight would increase the 
distribution volume, leading to a reduction in Cmax. 
 
The Cmax/D increased with an increase in albumin from low to normal by 17.4%, which 
may have been reflective of a decrease in volume of distribution. Mechanistically, this 
may be the case for drugs with large distribution to peripheral tissues, where higher 
plasma protein binding may restrict the amount of drug distributing into tissues, as seem 
to be the case for sorafenib. 
 
The decrease in Cmax/D by 1.2% with each unit increase in ALT was statistically 
significant, but appeared to be inconsistent with our mechanistic expectations. Increased 
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ALT levels suggest liver dysfunction; mechanistically this would suggest a reduction in 
hepatic first-pass and systemic metabolism, which should increase Cmax of sorafenib. 
However, this inverse trend was driven by ALT values from only 5-6 patients; exclusion 
of them would have made this relationship non-significant, suggesting that this 
observation may be artifactual. 
 
The VEFR2 H472Q was also a significant covariate for ln (Cmax/D), but the effect size of 
this relation was very small as shown in the JMP-generated factor profiler in Fig 4-9.  
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Fig 4-9 JMP predicted effect of VEGFR2 H472Q polymorphism on ln (Cmax/D). 1=wild 
type (N=66), 2=heterozygous (N=32), 3=variant genotype (N=5). Least squares mean ± 
SE for 1 = 1.59 ± 0.09, 2 = 1.98 ± 0.13, and 3 = 1.45 ± 0.34. 
 
 
Ln (Cmax/D) was marginally higher for heterozygotes compared to wt or homozygous 
variant genotypes. Tukey’s HSD test revealed that the mean ln (Cmax/D) for only 
heterozygotes was marginally different from wt carriers (p=0.048), and the difference 
between heterozygous and variant genotype was not significant. The small sample size 
and imbalances in number of subjects across genotype subgroups might have influenced 
this apparent association, which requires further evaluation with a larger sample size.  
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Table 4-10 Covariate screening for ln (Cmax/D) 
Candidate covariate r2 intercept slope 
Ref 
group p-value †slope*100 
Dose 0.016 1.76 0.1166 200 0.1913 11.66 
Trial 0.048 1.74   0.1637  
Gender 0.074 1.78 0.225 F 0.0049 22.5 
Ethnicity 0.01 1.84   0.9019  
Age [years] 0.002 1.91 -0.0034  0.6059 -0.34 
Weight [kg] 0.066 2.54 -0.01  0.0078 -1 
Height [cm] 0.0177 3.42 -0.01  0.1733 -1 
BSA [m2] 5.60E-02 2.93 -0.64  0.0149 -64 
SCr [g/dL] 9.50E-04 1.6 0.099  0.7532 9.9 
SCr [N/L] 0.053 1.99   0.0613  
CLCrCG [mL/min] 0.053 2.26 -0.00613  0.0174 -0.613 
CLCrCG [H/N/L] 0.053 1.92   0.0601  
Albumin [g/dL] 0.023 0.69 0.2812  0.1196 28.12 
Albumin [H/N/L] 0.052 1.7 -0.174 L 0.0184 -17.4 
Protein, Total [g/dL] 0.0056 1.05 0.098  0.4437 9.8 
Protein, Total [H/N/L] 0.0063 1.68   0.7211  
ALT [U/L] 0.037 1.98 -0.012  0.047 -1.2 
ALT [H/N/L] 0.042 1.44 -0.29 H 0.0342 -29 
AST [U/L] 0.0058 1.84 -0.005  0.4364 -0.5 
AST [H/N/L] 7.40E-03 1.65 -7.70E-02 H 0.3795 -7.700 
AP [U/L] 1.10E-03 1.74 -4.50E-04  0.7273 -0.045 
AP [H/N/L] 0.012 1.56   0.5361  
Bilirubin, Total [mg/dL] 0.003 1.58 0.17  0.5763 17 
Bilirubin, Total [H/N/L] 0.0001 1.71 0.019 H 0.8901 1.9 
CYP3A4*1B 0.011 1.6   0.5613  
CYP3A5*3C 0.007 1.68   0.7003  
UGT1A9*3 0.036 2.2   0.1541  
VEGFR2 H472Q 0.059 1.7   0.0471  
VEGFR2 V297I 0.005 1.77   0.775  
    Please check the footnotes on next page. 
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†Slopes are multiplied with 100 in order to interpret the ln-transformed data on normal scale. 
p-value cut-off was <0.05 and r2 cut-off was >0.1. 
Ref: reference 
 
4-5.2.3.3 Covariate screening for ln (AUC0-12/D) using linear regression or ANOVA 
The results of covariate analysis for ln (AUC0-12/D) are summarized in Table 4-11. 
Gender, weight, BSA, SCr [L/N], albumin and VEGFR2 H472Q had significant 
univariate effects on ln (AUC0-12/D) at p<0.05 level; but accounted for only 5.6%, 5.3%, 
5.1%, 6.3%, 4.3%, 6.7% and 0.37% variability in ln (AUC0-12/D), respectively. The r2 
values for none of these covariates met the pre-specified criteria of ≥ 0.1. No other 
covariate met either of the pre-specified criteria of r2 values ≥ 0.1 or p-values of <0.05; 
hence, were not considered further. 
 
As mentioned in section 4-5.2.2, the effects of gender and BSA were confounded by 
body weight. The effect of SCr [L/N] on ln (AUC0-12/D) appeared to be artifactual, since 
the relationship between (AUD0-12/D) and SCr was not in the expected rank order. The 
(AUC0-12/D) increased in the order of AUCSCr[H]>AUCSCr[L]>AUCSCr[N] for SCr groups. 
Mechanisticaly, we did not expect any association between sorafenib exposures and SCr, 
because the renal excretion of parent drug was negligible (33). 
 
The effect of weight on ln (AUC0-12/D) was mechanistically plausible, with a 9.4% 
decrease in AUC0-12/D for each 10 kg increase in weight. Both volume of distribution and 
systemic clearance (metabolic activity) may increase with increase in weight, which 
could lead to decrease in sorafenib exposures. 
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Another mechanistically plausible relation was increase in ln (AUC0-12/D) with increase 
in albumin. Sorafenib binds to human serum albumin, α-, β-globulin and the low density 
lipoproteins (LDL) with the fraction unbound in plasma ranging from 1.02 to 3.55 % 
(33). With elevated albumin levels, the concentration of sorafenib not bound to plasma 
proteins (fu) will decrease, resulting in reduced distribution of free drug to peripheral 
organs including liver. Reduced distribution to liver may reduce the amount of drug 
undergoing metabolism (i.e., reduction in fu*CLint). For drugs with low hepatic extraction 
ratio, such as is likely the case for sorafenib, fu*CLint is the main determinant of hepatic 
clearance (CLhep) based on the Wilkinson-Shand well-stirred model: 
int
int
*
*
*.
CLfQ
CLfQERQCL
u
u
hephep +==  
where Q is the hepatic blood flow and CLint is the intrinsic rate at which liver clears the 
drug from blood in absence of any flow restrictions 
 
AUC0-12/D increased by approximately 4% per 0.1 g/dL increase in serum albumin, and 
the average (AUC0-12/D) for patients with normal albumin levels was 20.4% higher than 
patients with low serum albumin levels. 
 
The VEGFR2 H472Q was a significant covariate for ln (AUC0-12/D), but similar to its 
effect on ln (Cmax/D), effect size was small, and sample sizes in genotype subgroups were 
imbalanced. The factor profiler generated by JMP (Fig 4-10) shows that patients with 
heterozygous genotype had significantly higher ln (AUC0-12/D) compared to wt carriers 
(p=0.0043); however, the variant genotype was not different from either of the remaining 
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genotypes. These results might have been influenced by imbalances in sample size across 
genotype groups and need to be further evaluated with larger sample size. 
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Fig 4-10 JMP predicted effect of VEGFR2 H472Q polymorphism on ln (AUC0-12/D). 
1=wild type (N=66), 2=heterozygous (N=32), 3=variant genotype (N=5). Least squares 
mean ± SE for 1 = 3.54 ± 0.10, 2 = 3.99 ± 0.14, and 3 = 3.44 ± 0.35. 
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Table 4-11 Covariate screening for ln (AUC0-12/D).  
Candidate covariate r2 intercept slope 
Ref 
group p-value †slope*100
Dose 0.008 3.71 0.086 200 0.3609 8.6 
Trial 0.032    0.3524  
Gender 0.056 3.75 0.204 F 0.0153 20.4 
Ethnicity 0.025    0.6357  
Age [years] 0.004 3.94 -0.004  0.5318 -0.4 
Weight [kg] 0.053 4.45 -0.00900  0.0191 -0.9 
Height [cm] 0.0169 5.44 -0.01  0.1876 -1 
BSA [m2] 0.051 4.89 -0.63  0.0215 -63 
SCr [g/dL] 6.11E-05 3.65 0.026  0.9372 2.6 
SCr [L/N/H] 6.30E-02    0.0372  
CLCrCG [mL/min] 0.034 4.14 -0.005  0.0614 -0.5 
CLCrCG  0.039    0.1356  
Albumin [g/dL] 0.043 2.26 0.395  0.0342 39.5 
Albumin [L/N] 0.067 3.68 -0.204 L 0.008 -20.4 
Protein, Total [g/dL] 0.012 2.73 0.145  0.2786 14.5 
Protein, Total [H/N/L] 0.013 3.62   0.5084  
ALT [U/L] 0.019 3.89 -0.009  0.1162 -0.9 
ALT [L/N] 0.016 3.49 -0.198 H 0.2018 -19.8 
AST [U/L] 0.002 3.76 -0.003  0.6511 -0.3 
AST [L/N] 0.012 3.62 -0.1033 H 0.2653 -10.33 
AP [U/L] 1.55E-07 3.67 5.49E-06  0.9968 0.001 
AP [L/N/H] 5.00E-03    0.7711  
Bilirubin Total [mg/dL] 0.001 3.59 0.121  0.7042 12.1 
Bilirubin Total [N/H] 0.001 3.72 0.055 H 0.7087 5.5 
CYP3A4*1B 0.0099 3.6   0.6082  
CYP3A5*3C 0.011 3.66   0.5606  
UGT1A9*3 0.034 4.01   0.1797  
VEGFR2 H472Q 0.069 3.65   0.0298  
VEGFR2 V297I 0.0037 3.63   0.8353  
    Please check the footnotes on next page. 
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†Slopes are multiplied with 100 in order to interpret the ln-transformed data on normal scale 
p-value cut-off was <0.05 and r2 cut-off was >0.1. 
Ref: reference 
 
Table 4-12 Final model for ln (Cmax/D)   
 
Final Model SSQtot r2  p-value 
 37.8 0.2518  <0.0001 
 
 
Final Covariate SSQ intercept Slope p-value †Slope*100 
BSA [m2] 2.9 2.09 -0.6461 0.0111 -64.61 
Albumin [g/dL] 2.9  0.6043 0.0025 60.43 
AP [U/L] 1.5  0.0017 0.1781 0.17 
ALT [U/L] 3.5  -0.0169 0.0072 -1.69 
UGT1A9*3 
(wt & het) vs. var 3.1  -1.0293 0.0076 -102.9 
VEGFR2 H472Q 
(wt & het) vs. var 2.0  -0.1623 0.0328 -16.23 
†Slopes are multiplied with 100 in order to interpret the ln-transformed data on normal scale 
 
Table 4-13 Final model for ln (AUC0-12/D) 
 
Final Model SSQtot r2  p-value 
 39.1 0.2662  <0.0001 
 
 
Final Covariate SSQ intercept Slope p-value †Slope*100 
BSA [m2] 3.1 3.6 -0.6841 0.009 -68.41 
Albumin [g/dL] 4.4  0.7429 0.0003 74.29 
AP [U/L] 2.0  0.0021 0.1131 0.21 
ALT [U/L] 3.1  -0.0171 0.0134 -1.71 
UGT1A9*3  
(wt & het) vs. var 3.1  -1.0488 0.008 -104.8 
VEGFR2 H472Q  
(wt & het) vs. var 2.6  -0.1888 0.0165 -18.88 
†Slopes are multiplied with 100 in order to interpret the ln-transformed data on normal scale 
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4-5.2.3.4 Final covariate model for ln Cmax/D and ln (AUC0-12/D) 
Parameters from final covariate models for ln (Cmax/D) and ln (AUC0-12/D) are shown in 
Tables 4-12 and 4-13. Both models included BSA, albumin, alkaline phosphatase, ALT, 
UGT1A9*3 and VEGFR2 H472Q as covariates. Overall, these covariates together 
accounted for only 25% and 27% variability of the observed total variability in ln 
(Cmax/D) [%CV, 45%] and ln (AUC0-12/D) [%CV, 22%]. Except alkaline phosphatase, all 
other covariates were statistically significant at the p<0.05 level. BSA, albumin, ALT, 
UGT1A9*3 and VEGFR2 H472Q accounted for 18%, 18%, 22%, 19% and 13% of 
model SSQ for ln (Cmax/D) and 17%, 24%, 17%, 17% and 14% of model SSQ for ln 
(AUC0-12/D). All of these were very similar and minor effects. 
 
An 0.1 m2 increase in BSA resulted in a 6.5% decrease in Cmax/D and 6.8% decrease in 
AUC0-12/D, after correction for other covariates. The slopes and (inverse) directions of 
these relations were similar to the results of univariate covariate screening. BSA is a 
composite matrix of body weight and height, and increase in BSA would indicate 
increase in volume of distribution and/or metabolic rate. Sorafenib is primarily eliminated 
by hepatic metabolism and heptobiliary excretion, and has large apparent volume of 
distribution. An increase in volume of distribution would reduce the Cmax, and increased 
metabolism may reduce the total drug exposure over time, i.e., AUC. Regardless of the 
underlying mechanism, the effect of BSA on Cmax and AUC was likely to be of limited 
clinical relevance because of their minor contribution to overall variability in Cmax and 
AUC – within the range of BSA included in this analysis, i.e., 1.2 to 2.5 m2. Contribution 
of BSA in the overall variability explained by the model for ln (Cmax/D) or ln (AUC0-12/D) 
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was only 4.5% (i.e., 18% of 0.2518 for ln (Cmax/D) and 18% of 0.2662 for ln (AUC0-
12/D)).  
 
The effects of albumin levels on Cmax/D and AUC0-12/D were also previously detected 
during univariate covariate screening; however, after correction for other covariates, their 
sensitivity (effect size) was enhanced. The 0.1 g/dL increase in albumin resulted in 6% 
and 7% increase in Cmax/D and AUC0-12/D, respectively. This was likely an outcome of 
identification of alkaline phosphatase as separate covariate, which had weak inverse 
correlation (r=-0.32) with albumin (Table 4-9). Separation of effects for alkaline 
phosphatase and albumin in full model eliminated the confounding effects. As described 
earlier in sections 4-5.2.3.2 and 4-5.2.3.3, the increase in albumin may restrict the 
concentrations of sorafenib undergoing metabolism or distributing into tissues, which 
may result in decreased CL/F and/or V/F leading to increase in AUC and Cmax. These 
effects are also not clinically relevant, considering their small contribution to overall 
variability in ln (Cmax/D) (i.e., 4.5%) and ln (AUC0-12/D) (i.e., 6.4%). 
 
Although, the effects of alkaline phosphatase on Cmax/D and AUC0-12/D were statistically 
insignificant, they were mechanistically plausible. Each unit (1 U/L) increase in alkaline 
phosphatase resulted in 0.1% and 0.2% increase in ln (Cmax/D) and ln (AUC0-12/D). 
Increased alkaline phosphatase levels might indicate obstruction in bile duct, which 
would impede the biliary elimination of sorafenib. However, another more likely reason 
for the increase in alkaline phosphatase levels is bone metastases, and most of the 
patients on these trials had advanced metastatic disease. Regardless of the cause, clinical 
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relevance of this effect is negligible because of negligible effect size and negligible 
contribution to variation in ln (Cmax/D) and ln (AUC0-12/D). 
 
The effects of ALT on both ln (Cmax/D) and ln (AUC0-12/D) were statistically significant, 
but it was unexpected for AUC0-12/D because similar effect was not detected during 
univariate covariate screening. Both Cmax/D and AUC0-12/D decreased by 1.7% for per 
unit (1 U/L) change in ALT. Elevated ALT levels often suggest liver damage (e.g., 
cirrhosis) or bile duct obstruction, which would mechanistically indicate a reduction in 
hepatic metabolism/excretion of sorafenib. However, the findings in current analysis 
were not in agreement with this plausible mechanism. Some co-administered drugs such 
as statins, antibiotics, chemotherapy, aspirin and narcotics may also increase ALT with 
simultaneous displacement of sorafenib from plasma proteins, causing increase in its 
metabolism. In that case relationship between ALT and sorafenib exposures might be 
artifactual. Nevertheless, because of small effect size and small contribution to variability 
in Cmax/D and AUC0-12/D, effect of ALT on exposure metrics for sorafenib would not be 
clinically relevant. The distribution of ALT was skewed to the right; the number of 
patients with above normal values was higher than that of lower ALT levels. The effects 
of chronic liver dysfunction on sorafenib exposures was earlier studied in a prospective 
clinical trial. Patients with various degree of liver dysfunction, as determined by albumin, 
AST and bilirubin levels, were treated with sorafenib, and sorafenib pharmacokinetics 
was analyzed for patients. The AUC0-12 did not appear to be associated with liver 
dysfunction; however, based on long-term follow-up for safe dose, the tolerable dose for 
patients with moderate to severe liver damage was apparently lower than clinically 
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approved dose (i.e., 200 mg QD/BID compared to 400 mg BID) (94). Further studies 
with long-term exposure metrics might be needed to confirm the effects of liver damage 
on sorafenib disposition. 
 
The effects of UGT1A9*3 polymorphism on both ln (Cmax/D) and ln (AUC0-12/D) were 
statistically significant, but were not detected during univariate covariate screening. Only 
1 of 106 patients carried UGT1A9*3*3 variant genotype and 3 patients carried 
heterozygous UGT1A9*1*3 genotype; hence the estimated effects were likely biased 
towards UGT1A9*1*1 wild-type genotype. The Cmax/D and AUC0-12/D appeared to be 
103% and 105% higher for carriers of UGT1A9*3*3 compared to UGT1A9*1*1 or 
UGT1A9*1*3 carriers. The UGT1A9*3*3 polymorphism has been shown to reduce the 
UGT1A9 glucuronidation activity (75)(see section 1-4.1.2), which could mechanistically 
explain the current findings. However, these results should be interpreted with caution 
because of limited sample size (only 1 of 106 patients carried the UGT1A9*3*3 
genotype) and requires further confirmation in a larger cohort. 
 
Finally, VEGFR2 H472Q was statistically significant for both Cmax/D and AUC/D, which 
was also identified during univariate covariate screening; however, these effects were 
mechanistically implausible. Based on the results, patients with variant genotype had 16.2 
% lower Cmax/D and 18.8% lower AUC0-12/D compared to patients with wild type or 
heterozygous genotype. Imbalances in subgroup sizes based on genotype might also have 
biased these relationships. 
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4-5.3 Conclusions for non-compartmental pharmacokinetic analysis and covariate 
search by general linear modeling 
1. As expected, sorafenib pharmacokinetics was highly variable among patients with 
various solid tumors. Inter-patient variability in Cmax and AUC0-12 were 
respectively 46-87% and 45-79% for the 200/400 mg BID dose administered in 
patients with mCRPC, NSCLC, CRC and ST. 
2. Co-administration of bevacizumab and ritonavir did not appear to have any 
significant effects on exposures of sorafenib. 
3. Exposure metrics were normalized with the amount of administered drug (D) in 
order to account for the differences in dose levels. Dose-normalized 
pharmacokinetic metrics, Cmax/D and AUD0-12/D, were not statistically different 
between trials or two dose levels, which was consistent with linear 
pharmacokinetics. This justified pooling of data across trials, irrespective of 
administered dose. 
4. Inter-patient variability in pooled exposure metrics Cmax/D and AUD0-12/D were 
73% and 77%. Distributions for these metrics were skewed; hence, ln-
transformation was performed prior to covariate analysis. The inter-patient 
variability for ln-transformed values was modest: 46% for ln (Cmax/D) and 22% 
for ln (AUC/D). 
5. Body size metrics, namely body weight and BSA, were statistically significant 
covariates for both exposure metrics, where ln (Cmax) and ln (AUC0-12) were 
inversely related with these covariates. The directions of these relations were 
mechanistically plausible, likely reflecting the impact of an increase in body size 
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on sorafenib’s metabolic clearance and/or volume of distribution. However, these 
covariates accounted for only less than 7% of variability in exposure metrics and 
the effect sizes were also relatively small [~1% and ~6.5% decrease in 
pharmacokinetic metrics for each kg increase in weight and 0.1 m2 increase in 
BSA]. These findings are of little clinical relevance and do not justify any dose 
adjustments. Minor effects of gender on ln (Cmax/D) and ln (AUC0-12/D), and 
effects of CLCr on ln (Cmax/D) were statistically significant, but were confounded 
by weight. 
6. Baseline serum albumin levels had a small univariate effect (<4%) on both the 
Cmax/D and AUC0-12/D; which increased to 6.5% after correcting for effect of 
other covariates. Although these effects can be explained mechanistically by 
increased distribution/clearance at low albumin levels due to increase in unbound 
fractions (fu), their small contribution to overall variability makes the effect 
clinically irrelevant. 
7. Baseline serum levels of ALT and VEGFR2 H472Q genotype were statistically 
significant covariates for ln (Cmax/D) and ln (AUC0-12/D). However, the ALT 
distribution was imbalanced (slightly skewed to right) and the direction of its 
relation with exposure metrics (1.7% decrease in Cmax/D and AUC0-12/D per unit 
increase in ALT) were mechanistically implausible. The small effect size and 
mechanistic implausibility for relationship with target receptor (i.e., VEGFR2) 
polymorphism suggested that it was clinically irrelevant.  
8. In the final model, UGT1A9*3 genotype was a significant covariate for both 
Cmax and AUC. The effect size was large; Cmax or AUC for homozygous 
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variant genotype (UGT1A9*3*3) increased by >100% compared to wild-type or 
heterozygous genotypes. However, these observations were strictly limited by 
small sample size (only 1 of 106 patients carried variant genotype), and needs 
further evaluation. 
 
4-6  Population pharmacokinetic model building – non-linear mixed effect 
modeling approach 
4-6.1 Introduction 
The non-linear mixed effect modeling (NONMEM) is a one-stage (i.e., pooled analysis) 
approach, which considers the complete population study sample, rather than individuals, 
as a unit of analysis for estimation of pharmacokinetic parameters, their distribution and 
their relationship with covariates within the population. NONMEM methods estimate the 
pharmacokinetic model parameters (both structural and statistical) using the maximum 
likelihood approach. The probability of observed individual plasma concentration-time 
profiles conditioned to the model is written as a function of model parameters (i.e. log- 
likelihood function), also referred as objective function value, and estimates for 
parameters are chosen to maximize this probability (95). The best parameter estimates are 
those which makes the observed data most probable than under any other set of 
parameters (95). 
 
The minimization of objective function requires various degrees of approximations (or 
generalizations), depending on the estimation method used in the analysis, each of which 
also determine accuracy and precision of estimated parameters and computational time. 
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The common parameter estimation methods are Laplacian, first-order conditional method 
(FOCE) with or without interaction (i.e., INTER), and the first-order (FO) method. The 
Laplacian method makes least approximations, whereas FO method is based on several 
assumptions, which significantly reduces the computational time. The FOCE with INTER 
is the most commonly used method, estimates of which are acceptably close to the true 
underlying values.  
 
In order to find the best set of parameters, the selection of various values for vector of 
model parameters is guided by gradient minimization approaches such as simplex or 
steepest-descent algorithm and Gauss-Newton algorithm. Some times these algorithms 
converge into local maxima rather than global maxima, which would falsely indicate that 
likelihood function has been maximized. To avoid such possibilities, final models are 
always re-run after perturbing the initial estimates of model parameters, until stable 
parameter values are obtained. This ensures that estimated model-parameters are likely to 
represent the global maxima (or maximum possible likelihood function value) and not the 
local maxima. 
 
Population pharmacokinetic analysis involves at least two hierarchical models. In the first 
stage, the observed plasma concentration-time profile data for a particular individual is 
modeled, conditioned to the individual specific parameters; and in the second stage the 
individual parameters are modeled as a function of individual-specific covariates to 
obtain the typical (population average) pharmacokinetic values (96). 
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1st hierarchy 
For each subject, the observed plasma drug concentrations are modeled as below (97): 
 yij = f (xij, φi) + εij 
where, i = 1, 2, 3, ….N individuals, from whom data are collected for population 
pharmacokinetic analysis.  
yij is the observed concentration for ith individual at jth time point  
f (xij, φi) is the model predicted concentration for ith individual at jth time point, where f 
stands for some pre-specified form of model such as monoexponential, biexponential etc. 
xij indicates the known quantities for jth time point for ith individual such as time (tij) and 
dosing (di) information.  
φi represents the individual (i) specific model parameters (individual’s fixed effect 
parameters) 
εij denotes the random difference between observed (yij) and model predicted (f (xij, φi)) 
concentrations, also known as residual error. It follows normal distribution with mean of 
0 and variance of σ2, i.e., ε~N(0, σ2).  
 
2nd hierarchy 
Individual pharmacokinetic model parameters, e.g., rate constants, Vd, CLtotal, are 
modeled as a function of individual-specific covariates, as below (97): 
φi = g (zi, θ) + ηi 
where, φi denotes the model parameters for individual i 
zi  represents the fixed covariate effect for individual i, such as individuals weight and 
BSA  
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θ, represents the vector of population parameters 
g (zi, θ), is a function of fixed covariate effects, zi , and fixed effects parameters, θ. It 
represents the typical population (mean) values of model parameters for an individual 
with zi fixed effects (e.g., population CL for typical 70 kg weight male). 
ηi denotes the random difference between typical population mean values of model 
parameters (g (zi, θ)) and individual-specific model parameters. The η values are assumed 
to follow normal distribution with mean of 0 and variance of ω2, i.e. η~N(0, ω2). The ω 
represents the inter-individual or between subject variability in model-predicted 
parameters. 
 
These two hierarchical models explicitly partition the variability between model-
predicted and observed plasma concentration – time profiles into two components, 
namely inter-individual variability (ω) and within-subject or intra-individual variability 
(σ). The objectives of population pharmacokinetic modeling are (i) to identify the 
covariates which can explain these inter-individual variabilities, and (ii) to quantify and 
minimize the residual variability. 
 
The population pharmacokinetic modeling approach consists of three basic components: 
(i) structural pharmacokinetic model, which describes the (compartmental) structure of 
pharmacokinetic model underlying the observed plasma concentration – time profiles, (ii) 
statistical error models or random effect models, which comprise the error models for 
inter- and intra individual and inter-occasion variability, and describe the random 
differences between observations and structural model predictions., and (iii) covariate 
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model, which describes the relationship between covariates (demographic, 
pathophysiological etc.) and pharmacokinetic parameters. 
 
4-6.2 Structural models  
Structural models are usually the pharmacokinetic models (e.g., one-compartmental, two-
compartmental model) which describe the plasma concentrations across observation 
time-points. These models generate predictions of concentrations at appropriate time 
points as a function of model parameters (pharmacokinetic and non- pharmacokinetic), 
doses and observation time points (98). The structural model, if possible, should be 
selected based on a-priori available information about the drug; a less complex, but 
statistically significant model should be preferred over complex models. For example, if a 
drug follows entero-hepatic recycling, models with entero-hepatic recycling components 
should also be tested along with other simplified models. Structural models are usually 
expressed using primary pharmacokinetic parameters such as clearance (CL) and volume 
of distribution (V) rather than rate constants, which allow the direct assessment of impact 
of covariates on these parameters.  
 
4-6.3 Statistical error models 
4-6.3.1 Residual error model 
This statistical model describes the distribution of random residual errors. Residual error 
is the difference between ‘model predicted true subject concentrations’ and ‘observed 
concentrations’. It includes, but is not limited to, intra-individual variability, model 
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misspecifications, errors in assay method, dosing errors and errors in recording of dosing 
times. The three most common error structures are: 
a. Additive error model: 1ε+= TYY  
b. Constant coefficient of variation or proportional error model:                      
 )11(* ε+= TYY  
c. Mixed additive + constant CV model: 
2)11(* εε ++= TYY  
Where, Y represents the actual observation, TY is the ‘model predicted true value’ of the 
observation and 1ε and 2ε  are the residual error terms used to describe the difference 
between Y and TY. 
 
4-6.3.2 Inter-individual variability model 
This is another type of statistical model, which describes the inter-individual variation in 
pharmacokinetic parameters after adjusting for fixed effects. Inter-individual variations 
are random differences between typical population mean values and true individual 
values, i.e. η. Commonly, the exponential or log-normal model is used to define this 
variability, such as: 
  )exp(* CLTVCLCL η=  
The other two less commonly used structures are: 
Additive error model: CLTVCLCL η+=   
Proportional or constant coefficient of variation model: 
)1(* CLTVCLCL η+=     
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Where, TVCL is the typical value of clearance (CL) and CLη is the difference of the 
patient-specific value from the typical (population mean) value. 
 
4-6.3.3 Inter-occasion variability model 
For data which are collected on multiple occasions for the same individual, such as 
plasma concentration – time profiles collected after single dose and at steady-state, an 
additional variability parameter, the inter-occasion variability, is sometimes used to 
describe the random variability in individual pharmacokinetic parameters across 
occasions. It is modeled as: 
)exp(* 1BOVTVCLCL CL += η    
Where,  = 1BOV kη  (k=number of occasions=1, 2,..N). kη  is a normally distributed 
random variable with mean of zero and variance , i.e. 2kπ kη ~N (0, ). 2kπ
 
4-6.4 Covariate model 
Covariate model building involves the quantitative assessment of relationship between 
covariates and structural pharmacokinetic model parameters, in order to evaluate the need 
for special dose adjustments in a subgroup of patients. The process for identification of 
covariates and steps used for their inclusion in the final model are summarized below: 
 
4-6.4.1 Identification of covariates and inclusion in the model 
Candidate covariates are selected based on graphical and statistical assessment of their 
relationship between covariates and post-hoc Bayesian estimates of individual random 
effects ( iη  values). Statistical correlations are assessed by regression analysis or one-way 
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ANOVA, using statistical software such as JMP and S-plus. The covariates which are 
significant at a pre-specified significance level of p<0.05, and for which we have suitable 
mechanistic explanation, are included in the model using stepwise forward regression 
method. The hierarchical models (with and without covariates) are then compared using 
likelihood ratio test. Covariates, inclusion of which results in decrease in objective 
function value (OFV) by 3.84 (Chi-square statistics at p=0.05 and df=1), are retained in 
the model. The covariate search process is repeated until all significant covariates (at 
p=0.05 level), are included in the model, after which stepwise backward elimination is 
performed. A significance level of 0.01 is used for backward analysis, where covariates, 
elimination of which increases the OFV by 10.83 (Chi-square statistics at p=0.01 and df 
=1), are retained in the model. The backward elimination process is repeated until all the 
remaining covariates are significant at p=0.01 level. This approach is referred as a 
stepwise forward inclusion and backward elimination method. Alternatively, only 
stepwise forward inclusion or stepwise backward elimination approaches are used. 
 
4-6.4.2 Covariate model structures 
Several different structures can be used to enter the covariates into the model, depending 
on the form of relation between covariate and iη  values. Some examples of covariate 
model structures for continuous and categorical covariates are shown below: 
Linear structure 
Continuous covariate: )(* medianiWtCLi WtWtTVCL −+= θθ  
Categorical (binary) covariate: imalefemaleCLi GenderTVCL *, θθ +=                              
Power structure 
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Continuous covariate:  WtmedianiCLi WtWtTVCL
θθ )/(*=
Categorical (binary) covariate:                                    iGendermalefemaleCLiTVCL )(*, θθ=
Exponential structure 
Continuous covariate:  )*exp(* iWtCLi WtTVCL θθ=
Categorical (binary) covariate: )*exp(*, imalefemaleCLi GenderTVCL θθ=  
Where, CLθ  is the population mean for CL, Wtθ  is the effect size for weight’s relation 
with CL,  is the individual weight and  is the median weight for study 
population. Similarly, 
iWt medianWt
femaleCL,θ  is the population (mean) CL for females and maleθ  is the 
effect size for impact of (male) gender on CL. The gender variable was 1 for males and 0 
for females. 
 
4-7 Characterization of pharmacokinetics by population- pharmacokinetics analysis 
4-7.1 Methods 
4-7.1.1 Patients and data collection 
Full plasma concentration-time profiles after initial-doses and at steady-state as well as 
sparse samples from 112 patients were used for population pharmacokinetic analysis, 
which included the 106 patients used for non-compartmental analysis, 2 patients with KS 
for which only day 7 pharmacokinetics was drawn and 4 additional solid tumor patients 
on sorafenib and bevacizumab combination trial for which non-compartmental analysis 
was not performed due to limited sampling (Table 4-14). Data from 6 patients with KS 
who received sorafenib in combination with ritonavir were not included in the analysis, 
because of the potential for drug interaction. Study design and dosing regimen for these 
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trials are described under non-compartmental analysis in section 4-4.1.1. Apart from 
samples for pharmacokinetics and pharmacogenetic analysis; demographic, liver and 
kidney function markers were collected at baseline. Data from both the dose levels, and 
from day 1 as well as steady-state were used together to perform this analysis.   
 
4-7.1.2 Pharmacokinetic sampling and sample analysis 
Sampling schedules for patients enrolled in sorafenib trials are summarized in Table 4-2. 
All the samples were analyzed by using the validated liquid chromatographic method 
with mass spectrometric detection described in chapter 3.  
 
4-7.1.3 Genotyping analysis 
As described in section 4-4.1.3, genotyping was performed for CYP3A4*1B, 
CYP3A5*3, UGT1A9*3, UGT1A9*5, VEFR2 H472Q and VEGFR2 V297I SNPs using 
PCR sequencing reaction. Details of these procedures are described in chapter 7.  
Table 4-14 Details of sorafenib trials. 
No. of patients with 
sampling after 
Ethnicity Therapy Sorafenib 
dose 
Cancer 
type 
Initial 
doses 
Steady-
state 
Cauc AA Others
Monotherapy 400 mg BID mCRPC 46 NA 38 5 3 
Monotherapy 400 mg BID NSCLC 18 17 12 2 4 
Combination 200 mg BID ST 28 12 27 0 1 
Combination 400 mg BID CRC 18 NA 13 3 2 
Monotherapy 
/ Combination 
200 mg 
QD/BID 
KS NA 2 2 0 0 
Total   110 31 92 10 10 
Cauc: Caucasian, AA: African-American, Others: Asians and Hispanics 
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mCRPC: metastatic castrate resistant prostate cancer, NSCLC: non-small cell lung 
cancer, ST: solid-tumor, CRC: colorectal cancer, KS: Kaposi’s sarcoma 
 
4-7.1.4 Software 
Population pharmacokinetic model development and simulations were performed by non-
linear mixed effect modeling approach. The software package used was NONMEM 
version VI level 2.0 (ICON Development Solutions, North Wales, PA). NONMEM was 
compiled by Intel Visual Fortran compiler version 10 (Intel Corporation, Santa Clara, 
CA) on Windows XP operating system. Data processing and statistical analyses were 
performed using JMP statistical software version 8.0 (SAS Institute, S Cary, NC). The 
appropriateness of models was assessed by graphical diagnostics, using Xpose version 4, 
an R-based model building software.  
 
4-7.1.5 Estimation method 
For initial models the FO POSTHOC estimation method was used, with the intent to 
identify the suitable initial estimates for vector of model parameters. After finding initial 
estimates, all NONMEM analyses were performed using the FOCEI. Estimates from 
FOCEI method were found to be close to the real values compared to FO method (99). 
 
4-7.1.6 Selection of structural model 
Previously, a two-compartmental model with first-order absorption, first-order 
elimination and absorption lag time has been shown to describe the sorafenib 
pharmacokinetics, using a much larger data set than used in current analysis (51). 
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However, in our NCI trials, insufficient samples were drawn during the drug distribution 
phase, resulting in unstable estimates for distribution phase parameters during testing of 
two-compartment models. To account for entero-hepatic recycling and GI solubility 
limited absorption, entero-hepatic recycling, mixed zero- and first-order absorption, and 
GI absorption transit compartments were evaluated with one- or two-compartment 
models. A log-transformation of both side (LTBS) approach was used, where logarithm 
of observed concentrations were fitted to the model to predict the log-transformed 
concentrations. 
 
4-7.1.7 Statistical models 
The difference between model-predicted individual concentrations, , and observed 
plasma concentrations, , i.e. residual error, was modeled using a combined 
proportional 
ijCˆ
ijC
)1( ijε  and additive error ( ij2ε ) model: 
2
2
2 21)ln()ln(
ij
ij
ijijij C
CC )
) εε ++=   
),(ˆ ijiij tpfC =  
where  [ng/mL] and [ng/mL] are the observed and predicted concentrations at jth 
time point measured in the ith patient, and the 
ijC ijCˆ
)( ijkε  (k=1, 2) are random error terms. 
These errors follow normal distribution with mean of zero and variance of , and the 
variance  is estimated during analysis. Predicted concentrations  are modeled as a 
2
kσ
2
kσ ijCˆ
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function of individual pharmacokinetic variables for ith subject, (described below), at a 
time tij. 
ip
 
The difference between ‘model-predicted individual true pharmacokinetic parameters’ 
and ‘mean population pharmacokinetic parameters’, i.e. inter-individual variability, was 
modeled using an exponential error model: 
)exp(* iip ηθ=  
Where, θ denotes the typical value of pharmacokinetic parameter P (e.g., CL, V) in the 
population,  is the individual value for P for ith individual, and ip iη  is a random variable 
with a mean of zero and variance . The variance  is estimated during analysis. 2pω 2pω
 
The inter-occasion variability was modeled as third type of random effect, where day 1 
and steady-state were defined as two separate occasions: 
)exp(* ikikip ηηθ +=   
Where, is the individual value of pharmacokinetic parameter P (e.g., CL, V) in ith 
individual at occasion k, 
kip
iη  is a random variable with a mean of zero and variance , 
and 
2
pω
ikη  is a random variable with a mean of zero and variance at occasion k and zero 
otherwise.   
2
pπ
 
4-7.1.8 Model building criteria 
Model selection was guided by the following goodness-of-fit criteria: 
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i) The likelihood-ratio test, also known as the log-likelihood criteria, was used to 
compare nested alternative models. The difference in log-likelihood [-2 (log L1 - 
logL2)] or the ratio of the NONMEM objective function values [-2 log (L1/L2)] 
follows a Chi-square distribution. Hence the reduction in objective function by 3.84 
units (Chi-square distribution value at probability of 0.05, df=1) was considered 
significant for the selection of the alternative model. For non-nested models, the 
Akaike Information Criteria (AIC) was used, which was derived as follows: 
AIC= -2 log likelihood + 2*k   where k = no. of model parameters  
ii) Diagnostic plots: The following diagnostic plots were used to evaluate the goodness 
of fit. 
- scatter plot of observed and predicted concentrations vs. time (DV, PRED and 
IPRED vs. Time) 
- Observed vs. population or individual predicted concentration (DV vs. PRED or 
DV vs. IPRED) 
- Weighted residuals vs. time 
- Weighted residuals vs. PRED 
iii) Precision of parameter estimates. The covariance matrix was used to assess the 
standard errors on estimated (population mean and inter- and intra-individual 
variability) parameters. Large standard errors could indicate over-parameterization.   
 
4-7.1.9 Covariate model 
The covariates which were explored are summarized in Table 4-15. There were no 
missing values for any of the continuous covariates. Candidate covariates were first 
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identified by evaluating the graphical and statistical relationship between covariate and 
empirical Bayesian estimates of the relevant individual random effects (η). The 
covariates which met the pre-specified significance criteria of p<0.05 were included in 
the model, one-by-one, using the stepwise-forward regression method. Body weight was 
included in an allometric model on volume with allometric quotient fixed to the literature 
value of 1 (100, 101). Other candidate, continuous covariates were entered using the 
linear models. If there were multiple covariates for the same parameter, their combined 
effect was described by multiplicative equations. For example, if both BW and albumin 
were covariates for volume of distribution (V), the covariate model for typical value of V 
(TVV) was describes as below: 
))(*1(*)/*( 1 medianiALBmedianivi ALBALBWTWTTVV −+= θθ  
where body weight (BW) is standardized by median value and albumin (ALB) is centered 
at median value. 
Categorical covariates, if found significant, were included in linear form in the model, as 
shown in example below: 
)*1(* _ idiffmalefemalei GenderTVCLCL θ+=  
Where, Gender variable is 1 for males and 0 for females, and diffmale _θ  indicates the 
percentage by which male clearance is higher than females. 
After all the significant covariates were entered into the model, the model was further 
refined by stepwise backward elimination. The covariates that already existed in the 
model were removed; one at a time, and the resulting objective function values were 
compared with the previous models, with a significance level of 0.001. If the increase in 
objective function value was ≥10.83, the covariate was retained in the model. 
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Graphical goodness-of-fit assessments, as described in section 4-7.1.8, were also 
performed simultaneously with statistical testing. 
 
4-7.1.10 Model evaluation 
The predictive performance of the model was tested by performing the visual and 
posterior predictive checks. The final model and the final parameter estimates were used 
to simulate the data for 10000 virtual patients. The 5th, 50th (median) and 95th percentiles 
were estimated for simulated concentrations at each time point. The distribution of 
simulated concentrations was then compared with the distribution of actual observed 
sorafenib concentrations (102). 
 
For the posterior predictive check 500 Monte Carlo simulation replicates of the original 
dataset were created using the final model. Average dose normalized concentrations for 
one dosing interval (Cavi (0-12)) were estimated for each individual, after initial doses and 
at steady-state. For each simulated data replicate, summary statistics such as first quartile, 
median and third quartile were calculated, which were referred to as the prediction test 
quantities. Prediction distribution for each test quantity was generated using the data from 
500 replicates. These were compared with the similar test quantities calculated using the 
observed dataset (dose normalized concentrations), which were referred to as the realized 
test quantities. A prediction P value (Pp) was calculated for each test quantity as the 
fraction of simulated values that were equal or greater than the realized values (equation 
1) (103). The Bayesian Pp value was the probability of replicated data being equal or 
more extreme than the observed data. 
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where, I(•) is an indicator function with value of 1 when its argument is true or zero 
otherwise, yirep is the value of test quantity for ith replicate data set, yod is the respective 
test quantity for observed data set, θ represents individual specific pharmacokinetic 
parameters, and Nrep is the total number of replicates. 
 
We also calculated the probability of equivalence (Peqv) for dose normalized trough 
concentrations, i.e, concentrations at 12th and 24th hr (C12 and C24), both after initial 
doses and at steady-state, using the following equation (103): 
∑ ∑
= = ⎟
⎟
⎠
⎞
⎜⎜⎝
⎛ ≤≤=
rep subN
i
obs
j
rep
ij
N
jsubrep
eqv yT
yT
I
NN
P
1 1
25.1
)(
)(
80.011           (2) 
where Nsub is the total number of subjects in one replicate data set, and yijrep is a test 
quantity for the jth patient in the ith replication.  
In this approach, the ratio of test quantity for simulated data set (T (yijrep)) and observed 
data were determined for each subject. Indicator function was assigned a value of 1, when 
this ratio was between 0.8 – 1.25 (both inclusive), or zero otherwise, as shown in 
equation 2. The proportion, for which the test statistic for replicated data set was between 
0.8-1.25 times of realized test statistic, was indicative of probability of equivalence. 
 
4-7.2 Results 
4-7.2.1 Patient demographics and genotypes 
The population pharmacokinetic analysis was started with 112 patients; however, one 
patient was excluded during analysis because of an extremely high value (outlier) for 
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volume of distribution, which caused destabilization of the model. As mentioned earlier, 
patients were enrolled in 5 different phase I/II clinical trials, and sorafenib was 
administered as either single agent or in combination with chemotherapies at 200 or 400 
mg BID dose levels. The demographic and clinical characteristics of 111 patients used in 
final analysis are summarized in Table 4-15. Genotype and allelic frequencies for 
polymorphisms in metabolic enzymes and drug target are described in Table 4-16. In 
total, 1276 plasma concentrations were used in the analyses. Initial-dose plasma 
concentration data were available from 110 patients and steady-state data were available 
from only 31 patients (Table 4-14). There were no missing values for continuous 
covariates, but genotype data were missing for 4 to 6 patients because of difficulties in 
PCR amplification.  
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Table 4-15 Patient characteristics 
 Mean ± SD Median Range 
Number of patients 111   
Trial / Tumor type† mCRPC, 45 (stage 1, 22; stage 2, 23);  
NSCLC, 18 
CRC, 18 
KS, 2 
ST, 28 (Arm A, 13; Arm B, 15) 
Dose 400 mg BID, 81 
200 mg BID, 30 
Occasion Single dose, 109 
Steady-state, 31 (patients with only steady-state, 2) 
Ethnicity Caucasian, 90; African-Americans, 12; Others, 9 
Age, years 62.6 ± 11.1 63.9 30.3 – 84.9 
Sex, male/female 77 / 34   
Body weight, kg 82.7 ± 19.4 81.4 35.2 – 132.5 
BSA, m2 1.9 ± 0.27 1.9 1.2 – 2.5 
Biochemical Parameters    
  Albumin, g/dL 3.6 ± 0.4 3.6 2.2 – 4.4 
  Total protein, g/dL 6.6 ± 0.6 6.6 4.6 – 8.0 
  Alk phosp, U/L 99.5 ± 57.3 82 34 – 414 
  Total bilirubin, mg/dL  0.65 ± 0.25 0.6 0.1 – 1.7 
  AST, U/L 28.6 ± 11 26 13-90 
  ALT, U/L 23.9 ± 12.6 21 8 – 75 
  SCr, g/dL 0.96 ± 0.23 0.9 0.4 – 1.9 
  CLCr, mL/min 97.7 ± 34.3 95.3 25.6 – 225.7 
†Each trial evaluated the sorafenib’s efficacy in different type of solid tumors  
mCRPC: metastatic castrate resistant prostate cancer; NSCLC: non-small cell lung 
cancer; CRC: colorectal cancer; KS: Kaposi’s sarcoma; ST: solid tumors; BID: twice-a-
day; Alk phos: alkaline phosphatase; AST: aspartate transaminase or SGOT; ALT: 
alanine transaminase or SGPT; SCr: serum creatinine; CLCr: creatinine clearance 
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Table 4-16 Summary of genotype distribution for patients on sorafenib trials 
Genetic Variants N Genotype Frequenciesa Allele Frequenciesb  
  Wt Het Var P q p-valuec 
CYP3A4*1B 108 89 (82.4) 10 (9.3) 9 (8.3) 0.87 0.13 0.14 
CYP3A5*3C 108 8 (7.4) 17 (15.7) 83 (76.9) 0.15 0.85 0.12 
UGT1A9*3 107 103 (96.3) 3 (2.8) 1 (0.9) 0.98 0.02 <0.01 
UGT1A9*5 107 107 (100) 0 (0) 0 (0) 1 0 NC 
VEGFR2 H472Q 106 66 (62.2) 35 (33.1) 5 (4.7) 0.79 0.21 0.87 
VEGFR2 V297I 106 78 (73.6) 25 (23.6) 3 (2.8) 0.85 0.15 0.99 
Wt, wild type sequence; Het, heterozygous and Var, homozygous variant sequences; 
p, q are standard Hardy-Weinberg nomenclature for allele frequencies 
a. Number represents number of patients with percentages in parentheses 
b. Data are given as relative frequency 
c. p-value for evaluation of Hardy-Weinberg equilibrium for Caucasian subjects only 
NC-Not calculated 
 
Fig 4-11 Representative plasma concentration – time profiles for patients included in 
current population pharmacokinetic analysis. Arrows represent the dose administration 
times. 
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4-7.2.2 Model building 
Typical plasma-concentration time profiles from patients on these trials are shown in Fig. 
4-11. Double peaks were observed for almost 8% patients on these trials, which is 
characteristic of drugs undergoing entero-hepatic recycling. For other patients, although 
distinct double peaks were not observed, the rate of decline in plasma concentrations was 
reduced after 5-6 h, suggesting that loss of drug from central compartment may have 
been hampered by EHR or re-distribution of drug from peripheral compartment. Earlier 
the pharmacokinetics of sorafenib was described by a two compartment model, with 
absorption lag-time and first order elimination (51).   
 
When we began the population pharmacokinetic modeling for sorafenib, data from only 
109 patients were available. One-compartment, two-compartment and entero-hepatic 
recycling models were tested using plasma concentration-time profiles on normal scale. 
Due to limited sampling in distribution phase, the estimated distribution parameters for 
two-compartment model were unstable; therefore, those parameters were fixed to 
previously reported values (51). Several different GI absorption models, including the 
absorption lag-time and sequential zero- and first-order absorption were tested to describe 
the solubility limited absorption for sorafenib. With data from 109 patients, when 
concentrations on a normal scale were fitted to the pharmacokinetic model to predict the 
normal scale concentrations, a one compartment model with sequential zero- and first-
order absorption, absorption lag time and first order elimination was found to adequately 
describe the observed plasma concentration-time profiles. The schema of this final model 
and parameters estimates are presented in Fig 4-12 and Table 4-17, which was also 
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presented at 2009 annual meeting of American Society of Clinical Pharmacology and 
Therapeutics (ASCPT) (104). 
 
 
Fig 4-12. Structural model for the initial population pharmacokinetic model, describing 
the plasma concentration – time profiles for sorafenib (104). 
 
Table 4-17. Parameter estimates from the initial population pharmacokinetic model 
(N=109) 
Parameter Population mean % BSV 
 (%RSE) (%RSE) 
CL/F, L/h 4.74 (11.6) 45 (27.9) 
V/F, L 156 (9.8) 80 (20.9) 
ka, 1/h 1.04 (17.0) 136 (35.6) 
Tk0, h 1.92 (16.5) 30 (39.4) 
ALAG1, h 0.196 (11.5) 145 (55.9) 
ALAG1~African American 0.696 (5.9)  
Residual error   
Additive (ng/mL) 68.3 (44)  
Proportional (%CV) 48 (12)  
% Relative standard error (RSE) = (SE/Mean)*100 
 
However, there were few limitations to this model, including (i) high residual errors in 
the predicted plasma concentrations (i.e., additive, 44 ng/mL and proportional, 50%), (ii) 
high imprecision for absorption parameters (i.e. standard error of 55% for Ka, 62% for 
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absorption lag-time, and 41% for duration of zero order absorption), and (iii) large 
residuals for the steady-state profiles. 
 
In continuing with model development, we updated the above model with data from a 
total of 112 patients; however, one patient was excluded from model building because of 
extremely high value (outlier) for volume of distribution, causing destabilization of the 
model. A total of 1276 plasma concentrations were used in updated analysis. To resolve 
the problem of large residuals, limitations (i) and (iii) above, both side log-transformation 
approach was used. The log-transformed observed concentrations were fitted with the 
model to make predictions of log-transformed concentrations. The poor description of 
absorption profile, limitation (ii) above, might have been because of model 
misspecification or estimation of delay in absorption as lag-time. At the point of lag-time, 
the differential equation solver in NONMEM attempts to integrate over a discontinuity, 
which may result in numerical problems (105). To resolve this problem, the apparent 
delay in absorption was modeled with GI transit absorption compartments, which 
described the concentration-time profile as a gradually increasing continuous function. 
This was also a better model to reflect the physiological absorption process. Hence, the 
GI transit compartments absorption model was tested as a replacement of mixed-order 
absorption process with lag-time, to overcome the limitation (ii) (see above). 
 
With these modifications, one- and two-compartment models with and without entero-
hepatic recycling were re-tested. Although several EHR models (106-108) had been 
tested initially, before we finalized the initial one-compartment model, a few additional 
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EHR models were also evaluated during this modification stage. Initial estimations were 
performed with FO POSTHOC method. Graphical and statistical assessment of evaluated 
models revealed that addition of EHR improved the model predictability for observed 
plasma concentration-time profiles both after initial-doses and at steady-state. Therefore, 
the EHR component was retained for further analyses. The number of GI transit 
compartments was adjusted (N=2, 3 or 4), and different arrangements (parallel vs. 
sequential) were tested. A model with four serial transit compartments was found to 
adequately describe the absorption phase. 
 
The best model from this stage, a one-compartment model with entero-hepatic recycling, 
GI transit absorption compartments (N=4) and first order elimination, was re-assessed 
with FOCE INTER estimation method. The number of GI transit compartments were also 
re-adjusted, but N=4 remained superior. The scheme of this optimized, final structural 
model is shown in Fig 4-13. Four transit-compartments, each of them receiving drug 
from the antecedent and releasing drug into the subsequent transit-compartment with a 
first-order rate constant ka, accommodated the apparent lag time and a highly variable 
Tmax. EHC was modeled with a semi-mechanistic model, where a fraction of drug from 
the central compartment (Fent) was hepatobiliarily excreted (transferred) into a gall-
bladder compartment with a first-order rate kb, which, in turn, periodically emptied drug 
into the last GI transit-compartment at a first-order rate of kEhc. For modeling purposes, 
Fent was logit-transformed, to constrain its value between 0 and 1, and to allow typical 
parameters to be estimated as a continuous function (between -infinity to +infinity). The 
periodic drug release from the gall bladder compartment was regulated by the “on-off” 
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switch ‘Ehc’, modeled by a square-wave function. The remaining fraction of drug in the 
central compartment, (1-Fent), was eliminated by a first-order rate process, characterized 
by  ke and reflecting hepatic metabolism and irreversible biliary excretion; ke was 
parameterized in terms of clearance (CL/F) and volume of distribution (V/F). 
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Fig 4-13 Final base model for describing the plasma concentration – time profiles for 
sorafenib. ka: first-order absorption rate constant, ke: first-order elimination rate constant, 
kb: first-order rate constant for transfer of sorafenib to gall-bladder, kEHR: first-order rate 
constant for secretion of sorafenib in bile to GI transit compartments, Fent: fraction 
undergoing entero-hepatic recycling, Ehc: switch to regulate the bile secretion, which 
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was turned-on at ADT time after administration of dose. A0, Ac.c.and Ag.b. are amounts of 
drug in absorption, central and gall-bladder compartment, and their initial conditions 
were set to zero except A0, which was assumed to contain the entire dose at time zero. 
 
During initial modeling, kb and ke were estimated independently, but assuming kb = ke 
(i.e., Fent =50%) adequately described the EHC for sorafenib. IIV was estimated only for 
CL/F, V/F and ka. For all other parameters, η’s had either high shrinkage (i.e., >30 %) or 
low precision; therefore, these η’s were fixed to zero. All the model parameters were 
estimated; however, BSV was estimated only for pharmacokinetic parameters, i.e., CL/F, 
V/F and ka. Incorporation of correlation between CL/F and V/F resulted in 30-units 
(p<0.001) decrease in objective function value compared to the base model, and 
introduction of inter-occassion variability in CL/F further reduced the objective function 
value by 44-units (p<0.001) compared to model without this variability. Since both these 
changes were statistically significant, they were retained in the model. Additional 
introduction of inter-individual or inter-occasion variability either de-stabilized the model 
and/or was not significant. These optimization steps are summarized in Table 4-18. 
 
After optimization of the base model, the covariate search was initiated using the post-
hoc Bayesian estimates of individual random effects (ηi values) from final base model. In 
first covariate screening, body weight, BSA, gender, albumin, ALT, VEGFR2 H472Q 
and Trial showed up as significant (p<0.05) covariates for ηV/F; only VEGFR2 H472Q 
and VEGFR2 V297I were significant for ηCL/F and ηka, respectively. The same covariates 
were significant for peak plasma concentrations (Cmax) and exposures (AUC0-12) during 
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covariate screening by non-compartmental analysis-general linear modeling (Section 4-
5.2.3.4, Tables 4-12 and 4-13). As described earlier in section 4-5.2.3.2, correlation of 
BSA and gender with ηV/F were confounded by body weight. In covariate model 1, the 
most apparent mechanism-based covariate, body weight, was included in V/F as an 
allometric model. The allometric coefficient (power) was fixed to the literature value of 
1.0, which has been derived based on structural and function properties of biological 
system (100, 101). The inclusion of weight on V/F resulted in 14-units (p<0.001) 
decrease in objective function value and inter-individual variability declined from 72% to 
69%. 
 
Covariate screening was re-performed for post-hoc Bayesian estimates of individual 
random effects from covariate model 1. Albumin and VEGFR2 H472Q were significant 
for both ηV/F and ηCL/F, and only VEGFR2 V297I was significant for ηKa; no other 
covariates were significant for all three parameters. Among these, only the relationship of 
albumin with and ηV/F and ηCL/F were mechanistically plausible. There appeared be a lack 
of gene-dose-response relationship for polymorphism in receptor for sorafenib, i.e., 
VEGFR2. It did not appear to be clinically important. Serum albumin was tested on both 
CL/F and V/F, separately. Incorporation of serum albumin in V/F, in a log-linear model 
with median centered covariate values, resulted in decrease in objective function value by 
5.9-units (p<0.05), while objective function value was not altered following inclusion of 
serum albumin in CL/F. Hence, in covariate model 2, serum albumin was retained as 
covariate for V/F in addition to body weight, which also reduced the inter-individual 
variability on V/F from 69% to 66%. 
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Table 4-18 Summary of selected modelssequentially tested for population 
pharmacokinetic analyses and their objective function values. 
S.N. Model description Remarks OBF ∆OBF† 
 Normal scale (For initial model with data from 109 patients)  
1 One compartment model with sequential zero 
and first order absorption (HYBRID method) 
Base model on 
Normal scale 
16372.5  
2 Two compartment model sequential zero and 
first order absorption (HYBRID method) 
Normal scale 16878.2 505.7 
3 Entero-hepatic recycling models Normal scale >16500 >125 
 Log-tranformed data (For final model with data from 112 patients)  
4 One compartment with entero-hepatic recycling 
and GI transit absorption model (N=4) 
(method=FOCEI) 
Base model on 
log scale 
423.9  
5 Model 4, after exclusion of one subject* and 
inclusion of correlation between CL and V in 
$OMEGA block  
 393.5 (-)30.4  
6 Model 5 + IOV on CL   349.4 (-)44.1 
7 Model 6 + BW as covariate for V/F (allometric 
model) 
CM‡ 1 335.0 (-)14.4 
8 Model 7 + Albumin as covariate for V/F (log 
linear model with albumin centered at median 
value) 
CM 2 329.1 (-)5.9  
9 Model 8 + ALT as covariate for V/F (linear 
model with ALT normalized with median) 
CM 3 320.8 (-)9.1 
10 Model 9, with exclusion of BW from V/F CM 4 355.7 34.9 
11 Model 9, with exclusion of albumin from V/F CM 4 330.5 9.7 
12 Model 9, with exclusion of ALT from V/F CM 4 329.7 8.9 
13 Final model§, model 6 + BW as covariate in 
V/F 
Final model 333.9  
*One subject with very high volume of distribution was excluded to stabilize the model  
†∆OBF = Objective function value for base model – alternate model 
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‡CM: Covariate model  
§Final model is presented below: 
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where θ  are fixed effect parameters and η represents random inter-individual variability. 
T is observation time point, DOST is dose administration time and ADT is absolute time 
after dose administration at which EHR switch turns on. 
Method = FOCE INTER 
NONMEM Subroutine: ADVAN9 TOL=4 
 
In covariate model 3, the covariate screening was repeated for individual post-hoc 
Bayesian estimates of random effects from covariate model 2, and ALT, UGT1A9*3, 
VEGFR2 H472Q and Trial came out as significant covariates for both CL/F and V/F, and 
only VEGFR2 V297I was significant for Ka. For UGT1A9*3, only 1 patient carried the 
homozygous variant genotype (UGT1A9*3*3); therefore, it was not possible to evaluate 
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its impact on pharmacokinetic parameters. The effects of VEGFR2 polymorphisms on 
CL/F, V/F and Ka were considered artifactual. 
 
For the covariate “Trial”, patients who were treated on stage 2 of mCRPC trial and arm B 
of ST trial had relatively low V/F and CL/F compared to the other patients. However, 
comparing the typical values for the pharmacokinetic parameters across entire trials, 
rather than their subdivisions into stages or arms, no significant differences in 
pharmacokinetics were observed. Stages 1 and 2 of mCRPC trial were different only in 
terms of the efficacy endpoints, and administered treatments and pharmacokinetic sample 
collection timepoints were similar between these two stages. In the ST trial, arm B 
patients received sorafenib in combination with bevacizumab after four weeks of 
receiving only bevacizumab (5 mg/m2 IV QS 2 week); while arm A patients first received 
sorafenib for 4 weeks, which was followed by administration of combined therapy (Fig 
4-3). No difference in pharmacokinetics was observed between arm A and arm B by non-
compartmental analysis, and in-vitro plasma protein binding studies also did not show 
any significant change in unbound fraction of sorafenib in plasma following co-
administration with bevacizumab (data not shown). Based on these reasons, the 
significant effect of Trial on CL/F and V/F was thought to be artifactual or associated 
with the small sample sizes and was not considered further. 
 
The ALT values were directly related with ηCL/F and ηV/F; however these relations were 
driven by observations from 5-6 individuals and also appeared to contradict the 
mechanistic expectations. Regardless of mechanistic contradiction, ALT was tested for 
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both CL/F and V/F, to check for any statistical influence. Inclusion of ALT on V/F in a 
linear model with median normalized values reduced the objective function value by 9 
units (p<0.05), while its inclusion on CL/F was not significant (∆obj ≤1). Hence ALT was 
retained on V/F. 
 
During re-screening by using the individual post-hoc Bayesian estimates of random 
effects from covariate model 3, no other covariate was found to be significant, except 
mechanistically implausible effects of VEGFR2 H472Q polymorphism on ηCL/F and ηV/F, 
and VEGFR2 V297I polymorphism on ηKa. 
 
After inclusion of all significant covariates into the model, the step-wise backward 
elimination process was started: In three alternate models, each of these covariates was 
excluded individually from the full model, and their objective function values were 
compared with that of full model. Exclusion of weight increased the objective function 
value by approximately 36 units, which was significant at p<0.001. Omission of serum 
albumin and ALT resulted in a 9.7 and 8.9 units increase in objective function value, 
which were statistically insignificant (p>0.001). Hence, only body weight was retained in 
the final model. Explicitly, the final model was a one-compartment model with following 
features: first-order absorption, GI transit absorption compartments (N=4), entero-hepatic 
recycling, first-order elimination, covariance between CL/F and V/F, BSV for CL/F, V/F 
and ka, inter-occassion variability on CL/F, body weight as covariate on V/F, and 
combined additive and proportional residual error model. 
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4-7.2.3 Goodness-of-fit plots and parameter estimates for the final base and 
covariate model 
Goodness-of-fit plots for sorafenib plasma concentrations predicted from final base and 
covariate model are shown in Fig 4-14 and 4-15. Model predictions were in reasonable 
agreement with observed concentrations. The individual weighted residuals did not 
reflect any systematic deviations. The parameter estimates from the final model are 
summarized in Table 4-19. For a patient with body weight of 81.5 kg, typical population 
clearance (CL/F) was estimated as 8.05 L/h with a volume of distribution of 217 L. 
However, these pharmacokinetic parameters were inter-related with a correlation 
coefficient of 0.77, and were associated with moderate to high inter-individual variability 
ranging from 18-69%. The between occasion variability on CL/F was 48%. 
 
The estimated typical value for CL/F of 8.05 L/h suggests low hepatic extraction, when 
compared to the hepatic blood flow of 90 L/h, which is in accordance with sorafenib’s 
known pharmacokinetic properties with oral bioavailability in rats and dogs ranging from 
67 to 80%, i.e., low hepatic first-pass metabolism. Similarly, the estimated typical value 
for volume of distribution (V/F) of 217 L is in accordance with estimates in rats and dogs 
after IV administration (0.65 to 0.74 L/kg) (33) and with population pharmacokinetic 
estimates in humans after oral administration (109.8 L) (51) observations. This high 
volume of distribution suggests extensive tissue distribution despite high plasma-protein 
binding. The significant relationship of body weight with volume of distribution might be 
explained based on physiological rationale that body volume increases with body weight, 
as dicussed previously. 
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A B
Fig 4-14 Diagnostic plots for the final population pharmacokinetic model on a log-log scale. (A) Population-predicted concentrations 
vs. observed concentrations, and (B) Individual-predicted concentrations vs. observed concentrations 
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Fig 4-15 Diagnostic plots for the final population pharmacokinetic model. Conditional weighted residuals vs. time since last dose 
(TSLD, hours) after (A) initial doses and (B) at steady-state, and (C) Individual-weighted residuals vs. individual predicted 
concentrations  
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The typical value for absorption transit time was 1.98 h, which is the average time spent 
by sorafenib in traveling from gut compartments to the central compartment. The typical 
value for plasma half-life - based on NONMEM estimated parameters - was 18.7 h, 
which was slightly lower than the previously reported range of 25-48 h (49); however, 
plasma sampling in our trials was limited to 12 hours post-dose because sorafenib was 
administered in BID dosing schedule compared to sampling upto 168 hours post-dose in 
selected patients in previous analysis (51). On an average, 50% of the sorafenib reaching 
the central (plasma) compartment underwent entero-hepatic recirculation. The typical 
value for the time of gall-bladder emptying (ADT) was 6.7 h post-dose. 
 
Table 4-19 Estimated NONMEM model parameters 
Parameter NONMEM estimate IIV (%CV) IOV (%)
CL/F (L/h) 8.05 21% 48% 
V/F (L) 217 66% NE 
Mean transit time* (h) 1.98 62% NE 
KEHR (h-1) 0.998 NE NE 
Fent 0.50 NE NE 
ADT 6.66 NE NE 
Correlation CL/F–V/F 0.77 NE NE 
Proportional residual error (%CV) 51.4%   
Additive residual error 0.0003   
*Mean transit time = (n+1)/ Ka = 5/2.51 = 1.98. NE: Not estimated 
 
4-7.2.4 Model evaluation 
The pharmacokinetic model evaluation, including the visual and posterior predictive 
checks, revealed that the final model predictions were in reasonable agreement with 
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observed concentrations. The Fig 4-16 represents the visual predictive check showing the 
median and 90% prediction intervals of model-predicted and observed plasma-
concentration time profiles, after initial doses and at steady-state. The Cav predictions 
from the final population pharmacokinetic model are shown in Fig 4-17. The model-
derived simulations appeared to be in agreement with observed data with Pp values of 
0.90, 0.67, 0.13 and 0.95, 0.66, 0.83 for first quartile, median and third quartile Cav(0-12) 
after initial doses and at steady-state. At both occasions, the PP values for median Cav(0-12) 
were close to 0.5, suggesting that distribution of predicted Cav(0-12) was approximately 
centered around the observed median Cav(0-12). 
The distributions of Peqv for trough concentrations are shown in Fig 4-18. Range of Peqv 
for C12 and C24 was 0.75-1, suggesting that on an average more than 75% of replicated 
simulations met the equivalence criteria. Overall, these results suggest that model-
simulated exposures from the final model were reasonably close to the observed 
exposures that were used for population pharmacokinetic modeling. 
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Fig 4-16 Visual predictive check for pharmacokinetic model. (A). after initial doses and 
(B) at steady-state. Solid (─) and dotted (---) black lines represents the median and 90% 
interval for dose-normalized model-predicted concentrations and observed 
concentrations, respectively; and crosses (x) depicts the actual dose-normalized observed 
concentrations.
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Fig 4-17 Results of the predictive check for final sorafenib population pharmacokinetic model: Histograms showing distributions of 
Cave for 500 replicate simulated data sets, after single dose (A) and at steady-state (B), calculated using the back-transformed (normal 
scale), dose normalized data. 
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Fig 4-18 Results of the predictive check for final sorafenib population pharmacokinetic model: Histograms showing distributions of 
Peqv for trough concentrations at 12th hr (A) and 24th hr (B) for 500 replicate simulated data sets, plotted separately for single dose and 
steady-state. Predictions on log-scale were dose normalized for the plot. 
Non-compartmental & Population Pharmacokinetic Analysis                       Chapter 4 
4-7.3 Discussion 
A mechanism-based pharmacokinetic model was developed and validated to describe the 
sorafenib plasma concentration – time profiles in patients with solid tumors. The 
description of sorafenib pharmacokinetics in most of the currently reported studies was 
based on non-compartmental pharmacokinetic analysis. The reported half-life of 
sorafenib was 25-48 hrs, however, it is mostly administered in a BID dosing schedule, 
making the collection of terminal phase samples unfeasible. Therefore, most 
pharmacokinetics parameters such as exposures upto 12 h (AUC0-12), peak plasma 
concentration (Cmax) and time to peak plasma concentration (tmax) were reported. Only 
one earlier population pharmacokinetic analysis has been reported, which included 226 
cancer patients and 69 healthy subjects and determined that two-compartment model with 
absorption lag-time was descriptive of observed plasma concentration-time profiles (51) 
 
Sorafenib shows a complex pharmacokinetic disposition profile after oral administration, 
where its GI absorption is limited by poor GI solubility and complicated by entero-
hepatic recirculation. High inter-patient variability was reported in sorafenib 
pharmacokinetics after initial doses, the magnitude of which further increased after 
multiple dosing. A mechanism-based pharmacokinetic model for sorafenib was 
developed, taking into account its known pharmacokinetic characteristics. Similar to the 
previous study (51), the impact of demographic and (patho-) physiological variables on 
sorafenib pharmacokinetics was evaluated; in addition, we also examined the impact of 
genetic variation in metabolic enzymes on sorafenib’s disposition. To best of our 
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knowledge, no other study has evaluated the impact of genotype on sorafenib 
pharmacokinetics. 
 
The final population pharmacokinetic model was a one-compartmental model with 
entero-hepatic recycling, serial GI transit absorption compartments (N=4) and first-order 
elimination and absorption. Goodness-of-fit plots showed that the predictions from the 
final model were reasonably consistent with observed data with no systematic bias. The 
implementation of entero-hepatic recycling component improved the predictions at 
steady-state concentrations compared to a one- or two-compartment model without this 
component (or compared to the initial model (104)). Characterization of the sorafenib 
pharmacokinetics with the current data was largely dependent on steady-state plasma 
concentration – time profiles, because collection of terminal phase pharmacokinetic 
samples was not feasible given its BID dosing schedule. Hence, adequate description of 
both plasma concentration-time profiles at steady-state as well as after initial doses was 
desirable.  Population mean values for CL/F, V/F and transit rate constant in the 
absorption model (Ka) were estimated, along with parameters used to describe the entero-
hepatic recycling. Inter-patient variability was estimated only for CL/F, V/F and Ka, and 
between-occasion variability was characterized only for CL/F. The between-occasion 
variability for CL/F was larger than the inter-patient variability. Model evaluation by 
visual and posterior predictive checks confirmed that model predictions were consistent 
with the observed data. 
The results from three different population pharmacokinetic models are compared in 
Table 4-20. 
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Table 4-20 Compariosn of study design and parameter estimates from three population pharmacokinetic models 
Property Prior published model (51) Initial model (N=109) 
(104) 
Final model (N=111) 
No. of patients 229 patients, 69 healthy subjects 109 patients 111 patients 
Dose range 50-800 mg BID 200-400 mg QD/BID 200-400 mg QD/BID 
Pharmacokinetic 
samples 
SD: serial/sparse samples upto 12 hr or upto 
168 hrs (few patients) 
SS: upto 12 hrs post-dose selected patients 
SD: serial samples upto 
12 hr (N=106) 
SS: serial samples upto 
12 hr (N=30) 
SD: serial samples upto 12 hr (N=110) 
SS: serial samples upto 12 hr (N=31) 
Structural (Base) 
model 
Two-compartment model with absorption 
lag time and first-order absorption and 
elimination. Frel modeled as a function of 
dose to incorporate the observed infra-
proportional increase in sorafenib exposure 
One-compartment model 
with absorption lag time 
and sequential zero- and 
first-order absorption 
One-compartment model with serial GI transit 
absorption compartments (N=4) model and EHC 
Final Parameter 
estimates 
CL/F = 3.31 L/hr (IIV, 25%) 
Vc/F =  85.2 L (IIV, 10%) 
Vp/F = 24.6 L (IIV, 45%) 
CL/F = 4.74 L/hr (IIV, 
45%) 
V/F = 156 L (IIV, 80%) 
CL/F = 8.05 L/hr (IIV, 18%; IOV, 48%) 
V/F = 217 L (IIV, 68%) 
Mean transit time = 1.98 hr 
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ka = 0.229 hr-1 (IIV, 104%) ka = 1.04 hr-1 (136%) 
Covariates Ethnicity (Japanese vs. non-Japanese) 
for ka and Frel 
Body weight for V/F 
 
Body weight for V/F 
Comments -Body weight (range 36-155 kg) was 
screened as a covariate for both Vc/F 
and Vp/F. Because two different 
volumes were estimated, weight may 
not have been identified as a significant 
covariate.  
-None of the studied covariates were 
clinically relevant. 
-Considering the IIV, 
estimated parameters 
are reasonably close to 
the previously reported 
values.  
-None of the studied 
covariates were 
clinically relevant. 
-Both CL/F and V/F are almost double than the 
previously reported values, which could be 
explained by 50% drug undergoing EHC. If we 
consider that 50% of the bioavailability is 
because of EHC, the estimated parameters 
would be reasonably close to previous reports. 
-None of the studied covariates were clinically 
relevant. 
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The clearance estimates from the final (8.05 L/h) were clearly different from the 
previously reported population pharmacokinetic analysis (3.31 L/h) and our initial model 
(4.74 L/h). Comparison with the previous analysis was limited by their dose-dependent 
relative bioavailability assumptions (across a large dose range) and better representation 
of terminal phase in their model (samples upto 168 hrs were collected for selected 
patients after single dose) (51). These differences can further be explained by the 
involvement of EHC in the final model (Table 4-20). On average, 50% of the sorafenib 
reaching systemic circulation underwent EHC; this suggests that EHC provides a major 
contribution to the overall plasma exposure of sorafenib. Steady-state concentrations 
were highly variable for these patients, which could not be properly described by our 
initial model. Therefore, pharmacokinetic parameters from our initial model should be 
carefully considered with this limitation. Nevertheless, all clearance estimates were 
indicative of low hepatic extraction ratio for drugs cleared by hepato-biliary elimination, 
which is consistent with predictions based on clearance from preclinical studies (33). 
Similarly, the estimate for apparent volume of distribution from our study (217 L) was 
different from previous analysis (volume of central compartment, 85.2 L and peripheral 
compartment, 24.6 L) and our initial model (156 L), but all of them suggest extensive 
tissue distribution. Again, these differences can be explained by involvement of EHC in 
the final model (Table 4-20). Mean transit time was estimated as 1.98 h. The BSV on 
these parameters ranged from 18-69% and IOV on CL/F was 48%. High variability 
estimates were in agreement with results of non-compartmental analysis (35, 38-40) and 
previously reported population pharmacokinetic analysis, where estimated BSV ranged 
between 10-104% (51). Potential reasons for this high pharmacokinetic variability were 
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mentioned above, including the poor GI solubility, differences in extent of entero-hepatic 
recycling among patients, high plasma protein binding and the possible effect of food on 
bioavailability. Sorafenib administration was not controlled or monitored in terms of food 
consumption in these trials. Pharmacokinetic parameters were not different based on 
studied dose levels (200 and 400 mg BID) which was in agreement with previous report 
(51) , and estimates of parameters were not altered significantly over multiple dosing, 
except CL/F.  
 
The previous study reported ethnicity (Japanese vs. Non-Japanese) as a significant 
covariate for absorption rate constant and relative oral bioavailability (51), which was not 
assessable with the current data since no Japanese patients were enrolled in trials at NCI. 
Our results show body weight as a significant covariate for V/F, which was not true in the 
previous analysis (51). However, inclusion of body weight explained less than 4% of the 
inter-patient variance on V/F and approximately 68% remained unaccounted for. 
Therefore, clinical dose adjustments based on weight are not recommended. The other 
examined demographic, physiological and pharmacogenetic covariates appeared to be 
unimportant for description of sorafenib pharmacokinetics, which is supported by the 
findings from previous population pharmacokinetic analysis (51) and clinical studies (37, 
94).  
 
Other potential covariates which were not studied, but could conceivably contribute to 
the variability in sorafenib pharmacokinetics include co-medications: Co-administration 
of sorafenib with antibiotics and/or proton-pump inhibitors may influence its GI 
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solubility and/or the extent of EHC, by altering the GI pH and deconjugation activity 
(mediated by intestinal bacteria). Information about co-administered medications was not 
available from all the trials involved in current analysis; hence, its impact could not be 
evaluated. Genetic polymorphism in drug transporters involved in hepatobiliary 
elimination, such as P-gp and MRP2, which were not measured in the study may also 
have contributed to EHC and be responsile for at least part of the remaining, unexplained 
pharmacokinetic variability/model imprecision. Co-administered drugs may also induce 
or inhibit the activity of transporters and metabolic enzymes (109). 
 
A recent clinical study prospectively enrolled 138 cancer patients with various degrees of 
liver and kidney dysfunctions (9 different cohorts) to study their impact on sorafenib 
pharmacokinetics (94). The majority of patient cohorts in this study were defined based 
on laboratory values for total bilirubin, AST and CLCr; serum albumin was also used to 
define one of the cohorts. Pharmacokinetics was measured after single-dose by non-
compartmental analysis and no significant differences in AUC0-12 of sorafenib or its N-
oxide metabolite were apparent between these patient cohorts (94). However, lower 
maximum tolerable doses of 200 mg BID to 200 mg QD were recomended for patients 
with moderate to very severe liver dysfunction based on long-term toxicity profile, in 
contrast to the clinically approved dose of 400 mg BID (94). These differences in 
tolerable dose may have been related with long-term sorafenib exposures (i.e., cumulative 
sorafenib exposures or steady-state pharmacokinetics), which was not assessed for these 
patients. The limitation of this study was that only two laboratory parameters (i.e., total 
bilirubin and AST) were considered to determine the functional state of the liver, as 
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against the five criteria (i.e., total bilirubin, serum albumin, INR, ascites and hepatic 
encephalopathy) used in Child-Pugh scoring system generally used to assess the severity 
of chronic liver disease. Further studies might be needed to better understand the impact 
of chronic hepatic impairment on long-term sorafenib exposures. Another study 
comparing the systemic exposure of sorafenib in patients with Child-Pugh A and B 
hepatocellular carcinoma, failed to find any statistical difference between two groups, 
although, the geometric mean for AUC0-8 and Cmax were higher for patients with Child-
Pugh B disease (44)(section 1-2.2.6). No dose adjustments were recommended for 
patients with renal impairment, which were not unexpected, given that only a small 
proportion (i.e., ~19%) of sorafenib is eliminated in urine as metabolites (33). 
 
Patients in current analysis were genotyped for single nucleotide polymorphisms in 
metabolic enzymes for sorafenib, namely CYP3A4*1B, CYP3A5*3C, UGT1A9*3 and 
UGT1A9*5. In studied population, no one carried the variant allele for UGT1A9*5, 
hence it was not included in covariate analysis. CYP3A4*1B and CYP3A5*3 were not 
related with sorafenib pharmacokinetics. These results were in agreement with findings 
from a clinical study where co-administration of ketoconazole, a potent CYP3A4 
inhibitor, had no significant effect on sorafenib pharmacokinetics (37). UGT1A9*3 was 
significant for both CL/F and V/F in third step of covariate analysis, but its impact on 
these pharmacokinetic metrics could not be studied because very few patient carried the 
homozygous or heterozygous variant genotype. This polymorphism also appeared to be 
important during non-compartmental analysis, where the patient who carried the 
UGT1A9*3*3 genotype had significantly high AUC0-12 and Cmax (between 90th-100th 
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percentile considering all patients), which was highest among patients with similar 
indication (mCRPC) (110). This polymorphism has been shown to result in reduced 
glucuronidation activity with only 3.8% glucuronidation activity for SN-38 in 
UGT1A9*3*3 genotype carriers compared to carriers of UGT1A9*1*1 genotype (75). 
Therefore, UGT1A9*3 polymorphism might be important for sorafenib disposition, but 
may not require clinical dose adjustments because of its low frequency and considering 
that toxicities associated with sorafenib treatment are not life-threatening. 
 
In summary, this study presents a mechanism-based population pharmacokinetic model 
of sorafenib in patients with various solid tumors. This is the only report where 
pharmacokinetic model based on prior understanding of sorafenib disposition has been 
developed; therefore results of this analysis are important addition to our current 
knowledge of sorafenib pharmacokinetics. Body weight was found to be a statistically 
significant covariate for volume of distribution, but its clinical relevance was minimal. 
Genetic variation in CYP3A4 and CYP3A5 did not appear to alter the sorafenib 
disposition. The UGT1A9*3 polymorphism might be an important determinant for 
sorafenib pharmacokinetics, but this effect needs further evaluation in a prospective 
clinical trial. 
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CHAPTER FIVE 
EVALUATION OF EXPOSURE-EFFICACY RELATIONSHIP, AND 
LABORATORY MARKERS FOR EFFICACY IN SOLID TUMOR 
PATIENTS TREATED WITH SORAFENIB  
 
 
5-1 Introduction 
A major goal of cancer therapy has been to obtain adequate clinical efficacy at the 
expense of tolerable toxicity. Biomedical scientists have long sought to identify the 
optimal therapy for individual patients – also known as personalized medicine.  It will be 
easy to realize these goals if we have a quantitative exposure-response relationship or if 
validated markers are available to make predictions about response based on patient 
characteristics prior to start of therapy or in early stages of treatment. 
 
Because of heterogeneity among different cancer types and patients, most cancer 
treatments are only effective in a minority (selected group) of patients undergoing 
therapy. Thus, there are great challenges and tremendous opportunities to improve the 
treatment outcome by discovering new treatment approaches, possibly involving the use 
of biomarkers / surrogate efficacy markers / surrogate toxicity markers / prognostic 
disease markers / pharmacogenetic markers etc. that will help in prediction of the right 
dose for right patient at right time. A biomarker is defined as any characteristic that can 
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be objectively measured and evaluated to indicate the normal biological or pathological 
process, or pharmacological response to a therapeutic intervention, and has putative 
diagnostic or prognostic value (111).  
 
Several such markers have been described in literature and included in drug prescribing 
information. These markers are generally identified by assessment of exposure-response 
relationships and by correlative studies for response variables. In oncology; however, 
most of the studies are focused on assessment of exposure-toxicity relationships, and only 
few have studied the impact of exposure on activity of an agent or efficacy. One such 
example is association of steady-state concentrations of methotrexate with therapeutic 
outcome in pediatric patients with acute lymphoblastic leukemia (ALL). Monitoring of 
steady-state drug concentrations and dose adjustments based on that were helpful in 
improving the treatment outcome (86). Robert and colleagues reported a linear 
relationship between plasma doxorubicin exposures and short-term tumor response in 
patients with breast cancer (112). Santini and colleagues demonstrated a trend of higher 
5-FU exposure in patients with complete response. A threshold exposure was identified 
which was later used to determine the 5-FU dosage in a prospective study. Patients who 
received the individualized dose had significantly better response rate than the group 
receiving the standard dose of 5-FU (47% complete response vs. 31%) (113). These 
examples highlight the importance of conducting the exposure-efficacy analysis. 
With advent of new targeted anticancer therapies use of molecular markers has become 
usual in identifying the likely responders to selected agents. Few examples of such 
anticancer agents are listed in Table 1-1. One example of molecular markers for efficacy 
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is the expression of ERCC1 mRNA along with thymidylate synthase, which was 
identified as an independent predictive marker of survival for 5-FU/oxaliplatin 
chemotherapy (p<0.001) (114). Pharmacogenetic markers are also being increasingly 
used to individualize the treatment.  
 
As described in chapter 1, sections 1-2.4 and 1-2.5, sorafenib treatment is associated 
with huge inter-patient variability in treatment outcome or efficacy, which may be caused 
by high variability in plasma drug concentrations and/or other factors such as 
pharmacogenetic variation. In order to maximize the efficacy and improve overall 
treatment outcome, we assessed the impact of exposure on efficacy, and explored 
pharmacogenetic and laboratory markers for efficacy. The results of association of 
pharmacogenetic variation and efficacy are described in chapter 7. Other efficacy 
markers evaluated are described below: 
i. use of prostate specific antigen (PSA) as a surrogate end point of efficacy in patients 
with mCRPC treated with sorafenib, and 
ii. use of ex-vivo anti-angiogenic activity for patient’s steady-state serum samples as a 
marker of clinical outcome in patients treated with sorafenib and bevacizumab 
combination 
The methodologies used for these analyses along with results are described in this 
chapter.  
5-2  Evaluation of exposure-efficacy relationship 
5-2.1  Methods 
5-2.1.1 Patients and study design 
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Data from 104 patients enrolled in phase II trial in mCRPC, phase II trial in NSCLC, 
phase II trial in CRC and phase I trial in ST were included in exposure-efficacy analysis. 
These patients were also a part of population pharmacokinetic analysis, described in 
chapter 4. Exposure-efficacy evaluation was performed separately for each clinical trial 
to account for the differences in tumor type and treatment regimen. The dosing regimen 
and design of these phase I / II clinical trials are described in detail in section 4-4.1. The 
phase I trial in KS was not included in this analysis, because, at the time of this analysis, 
only eight patients have been enrolled in this trial: Two received only sorafenib, while the 
remaining six received sorafenib along with ritonavir. 
 
5-2.1.2 Pharmacokinetic metrics 
The sorafeinb exposures (AUC = Dose/(CL/F)) calculated from the individual predictions 
of systemic clearances (CL/F) from the final population pharmacokinetic model were 
used to evaluate the exposure-efficacy relationships. Single-dose exposures were 
predicted for the 400 mg dose for patients with mCRPC, CRC and NSCLC, and for the 
200 mg dose for patients enrolled in ST trial. In case of dual therapy, exposures of the co-
administered agents (i.e., bevacizumab or cetuximab) were not available for use in 
evaluation of the exposure-efficay relationships. 
 
5-2.1.3 Efficacy metrics 
Treatment response, measured using the response evaluation criteria in solid tumors 
(RECIST), and the duration of progression-free survival (PFS) were used as efficacy 
metrics. Treatment responses were determined based on the change in tumor dimensions 
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and were divided into five groups – CR, PR, PD, not evaluable/refused further treatment 
(NE) and death. PFS was defined as the duration for which disease did not progress based 
on clinical (symptomatic/radiological/molecular) end points from the start of treatment.  
 
5-2.1.4 Statistical analysis 
Patients from each trial were divided into four exposure groups which were created based 
on the four quartiles of the sorafenib AUC distribution. Incidence rates (%) of clinical 
responses (CR, PR and PD) were compared among these exposure quartiles, separately 
for each clinical trial. Direct correlations between AUC and PFS were also assessed. The 
statistical analyses were performed using JMP 8.0 (SAS Institute Inc., Cary, NC, USA) 
statistical software. 
 
5-2.2 Results  
The observed best response for solid tumor patients treated with sorafenib as a single 
agent or in combination therapy is summarized in Table 5-1. Sorafenib had moderate 
activity in patients with mCRPC, with a median PFS of 3.7 months and median overall 
survival time of 18.3 months for a median follow-up for 27.2 months (110). Sorafenib 
appeared to benefit patients with NSCLC with upto 50% of treated patients responding 
with partial response or stable disease. Combination therapy with sorafenib and 
bevacizumab had promising clinical activity in patients with solid tumors including the 
ovarian cancer (N=13), renal cell carcinoma (N=3), melanoma (N=7), colon cancer 
(N=2), sarcoma (N=5) and others (N=9) (115). Six of thirteen ovarian cancer patients (i.e. 
46%) had PR and three (i.e. 23%) had disease stabilization for at least 4 months (115). 
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This combination is further being evaluated in a phase II clinical trial in patients with 
ovarian cancer (115). Another combination therapy trial, involving sorafenib and 
cetuximab, also appeared to have significant activity in patients with CRC, where eleven 
of the fourteen evaluable patients (78.6%) had PR or SD. So far only few patients were 
enrolled in KS trial; hence, it was not possible to make conclusions about sorafenib’s 
efficacy in those patients.  
 
Overall, it appears that the combined inhibition of multiple proteins in signaling 
pathways shows better clinical activity than treatments with single agents alone. 
However, the incidence of treatment-associated toxicities may also increase with 
combination therapy, hence, assessment of benefit-risk ratio for each individual patient, 
based on their characteristics, is important in order to achieve the optimal therapeutic 
benefit. Results of exposure-efficacy analysis for each clinical trial are separately 
discussed in following sections. 
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Table 5-1 Summary of best clinical response for solid tumor patients treated with sorafenib alone or in combination with other agents 
N Best clinical response %, (N) Tumor 
type 
Treatment 
 PR SD PD REF/Not assessable Death Response not available
mCRPC Sorafenib 46 2 (1) 43 (20) 35 (16) 13 (6) 2 (1) 4 (2) 
NSCLC Sorafenib 18 11 (2) 39 (7) 50 (9) 0 (0) 0 (0) 0 (0) 
ST Sorafenib + bevacizumab 28 18 (5) 61 (17) 14 (4) 4 (1) 0 (0) 4 (1) 
CRC Sorafenib + cetuxiamb 18 6 (1) 56 (10) 17 (3) 6 (1) 0 (0) 17 (3) 
KS Sorafenib +/- ritonavir 8 25 (2) 38 (3) 13 (1) 25 (2) 0 (0) 0 (0) 
mCRPC: metastatic castrate resistant prostate cancer; NSCLC: non-small cell lung-cancer; ST: solid tumors; CRC: colorectal 
cancer; KS: Kaposi’s sarcoma; PR: partial response; SD: stable disease; PD: progressive disease; REF: refused further treatment 
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5-2.2.1  Phase II trial in patients with mCRPC treated with sorafenib as a single 
agent 
Results of exposure-efficacy analysis for patients with mCRPC are shown in Fig. 5-1 and 
5-5. No major change in frequency of SD was observed with increase in exposure from 
the lower to the upper quartile, as shown in Fig 5-1. Incidence rate of PD declined and 
refusals of treatment were unaltered from 2nd to 4th exposure quartile, and one patient 
with exposure in 4th quartile expired on the trial. This patient was 85 years old, with a 
pre-existing cerebrovascular accident within the past 5 years, and was on study for only 
20 days when he had a recurrent haemorrhagic cerebrovascular accident (110). Notably, 
this patient was one among the three who had relatively high sorafenib exposures in 
mCRPC trial. No significant correlation was observed between AUC and PFS (Fig 5-5 
(A)). These results suggest a lack of exposure-efficacy relationship in mCRPC patients 
treated with sorafenib. 
 
5-2.2.2 Phase II trial in patients with NSCLC treated with sorafenib as a single 
agent 
The exposure-efficacy analysis results for patients with NSCLC are shown in Fig 5-2 
and 5-5. No change in PR, increase in SD and decrease in PD was observed with an 
increase in sorafenib exposure from the lower quartile to the upper quartile, as shown in 
Fig 5-2. These observations were indicative of a positive exposure-efficacy relationship; 
however, the sample size in these groups was too small to draw definitive conclusions. 
The lack of correlation between AUC and PFS (Fig 5-5 (B)) also fails to demonstrate a 
favorable exposure-efficacy relationship based on Fig 5-2. The exposure-efficacy 
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relationship in patients with NSCLC needs to be evaluated with a larger sample size. This 
trial is currently (after this analysis) enrolling patients with a targeted accrual of 37 
patients. 
 
5-2.2.3 Phase I trial in patients with ST treated with sorafenib and bevacizumab in 
combination 
In patients with ST treated with sorafenib and bevacizumab combination, we observed no 
significant change in PR, SD and PD across sorafenib’s exposure quartiles, as shown in 
Fig 5-3. Also, PFS was not significantly correlated with AUC of sorafenib for these 
patients (Fig 5-5 (C)). The exposures of sorafenib appeared not to be associated with 
efficacy in patients with ST, following treatment with the sorafenib and bevacizumab 
combination. Note that addition of bevacizumab had improved the response rate of 
sorafenib. Hence, a non-significant relation of only sorafenib exposure with efficacy is 
not unlikely. A surrogate marker of efficacy, accounting for both sorafenib and 
bevacizumab exposures, would possibly be a better predictor of treatment outcome. We 
evaluated ex-vivo anti-angiogenic activity using patient serum samples, a laboratory 
marker assumed to account for both sorafenib and bevacizumab exposures, as one 
potential surrogate of clinical response, which is described in section 5-3. 
 
5-2.2.4 Phase II trial in patients with CRC treated with sorafenib and cetuximab in 
combination 
For patients with CRC, with increase in sorafenib exposure, we observed no 
change/decrease in SD, increase in PD and one treatment refusal (Fig 5-4), which is the 
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opposite of what would be expected in a positive exposure-response relationship. Also 
the sorafenib AUC was not predictive of PFS (Fig 5-5 (D)). These results suggest a lack 
of significant association between sorafenib exposure and efficacy for patients with CRC 
treated with sorafenib and cetuximab combination. Again, we need to identify some 
surrogate markers accounting for both sorafenib and cetuximab exposures, for an 
appropriate assessment of the true, underlying exposure-efficacy relationship. Note that 
addition of cetuximab to sorafenib also appears to increase the response rate compared to 
the historical 10% response rate with only cetuximab (27).
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Fig 5-1 Evaluation of exposure response relationship for patients with metastatic castrate resistant prostate cancer (mCRPC) following 
treatment with single agent sorafenib 
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Fig 5-2 Evaluation of exposure response relationship for patients with non-small cell lung cancer (NSCLC) following treatment with 
single agent sorafenib 
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Fig 5-3 Evaluation of exposure response relationship for patients with solid tumor (ST) following treatment with sorafenib and 
bevacizumab combination 
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Fig 5-4 Evaluation of exposure response relationship for patients with colorectal cancer (CRC) following treatment with sorafenib and 
cetuximab combination 
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Fig 5-5 Evaluation of correlation between exposure (AUC) and progression free survival (PFS) for patients with (A) metastatic 
castrate resistant prostate cancer (mCRPC), (B) non-small cell lung cancer (NSCLC), (C) solid tumors (ST) and (D) colorectal cancer 
(CRC) 
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5-2.3 Conclusions 
Sorafenib was found to have moderate efficacy in patients with mCRPC. Addition of 
bevacizumab and cetuximab appears to have a synergistic effect on sorafenib’s efficacy. 
The combination of agents with the activity against upstream and downstream targets in 
the same signaling pathway seems to result in better treatment outcomes than single-
agent treatment. However, the frequency of treatment-associated toxicities may also 
increase. Sorafenib’s activity in NSCLC cannot be determined definitively because of the 
small sample size of the trial. Further evaluation with a larger sample size is required.  
 
No significant exposure-efficacy relationship was observed based on sorafenib exposures 
for trials studying the patients with mCRPC, CRC and ST. It is less likely to explain the 
differences in response by exposure of just one drug, when patients are treated with more 
than one drug. A combined exposure metrics or a surrogate marker accounting for 
exposure of all the administered agents would be more useful. Patients with NSCLC had 
higher incidences of stable disease and reduced numbers of progressive disease, with 
increase in sorafenib exposure. But data from only 18 patients were evaluable, which 
weakens the credibility of these results and requires further evaluation with a larger 
number of subjects. The results of these exposure-efficacy analyses may not be 
conclusive, because of (i) lack of random assignment for exposures, and (ii) lack of clear 
evidence for sorafenib’s activity in studied indications. An exposure-efficacy analysis for 
sorafenib could be performed for tumor types for which there is a clear evidence of 
sorafenib’s activity (with a known plausible mechanism of action), by enrolling the 
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patients prospectively, and by their random assignment into different dose/exposure 
groups followed by comparison of response rate in these groups. 
 
Sorafenib is a cytostatic agent, which requires long-term administration to achieve 
therapeutic benefit. For such agents, there is a low probability of significant correlation 
between exposure after a single-dose and treatment outcome. Alternative metrics such as 
cumulative dose or cumulative drug exposure would possibly be a better predictor of 
clinical response. However, the disadvantage of using these metrics would be that their 
correlation with PFS will not be informative, because it will always be forced positive, 
such as patients with longer PFS would always have longer duration on treatment and 
higher cumulative dose or cumulative drug exposure. 
 
Another reason for the lack of exposure-efficacy relationship in cancer patients is that, it 
is a heterogeneous disease with significant inter-patient variability in tumors, which may 
also vary considerably in their responsiveness towards treatments. 
 
5-3 Ex-vivo anti-angiogenic activity as a biomarker of clinical response 
5-3.1 Introduction 
A correlative study was conducted to study the association of ex-vivo anti-angiogenic 
activity for steady-state serum samples from patients on sorafenib and bevacizumab 
combination and observed best clinical response. It was hypothesized that patients with 
higher steady-state concentrations of these drugs will likely have better clinical response, 
assuming no major differences in responsiveness for this drug combination between 
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subjects. If these steady-state serum samples were to be used for ex-vivo angiogenesis 
assay (rat aortic ring assay), we would also observe a higher percent anti-angiogenic 
activity for samples with high drug concentrations and vice versa. Hence, the percent 
anti-angiogenic activity in this assay could possibly predict the clinical response, 
assuming no significant difference in responsiveness towards sorafenib and bevacizumab 
combination between rat aortas and human endothelial cells (Fig 5-6). For example, a 
patient with higher steady-state drug concentrations would be expected to have a better 
clinical response, and serum samples from these patients will also possibly show a higher 
percent anti-angiogenic activity in ex-vivo assay. If this hypothesis were to prove true, it 
would be possible to predict the clinical response based on activity in ex-vivo assay, 
which may also guide the dose adjustments to achieve the optimum therapeutic outcome. 
 
 
Fig 5-6 Illustration of hypothesis for testing the ex-vivo anti-angiogenic activity as   
biomarker of clinical response 
 
Ex-vivo Rat aortic ring assay was originally developed by Nicosia and colleagues (116). 
It combines together the advantages of both the in-vitro and in-vivo systems. This assay 
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avoids the effect of inflammatory reactions seen in in-vivo assays (117) and makes it 
possible to collectively examine the different stages of angiogenic development, which is 
difficult to monitor with in-vitro system (118). In addition, multiple assays can be 
conducted per animal (117). This assay has previously been used with human serum 
samples to study the effect of protein binding on anti-angiogenic activity of suramin, 
carboxyamidotriazole and UCN-01 (119). We used the same assay procedure (119) to 
test the current hypothesis. 
 
5-3.2  Methods 
5-3.2.1 Patients and samples 
Baseline and steady-state serum samples from patients with solid tumors treated with 
sorafenib and bevacizumab combination were used to perform the rat aortic ring assay.  
Baseline samples were collected prior to start of treatment, and most of the steady-state 
samples were collected in treatment cycle 4, where each cycle was 28 days long. By 
cycle 4, steady-state for both sorafenib and bevacizumab were reached, based on their 
half-lives of 25-48 h (49) and 20 days (range 11-50 days) (120), respectively. 
 
5-3.2.2 Rat-aortic ring assay 
Twelve-well tissue culture grade plates were covered with 250 μL of Matrigel and 
allowed to gel for 30 to 45 min at 37 °C, 5%CO2. Thoracic aortas were excised from 8-10 
week old male Sprague Dawley rats, and the fibroadipose tissue was removed. 1 mm long 
cross-sections of aorta were cut and placed in the center on the Matrigel coated wells. 
These were then covered with an additional 250 μL of Matrigel and allowed to gel for 
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additional 30 to 45 min at 37 °C, 5%CO2. The rings were cultured for 24 h in 1 mL of 
EGM-II medium, which is a mixture of EBM-II medium (endothelial cell basal medium) 
and growth factors provided in the EGM-II Bullet kit (Cambrex Bio Science, 
Walkersville, MD). After 24 h, the medium was aspirated out and replaced with 1 mL of 
control or patient serum. Negative and positive control rings were treated with control 
serum containing 0.05% DMSO and 240µg/mL CAI, respectively. Serum samples from 
patients with solid tumors, collected at baseline and steady-state (for both sorafenib and 
bevacizumab) were used for the analysis. Sorafenib was stable for at least 4 days, the 
duration of assay, under incubator conditions; hence, the cells were treated only once. 
After 4 days of incubation with patient serum samples, on day 5, supernatant was 
removed and rings were pictured. The angiogenic vascular outgrowth was quantified in 
pixel counts using Adobe Photoshop (Adobe systems, Inc., San Jose, CA). The 
percentage inhibition was calculated as the ratio of growth for steady-state serum samples 
to that of growth for baseline serum samples. The ex-vivo anti-angiogenic activity was 
then used as an assessment of the relationship with clinical response. 
 
5-3.2.3 Statistical analysis 
The anti-angiogenic activity between different clinical response groups was compared 
using one-way ANOVA. The anti-angiogenic activity was considered as a marker of 
serum drug concentrations for the active circulating moieties; hence, the direct correlation 
between sorafenib exposures and anti-angiogenic activity was also assessed using linear 
regression. The bevacizumab exposures were not available to conduct the similar 
exposure-activity assessment. We also compared the sorafenib exposures between 
 200
Exposure-Efficacy Relationship Analysis & Efficacy Markers                         Chapter 5 
clinical response groups using one-way ANOVA, to examine whether serum 
concentrations between these groups were considerably different to translate into 
significant differences in ex-vivo anti-angiogenic activity. The statistical analyses were 
performed using JMP 8.0 (SAS Institute Inc., Cary, NC, USA) statistical software. 
   
5-3.3 Results and Discussion 
The ex-vivo anti-angiogenic activity (or percent angiogenic inhibition) and clinical 
response for solid tumor patients treated with sorafenib in combination with bevacizumab 
are shown in Table 5-2. As shown in Fig 5-7, the ex-vivo anti-angiogenic activity ranged 
from 10 to 75%; and no specific cut-off for percent angiogenic inhibition was apparent, 
which would result in a favorable clinical response (stable disease or partial response), at 
least based on patients included in this analysis. Also, the association between percent 
angiogenic inhibition and observed best clinical response was not statistically significant 
(p=0.58).  
 
The sorafenib exposures after the first dose were not related with the ex-vivo anti-
angiogenic activity calculated using corresponding sorafenib/bevacizumab steady-state 
samples (Fig 5-8). Comparison of sorafenib exposures between clinical response groups 
revealed marginally significant differences in mean exposures for PR, SD and PD groups 
(p=0.045; Fig 5-9). Tukey’s HSD test showed that the exposures between only PR and 
SD groups were statistically different, and both of them were not significantly different 
from the PD group. There were only three patients in the PR group and the higher mean 
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for this group was driven by only one patient. Hence, it was difficult to conclude the 
relationship between exposure and efficacy based on limited sample size. 
Table 5-2 Summary of results for ex-vivo anti-angiogenic activity, clinical response and 
sorafenib exposures for solid tumor patients treated with sorafenib and bevacizumab 
Pt Id 
% Angiogenic 
Inhibition 
(ex-vivo)† 
Best clinical 
response 
Sorafenib AUC0-12 
(mg/L*h), in-vivo 
1 29.15 SD 17.33 
2 28.57 SD 4.61 
3 10.47 PR 14.49 
4 56.87 SD 3.06 
5 10.76 PR 17.43 
6 21.02 SD 4.04 
7 20.10 SD 11.7 
8 24.31 SD 7.03 
9 11.48 SD 7.89 
10 44.71 SD 17.18 
11 11.27 SD 4.49 
12 * SD 14.72 
13 * PR  
14 * SD 12.81 
15 11.17 SD 1.26 
16 75.27 SD 13.71 
17 21.01 SD 18.68 
18 13.77   
19 46.11 PR 39.72 
† % angiogenic inhibition = (pixel counts for ring with steady-state serum sample/pixel 
counts for ring with baseline serum sample)*100 
*There were technical problems with the rings from these patients. 
SD, stable disease; PR, partial response; AUC0-12, area under the curve after first dose of 
sorafenib, calculated by non-compartmental analysis 
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Fig 5.7 Box plot comparing the ex-vivo anti-angiogenic activity for patients with 
stable disease (SD) and partial response (PR). 
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Fig 5-8 Assessment of relationship between sorafenib exposures after first dose (AUC0-12, 
calculated by non-compartmental analysis) and ex-vivo anti-angiogenic activity for 
corresponding steady-state samples 
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Fig 5-9 Distribution of sorafenib exposures for different clinical response groups. (PR: 
Partial response; SD: stable disease; PD: progressive disease) 
 
5-3.4 Conclusions 
We evaluated ex-vivo anti-angiogenic activity for patient serum samples in rat aortic ring 
assay as a (laboratory) biomarker of clinical response. The ex-vivo anti-angiogenic 
activity was not apparent to be predictive of clinical outcome, at least based on available 
limited data. This ex-vivo anti-angiogenic activity for steady-state serum samples from 
patients treated with sorafenib and bevacizumab combination was also not apparently 
associated with only sorafenib exposures after first dose. Sorafenib exposures between 
different clinical response groups were also not statistically different. The major 
limitation of these correlative studies is the small sample size.  
 
In addition to the earlier described advantages of the rat-aortic ring assay (section 5-3.1), 
there are few limitations to its use which might have partly influenced the results. 
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Animals may have inherent variability among themselves in responsiveness towards 
drugs. Drug responsiveness between animals and humans may also vary, which might 
mask the true correlation between this laboratory marker and clinical response. Also, 
technical variability in implementation of this assay, may introduce some inconsistencies 
between experiments. 
 
5-4 Prostate specific antigen as a marker of efficacy in mCRPC patients treated 
with sorafenib 
5-4.1 Introduction 
Prostate cancer is the second leading cause of death by cancer among men in the United 
States. In 2009, number of prostate cancer cases are expected to be 192,280 and of them 
approximately 27630 will succumb to death because of disease (13). Patients with 
prostate cancer initially respond well to hormonal and radiation therapy, but 
unfortunately, most of them eventually become resistant. After a median duration of 18-
24 months on androgen deprivation therapy, tumor growth in these patients with 
metastatic disease becomes androgen-independent (121). This stage of disease is 
commonly referred to as ‘hormone refractory prostate cancer (HRPC)’ or ‘metastatic 
castrate-resistant prostate cancer (mCRPC)’. 
 
Only limited treatment options are available for patients with mCRPC. In 2004, the FDA 
approved docetaxel in combination with prednisone as first-line chemotherapy for 
mCRPC. Docetaxel 75 mg/m2 administered IV every 21 days and oral prednisone twice a 
day offered a statistically significant survival advantage over the mitoxantrone and 
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prednisone combination (18.9 vs. 16.5 months) (89). However, this regimen is not 
universally effective, and nearly all patients have tumor progression after docetaxel 
treatment (89). There is urgent need to identify new therapeutic options (second-line 
therapies) for these patients. Molecularly targeted therapies have emerged as potential 
drug candidates with shift in focus of drug discovery from conventional cytotoxic drugs 
towards rationally designed targeted therapies with activity against cancer-specific 
pathways. 
 
Angiogenesis has shown to play an important role in several human cancers including the 
breast, non-small cell lung, colorectal and prostate cancers (122-125). Angiogenesis is a 
fundamental event in tumor growth and metastatic dissemination. Simultaneous blocking 
of cell growth and angiogenesis by inhibition of Ras/Raf kinases and VEGF signaling by 
sorafenib has been considered as a potential method to restrict the growth of prostate 
tumors. To evaluate the efficacy of sorafenib as a second-line treatment for mCRPC, a 
phase II trial was initiated at NCI, Bethesda, MD, USA (83). Three other phase II trials, 
conducted in Iran, Europe and Canada, also assessed the role of sorafenib in the treatment 
of patients with mCRPC (56, 126, 127). All four trials had prostate specific antigen 
(PSA) as one of the determinants for primary end point. Sorafenib was reported to have 
limited activity as second line treatment in mCRPC, and almost half of the patients on 
sorafenib trials showed an increase in PSA concentrations while undergoing treatment. 
Historically, PSA concentrations have been shown to decline after treatment with 
cytotoxic agents and have long been used as a surrogate endpoint to evaluate the efficacy 
of these agents in mCRPC (128). Many published studies have noted a survival 
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advantage for patients with a >50% post-treatment decline in serum PSA levels (129) and 
its levels were also found to correlate with the tumor stage (130). Contrary to the 
conventional therapies, serum PSA concentrations increased following treatment with 
sorafenib. However, of note, serum PSA concentrations for these patients declined after 
discontinuation of sorafenib therapy (83, 126). Clinical responses for some of these 
mCRPC patients on sorafenib trials were also in disagreement with PSA responses. 
 
In the first stage of a mCRPC trial at NCI we observed an increase in PSA concentrations 
from baseline after the first cycle of treatment for seventeen of the twenty-two enrolled 
patients. Thirteen of the twenty-one evaluable patients progressed only by PSA criteria 
and PSA concentrations for six of them declined after discontinuation of sorafenib (in 
absence of initiating another treatment) (83). Also, two patients showed improvement in 
metastatic bone lesions despite of continuous increase in PSA levels after two and four 
cycles of sorafenib treatment (83). For one patient, the requirement of narcotics for pain 
management was significantly reduced (83). 
 
Similar results about change in PSA concentrations following treatment with sorafenib in 
patients with mCRPC were reported by Chi and colleagues (126) which are shown in 
Figures 5-10 and 5-11. Notably, they also observed 7-52% decline in PSA levels in 10 of 
the 16 patients who did not receive any immediate treatment after discontinuation of 
sorafenib therapy (126). Another ten patients who received radiation therapy or 
chemotherapy had larger PSA decline of 14-91% (126). 
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These observations indicate that sorafenib may itself increase the PSA concentrations - 
independent of its effect on cellular-growth - and it may not be a suitable surrogate of 
efficacy in prostate cancer patients treated with sorafenib. We evaluated this hypothesis 
in in-vitro cell line experiments. Methods used for evaluation, observed results and their 
discussions are summarized in this section. 
 
 
Fig 5-10 Plot of greatest percentage change in prostate-specific antigen (PSA) of 
individual patients while on sorafenib therapy (reproduced by permission of Oxford 
University press from Chi et al. (126)) 
 
 
 
Fig 5-11 Plot of percent change in prostate-specific antigen (PSA) of individual patients 
over time while on sorafenib therapy (reproduced by permission of Oxford University 
press from Chi et al.(126)) 
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5-4.2 Methods 
5-4.2.1 Experimental procedure 
The LNCaP human prostate carcinoma cell line was treated with RPMI medium 
containing sorafenib (freshly prepared dilutions). Final concentrations of sorafenib in the 
medium were 0, 2.5, 5 and 10 µM, which covered the range of measured peak plasma 
concentrations (Cmax) for stage 1 of phase II trial in patients with mCRPC, i.e. 1.8-4.1 
µM. The dilutions used to prepare these solutions are shown in Table 5-3. The treatment 
was repeated every 24 h until the final time points of 24, 48 and 72 h. For each 
concentration and each time point, cells were treated in quintuplicate. During repetition 
of treatment with sorafenib, the old medium was removed, and fresh medium containing 
sorafenib was supplemented. PSA levels in media supernatant were measured using PSA 
ELISA kit (Alpha diagnostic international, San Antonio, TX). Cell counts were 
performed with a Dojindo cell counting kit (Dojindo molecular technologies, Rockville, 
MD). 
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Table 5-3  Summary of dilutions for assessment of effect of sorafenib treatment on PSA 
release 
Primary stock: 10 mM 
Secondary stock: 500 µM  (200 µL of 10 mM stock + 3.8 mL of media ) 
Day 1 (35 mL each of 2.5, 5 and 10 µM) 
Concentration Qty of 500 µM stock Media Total volume % DMSO
DMSO only 175 µL of 100% DMSO 34 mL and 825 µL 35 mL 0.5 % 
2.5 µM 175 µL 34 mL and 825 µL 35 mL 0.025% 
5.0 µM 350 µL 34 mL and 650 µL 35 mL 0.05 % 
10.0 µM 700 µL 34 mL and 300 µL 35 mL 0.10 % 
Day 2 (25 mL each of 2.5, 5 and 10 µM ) 
Concentration Qty of 500 µM stock Media Total volume % DMSO
DMSO only 125 µL of 100% DMSO 24 mL and 875 µL 25 mL 0.5 % 
2.5 µM 125 µL 24 mL and 875 µL 25 mL 0.025% 
5.0 µM 250 µL 24 mL and 750 µL 25 mL 0.05 % 
10.0 µM 500 µL 24 mL and 500 µL 25 mL 0.10 % 
Day 3 (15 mL each of 2.5, 5 and 10 µM) 
Concentration Qty of 500 µM stock Media Total volume % DMSO
DMSO only 75 µL of 100% DMSO 14 mL and 925 µL 15 mL 0.5 % 
2.5 µM 75 µL 14 mL and 925 µL 15 mL 0.025% 
5.0 µM 150 µL 14 mL and 850 µL 15 mL 0.05 % 
10.0 µM 300 µL 14 mL and 700 µL 15 mL 0.10 % 
 
5-4.2.2 Cell culture 
The LNCaP cell lines were obtained from American Type Culture Collection (Manassas, 
VA, USA) and were grown in incubator at 37 ˚C, 5% CO2 using the cell-culture 
procedure mentioned below. Approximately 50,000 cells were plated per 2 cm well in 
five, twelve-well tissue culture plates. When the wells were almost 60% confluent, the 
 210
Exposure-Efficacy Relationship Analysis & Efficacy Markers                         Chapter 5 
cell medium was replaced with medium containing sorafenib. The layout of a tissue 
culture plate is shown in Fig 5-12. 
Cell culture procedure:  
a) Warm up RPMI medium, 0.25% trypsin and PBS in water bath. 
b) Prepare 50 mL tube for 125 cm flask (1 tube for each flask). 
c) Gently wash cells with medium in the flask and transfer the medium into 50 mL 
falcon tube. 
d) Add 1-2 mL trypsin and incubate the flask for 5-10 minutes to segregate the cells. 
e) Add 10 mL of medium to neutralize the trypsin and use 1 mL disposable pipette 
to separate the cells into single cells (by gently pipetting in and out). Transfer the 
medium into tube. 
f) Centrifuge tube at 1000 rpm for 5 minutes at 4 ˚C. 
g) Discard the supernatant. 
h) Add 10 mL PBS to the pellet in bottom and centrifuge again. 
i) Discard the supernatant. 
j) Add 1 mL trypsin and mix cells gently with 1 mL pipette tip to segregate the 
cells. 
k) Add fresh medium to neutralize the trypsin (medium : trypsin > 5:1). 
l) Centrifuge tube at 1000 rpm for 5 minutes at 4˚C. 
m) Discard the supernatant. 
n) Add fresh medium to the tube and split the cells into new flasks (3 to 5 flask for 
one original flask). 
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The composition of RPMI medium used in above procedure was as below: 
To 500 mL of RPMI medium following ingredients were added: 
i. 2.8 mL of 45% glucose solution (RPMI stock contains 2 gm/L of glucose and we 
need to add additional 2.5 gm/L or 1.25 gm/500 mL) 
ii. 5 mL of 1M HEPES 
iii. 5 mL of 10 mM sodium pyruvate 
iv. 50 mL fetal bovine serum 
v. 5 mL penicillin streptomycin solution 
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 Fig 5-12 Layout of twelve-well tissue culture plate and allocation of samples 
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5-4.2.3 PSA quantification 
Supernatant medium from cell culture plates were collected, and a 12.5 µL aliquot was 
mixed with 12.5 µL of fresh medium in Eppendorf tubes to dilute PSA concentrations, so 
that it falls into the range of the calibration curve for the PSA ELISA assay. Immediately 
after their collection, PSA levels in the supernatant were measured using the procedures 
for the PSA ELISA kit (131). A standard curve was run for each set of samples analyzed. 
 
5-4.2.4 Cell counting 
Cell counting was performed using the CCK cell counting kit (132). First, a reference 
standard curve was developed. Known cell counts of LNCaP cells were plated in twelve-
well plates (2 mL/well). These cells were treated with 50 µL of CCK reagent and were 
incubated for 1 h at 37 ˚C, 5% CO2. After 1 h, 200 µL of supernatant was transferred to a 
96-well plate (in duplicate), and absorbance was read at 450 nm using the plate reader. A 
standard curve was constructed by fitting the measured absorbance against the nominal 
cell-counts using linear regression. Samples with unknown cell-counts were processed 
similar to the samples with known cell counts, and calibration curve was used to estimate 
the cell count against the measured absorbance. 
 
5-4.3 Results and discussion 
5-4.3.1 Standard curve for cell counting 
Three replicates of cell counts ranging from 100 to 1,600,000 were treated with CCK cell 
counting reagent. The measured absorbance readings for these samples are listed in 
Table 5-4. The linear and polynomial standard curves for cell counting are shown in Fig 
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5-13 and 5-14. Cell count predictions from either of these curves were almost the same 
for the range of data observed in this study. Predictions based on linear curves are 
reported in this chapter.
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Table 5-4 Absorbance readings for construction of cell counting standard curve using CCK reagent 
  Replicate 1 Replicate 2 Replicate 3 
Plate Cell count Absorbance 450 nm  Absorbance 450 nm  Absorbance 450 nm  
  CR† 1 CR 2 Average 1 CR 1 CR 2 Average 2 CR 1 CR 2 Average 3
1 100 0.189 0.187 0.188 0.188 0.187 0.188 0.191 0.197 0.194 
1 500 0.172 0.184 0.178 0.175 0.178 0.177 0.185 0.195 0.190 
1 1000 0.177 0.183 0.180 0.183 0.184 0.184 0.187 0.188 0.188 
1 2000 0.177 0.188 0.183 0.179 0.203 0.191 0.186 0.190 0.188 
1 5000 0.183 0.188 0.186 0.176 0.180 0.178 0.184 0.196 0.190 
1 10000 0.187 0.194 0.191 0.185 0.188 0.187 0.203 0.196 0.200 
1 20000 0.190 0.190 0.190 0.207 0.191 0.199 0.199 0.215 0.207 
1 30000 0.192 0.201 0.197 0.188 0.194 0.191 0.205 0.214 0.210 
1 40000 0.204 0.205 0.205 0.207 0.195 0.201 0.213 0.211 0.212 
1 50000 0.208 0.212 0.210 0.210 0.209 0.210 0.219 0.219 0.219 
1 60000 0.219 0.214 0.217 0.211 0.219 0.215 0.216 0.220 0.218 
1 80000 0.226 0.225 0.226 0.219 0.228 0.224 0.239 0.238 0.239 
2 75000 0.248 0.260 0.254 0.263 0.259 0.261 0.273 0.274 0.274 
2 100000 0.321 0.271 0.296 0.270 0.263 0.267 0.281 0.278 0.280 
2 150000 0.317 0.330 0.324 0.323 0.305 0.314 0.313 0.315 0.314 
2 200000 0.320 0.322 0.321 0.344 0.335 0.340 0.379 0.367 0.373 
2 400000 0.447 0.437 0.442 0.435 0.445 0.440 0.429 0.445 0.437 
2 500000 0.571 0.560 0.566 0.607 0.595 0.601 0.544 0.540 0.542 
2 600000 0.516 0.522 0.519 0.670 0.618 0.644 0.710 0.651 0.681 
2 800000 0.635 0.666 0.651 0.714 0.737 0.726 0.776 0.814 0.795 
2 1000000 0.801 0.761 0.781 0.841 0.844 0.843 0.853 0.877 0.865 
2 1200000 0.856 0.930 0.893 0.984 0.883 0.934 1.038 1.075 1.057 
2 1400000 0.951 0.969 0.960 1.059 1.037 1.048 1.184 1.129 1.157 
2 1600000 1.117 1.076 1.097 0.972 1.055 1.014 1.182 1.203 1.193 
†CR: counting replicate (for each well absorbance was measured twice)
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Absorbance Equation to be used for back predictions 
<0.1849 Below limits of quantification 
≥0.1849 but <0.2389 Y = 5 e-7 X + 0.1849 
≥0.2389 Y = 6 e-7 X + 0.2389 
      X: cell count; Y: absorbance 
Fig 5-13 Linear fit for standard cell counting calibration curves for cell counts in range of 
(A) 100 to 80,000 and (B) 75,000 to 1,600,000 
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Fig 5-14 Polynomial fit for standard cell counting calibration curves for cell count in 
range of 100 –1,600,000 
 
5-4.3.2 PSA quantification 
The standard calibration curve for each day and PSA concentrations for sorafenib treated 
cell-supernatant samples are shown in Figures 5-15, 5-16 and 5-17 and Tables 5-5, 5-6 
and 5-7. The cumulative concentrations of PSA secreted from LNCaP cells following 
treatment with four different concentrations of sorafenib are shown in Fig 5-18 (A). Cell 
count-normalized concentrations of PSA increased with an increase in sorafenib 
concentrations. Comparison of cell count-normalized PSA concentrations for each 
treatment duration, as shown in Fig 5-18 (B), demonstrated that PSA secretion increased 
from the first treatment (0-24 h) to the second treatment duration (24-48 h), but declined 
for the third treatment duration (48-72 h). The decline in PSA for the third treatment 
duration was more prominent for higher (i.e. 5 µM) sorafenib concentrations. This may 
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be because fewer cells were viable for PSA secretion during 48-72 h duration compared 
to 24-48 h duration, and these cells may have already been exhausted out of PSA by 48 h. 
Cell counts for 10 µM concentration were below the limit of quantification; hence 
secreted PSA concentrations were undetectable. 
 
These in-vitro results are in agreement with clinical findings and do confirm our 
hypothesis that sorafenib increases PSA concentrations - independent of its effect on 
cellular-growth – and, thus, may not be a suitable surrogate of efficacy in prostate cancer 
patients treated with sorafenib. 
 
5-4.3.3 Cell counts following treatment with sorafenib 
Cell counts following treatment with escalating sorafenib concentrations over 72 h 
periods are shown in Table 5-8 and Fig 5-19. As expected, the ascending order of cell-
counts was: 
10 µM (undetectable) < 5 µM < 2.5 µM < only DMSO 
Cell counts for 10 µM concentration were undetectable using the standard cell-counting 
calibration curves (Fig 5-13). These results demonstrate dose-dependent antitumor 
activity of sorafenib in LNCaP cell lines.
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Day 1 
 
PSA 
concentration Absorbance
 ng/mL at 450 nm 
Std A 0 -0.031 
Std B 1.5 0.471 
Std C 5 1.209 
Std D 15 2.822 
Std E 30 4.028 
Std F 40 4.943 
 
 
 
Fig 5-15 Standard curve for PSA estimation on day 1 (at 24 hrs). 
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Table 5-5 PSA concentrations at 24-hr time-point 
Absorbance at 450 nM Mean SD 
Sorafenib concentration Plate 1 Plate 2 Plate 3 Plate 4 Plate 5   
DMSO 3.442 3.869 3.924     
2.5 uM 4.221 3.807 3.942 4.075 3.304   
5 uM 2.732 2.658 3.109 2.902 2.865   
10 uM 1.537 1.58 1.504 1.523 1.636   
Back-calculated PSA concentrations   
 Plate 1 Plate 2 Plate 3 Plate 4 Plate 5   
DMSO 25.27 28.83 29.29     
2.5 uM 31.77 28.31 29.44 30.55 24.12   
5 uM 19.35 18.73 22.49 20.76 20.46   
10 uM 9.38 9.74 9.11 9.26 10.21   
Cell count normalized PSA concentrations   
 Plate 1 Plate 2 Plate 3 Plate 4 Plate 5   
DMSO 0.0000634 0.0000699 0.0000547   0.0000627 0.0000076
2.5 uM 0.0000737 0.0000984 0.0000702 0.0000603 0.0000429 0.0000691 0.0000203
5 uM 0.0001656 0.0000736 0.0000686 0.0000560 0.0000653 0.0000858 0.0000451
10 uM 0.0001726 0.0001739 0.0000426 0.0000443 0.0000480 0.0000963 0.0000703
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Day 2 
PSA std curve day 2
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Absorbance = 0.1374*Cell count + 0.4102
 PSA concentration Absorbance 
 ng/mL at 450 nm 
Std A 0 -0.009 
Std B 1.5 0.471 
Std C 5 1.296 
Std D 15 3.117 
Std E 30 4.454 
Std F 40 5.7 
 
 
 
Fig 5-16 Standard curve for PSA estimation on day 2 (at 48 hrs). 
 
 
 
 
 
 
 
 221
Exposure-Efficacy Relationship Analysis & Efficacy Markers                         Chapter 5 
Table 5-6 PSA concentrations at 48-hr time-point 
Absorbance at 450 nM Mean SD 
Sorafenib concentration Plate 1 Plate 2 Plate 3 Plate 4 Plate 5   
DMSO 5.003 4.661 4.97     
2.5 uM 4.202 4.812 5.382 4.612 4.932   
5 uM 1.139 1.156 1.427 0.891 1.391   
10 uM 0.133 0.159 0.296 0.277 0.2   
Back-calculated PSA concentrations   
 Plate 1 Plate 2 Plate 3 Plate 4 Plate 5   
DMSO 33.43 30.94 33.19     
2.5 uM 27.60 32.04 36.18 30.58 32.91   
5 uM 5.30 5.43 7.40 3.50 7.14   
10 uM * * * * *   
Cell count normalized PSA concentrations   
 Plate 1 Plate 2 Plate 3 Plate 4 Plate 5   
DMSO 0.0000818 0.0000747 0.0000739   0.0000768 0.0000044
2.5 uM 0.0000742 0.0000794 0.0001012 0.0001788 0.0000550 0.0000977 0.0000482
5 uM 0.0000551 0.0001850 0.0002675 0.0002302 0.0001095 0.0001695 0.0000869
10 uM * * * * * * *
* Cell count for these time points were below the limits of quantitation 
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Day 3 
 PSA concentration Absorbance 
 ng/mL at 450 nm 
Std A 0 -0.051 
Std B 1.5 0.481 
Std C 5 1.58 
Std D 15 3.033 
Std E 30 4.004 
Std F 40 5.096 
 
 
 
Fig 5-17 Standard curve for PSA estimation on day 3 (at 72 hrs). 
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Table 5-7 PSA concentrations at 72-hr time-point 
Absorbance at 450 nM Mean SD 
Sorafenib concentration Plate 1 Plate 2 Plate 3 Plate 4 Plate 5   
DMSO 5.995 6.048 5.543     
2.5 μM 5.715 5.448 5.838 5.488 5.542   
5 μM 0.639 0.656 1.124 0.83 1.981   
10 μM -0.023 -0.006 -0.015 -0.029 -0.024   
Back-calculated PSA concentrations   
 Plate 1 Plate 2 Plate 3 Plate 4 Plate 5   
DMSO 45.64 46.08 41.86     
2.5 μM 43.30 41.07 44.33 41.40 41.85   
5 μM 0.89 1.04 4.95 2.49 12.11   
10 μM * * * * *   
Cell count normalized PSA concentrations   
 Plate 1 Plate 2 Plate 3 Plate 4 Plate 5   
DMSO 0.0000672 0.0000510 0.0000589   0.0000590 0.0000081
2.5 μM 0.0000664 0.0000669 0.0000855 0.0000708 0.0000452 0.0000670 0.0000144
5 μM 0.0000090 0.0000200 0.0000403 0.0000301 0.0000802 0.0000359 0.0000273
10 μM * * * * * * *
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* Cell count for these time points were below the limits of quantitation
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Fig 5-18 (A) Cumulative PSA (normalized to cell count) over 72 hrs. (B) Cell count-
normalized PSA in successive 24-hr intervals after treatment of LNCaP cells with DMSO 
(control), 2.5, 5 and 10 µmol/L sorafenib. Note: For the 10 μM sorafenib concentration, 
cell counts and PSA levels were below the limits of quantification for cell counting 
reference curve and PSA ELISA assay, respectively. 
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Table 5-8 Cell counts at 24-hr 48-hr and 72-hr time-points following treatment with sorafenib 
 
 
 
 
 
* Cell count for these time points were below the limit of quantitation
Cell counts at 24-hr time-point      
 Plate 1 Plate 2 Plate 3 Plate 4 Plate 5 Mean SD 
DMSO only 398500.00 412666.67 535166.67   448777.78 75149.54 
2.5 µM 431000.00 287666.67 419333.33 506833.33 561833.33 441333.33 103699.95
5 µM 116833.33 254333.33 327666.67 371000.00 313500.00 276666.67 98617.88 
10 µM 54333.33 56000.00 213500.00 209333.33 212666.67 149166.67 85826.05 
Cell counts at 48-hr time-point      
DMSO only 408500 414333.333 449333.333   424055.56 22084.64 
2.5 µM 371833.33 403500 357666.667 171000 598500 380500.00 152101.71
5 µM 96200 29333.3333 27666.6667 15200 65166.6667 46713.33 33344.36 
10 µM * * * * * * * 
Cell counts at 72-hr time-point      
DMSO only 679333.33 903500 711000   764611.11 121318.95
2.5 µM 651833.33 613500 518500 585166.67 926000 659000.00 157004.95
5 µM 99333.333 51833.3333 122666.667 82666.667 151000 101500.00 37830.03 
10 µM * * * * * * * 
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Fig 5-19 Cell counts upto 72 hrs, following treatment with four different concentrations 
of sorafenib and DMSO (negative control) 
 
5-4.4 Conclusions 
We demonstrated that sorafenib dose-dependently increases PSA secretion from LNCaP 
prostate cancer cell lines - independent of its effect on cell-growth inhibition. Similar 
findings were observed in clinical studies evaluating the efficacy of sorafenib in 
metastatic castrate resistant prostate cancer (mCRPC). These results indicate that PSA is 
not a suitable surrogate of efficacy for mCRPC patients treated with sorafenib. 
 
Use of PSA as surrogate endpoint of efficacy has been debatable since it was first 
identified by Ferro and colleagues (133). A decline in serum PSA concentrationswas 
shown to be a useful indicator of treatment outcome for many anticancer drugs tested in 
patients with mCRPC (129). However, contrary outcomes have been observed for agents 
such as TNP-470, sodium phenylacetate and phenylbutyrate, which increase PSA 
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expression in in-vitro, in-vivo models and clinical studies (134). These agents have shown 
to affect the PSA expression or secretion independent of alterations in tumor growth or 
volume (134).  
 
The exact mechanism by which these drugs increase PSA secretion is not known, but in 
part, it is thought to be an outcome of drug-induced increase in PSA transcription 
activity. Hence, it is important to validate the use of PSA for specific clinical settings and 
agents prior to its use as a surrogate marker for efficacy.  
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CHAPTER SIX 
EVALUATION OF THE EXPOSURE-TOXICITY RELATIONSHIP 
AND LABORATORY MARKERS FOR TOXICITY IN SOLID 
TUMOR PATIENTS TREATED WITH SORAFENIB 
 
 
6-1  Introduction 
The greatest challenge in oncology drug development is the identification of agents with 
optimum activity and a tolerable side effect profile. Therefore, therapeutic advances in 
the last several years have focused on development of agents with improved selectivity 
for their antitumor effect with the hope of reducing toxicities. However, the utility of 
these treatments remain limited, and a significant proportion of patients experience 
treatment-associated toxicities while deriving little or no benefit. These differences 
among patients are evident because of inherent heterogeneity. The findings in the areas of 
pharmacology, pathology and pharmacogenetics have shown that general population is a 
mix of subpopulations which differ from the population average with respect to 
disposition of drugs or response to treatment. Therefore, the individualization of 
treatment is increasingly being sought to optimize the therapeutic outcome, which 
includes the identification of patients who are likely to respond favorably to a specific 
therapy or those who will suffer from toxicities.  
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Individualization of therapy involves, among others, identification of predictive markers 
for toxicity and evaluation of exposure-(toxicity) response relationship. Several studies 
have evaluated such markers for oncology drugs. Methotrexate plasma concentrations 
have shown to be correlated with gastrointestinal and hematological toxicity (135, 136), 
and its concentrations were prospectively measured in patients for adjusting the 
leucovorin rescue (folic acid analogs used to prevent harmful effects of methotrexate) and 
preventing the toxicity (136). Similarly, exposures of a methotrexate analogue, 
trimetrexate, were also shown to be related with hematological toxicity (137-139). 
Etoposide’s steady-state plasma concentrations were higher in patients with significant 
hematological toxicity (140). Platelet counts following carboplatin treatment correlated 
with its exposure, which in turn was related with its renal clearance  (141). An equation 
was devised to prospectively determine the dose of carboplatin, which would result in 
non-toxic exposures (142). 
 
Pharmacogenetic variations were also shown to be related with toxicities. For example, 
genetic variation in TPMT was related with the concentrations of thioguanine 
nucleotides, which also correlated with the hematologic toxicities (143). Polymorphisms 
in the UGT1A1 gene correlated with SN-38 glucuronide concentrations, which in turn 
were related with treatment-associated neutropenia and diarrhea (144). Molecular and 
laboratory markers have also been evaluated to predict the efficacy and toxicity. For 
example the use of the HER2 and the estrogen receptor expression for decision of 
suitable chemotherapy in patients with breast cancer (145), and correlation of sweat 
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concentrations of doxorubicin with the occurrence of palmar-plantar erythrodysthesia 
syndrome (146), also known as the hand-foot syndrome. 
 
We evaluated the impact of exposure, and genetic and non-genetic markers on the 
frequency and/or severity of toxicities in patients with solid tumor treated with sorafenib 
as single agent or in combination therapy. The sorafenib treatment-associated toxicities 
observed in selected phase II/III clinical trials and their plausible mechanisms are 
described in section 1-3.7 and Table 1-4. The results of association between genetic 
markers and toxicities are described in chapter 7. The non-genetic marker evaluated was: 
sweat concentrations of sorafenib as a marker for the treatment-associated hand-foot skin 
reaction syndrome (HFSR). The methodologies, results and discussion of these 
correlative studies are described in this chapter.  
 
6-2  Evaluation of exposure-toxicity relationship 
6-2.1 Methods 
6-2.1.1 Patients and study design 
Data from a total of 112 patients included in the population pharmacokinetic analysis 
were used to assess the exposure-toxicity relationships. These patients were enrolled in a 
phase II clinical trial in mCRPC for single agent sorafenib (N=45), a phase II clinical trial 
in NSCLC receiving sorafenib only (N=18), a phase II trial in CRC receiving sorafenib in 
combination with cetuximab (N=18), a phase I trial in patients with ST receiving 
sorafenib in combination with bevacizumab (N=28), and a phase I trial in patients with 
KS receiving sorafenib only (N=2). Six patients in the KS trial receiving sorafenib with 
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ritonavir were not included in the current analysis because of the potential for a drug 
interaction (section 1-3.3). The exposure-toxicity analysis was separately performed for 
patients receiving only sorafenib (N=65), sorafenib with bevacizumab (N=28), and 
sorafenib with cetuxiamb (N=18). The dosing regimen and design of these phase I / II 
clinical trials have been described in section 4-4.1. 
 
6-2.1.2 Pharmacokinetic metrics 
The sorafeinb exposures (AUC = Dose/CL) calculated using the individual predictions of 
systemic clearances from population pharmacokinetic analysis were used to evaluate the 
exposure-toxicity relationships. Single-dose exposures were calculated using the 400 mg 
dose for patients with mCRPC, CRC and NSCLC, and with the 200 mg dose for patients 
enrolled in ST and KS trial. In case of dual therapies, exposures of the co-administered 
agents (i.e., bevacizumab and cetuximab) were not available to perform the similar 
analysis. 
 
6-2.1.3 Toxicity metrics 
In all of these trials, toxicities were reported using the Common Toxicity Criteria for 
Adverse Events (NCI CTC) version 3. The exposure-toxicity analysis was performed for 
most common sorafenib treatment-associated toxicities, which included fatigue, diarrhea, 
hand-foot skin reaction syndrome (HFSR), rash, desquamation and hypertension. The 
most severe grades of these toxicities observed anytime during the treatment were used 
for analysis. 
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6-2.1.4 Statistical analysis 
Patients from each analysis category (single dose sorafenib, sorafenib + bevacizumab, 
and sorafenib + cetuximab) were divided into four exposure groups which were created 
based on four quartiles of sorafenib AUC distribution. Incidence rates (%) of toxicities 
(grade ≥ 2) were compared among these exposure quartiles using the Chi-square 
statistics. The statistical analyses were performed using JMP 8.0 (SAS Institute Inc., 
Cary, NC, USA) statistical software. 
 
6-2.2 Results 
The incidences of the most common toxicities for sorafenib clinical trials included in 
current analysis are summarized in Table 6-1. The incidences of these toxicities in 
patients receiving only sorafenib were normally less than 50%. However, co-
administration of bevacizumab with sorafenib increased both the incidences (up to 
approximately 75%) and the severity of these toxicities, despite administration of half of 
the FDA approved dose of sorafenib (i.e., 200 mg BID) and bevacizumab (i.e., 5 mg/kg 
every other week). Up to 74% patients on dual therapy required dose reductions to 200 
mg QD levels (115). The exposure-toxicity analyses for sorafenib alone and combination 
therapy trials are discussed below: 
 
6-2.2.1 Combined single agent studies 
The combined results of single agent sorafenib trials are shown in Fig 6-1. With an 
increase in exposure from the lower quartile to the upper quartile, there was no major 
change in incidence rates of fatigue and HFSR. The incidence of diarrhea doubled from 
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exposures below the median to the 3rd quartile, but was absent in the 4th quartile. The 
incidence of rash significantly increased with increased exposures from below the median 
to above the median (p=0.0201), while the frequency of hypertension decreased with 
increased exposures. These results suggest an exposure-toxicity relationship only for 
treatment-associated rash, but not for other common toxicities following administration 
of single agent sorafenib in patients with solid tumors. 
 
6-2.2.2 Phase I trial in patients with solid tumors treated with sorafenib and 
bevacizumab combination 
In patients with solid tumor treated with the sorafenib and bevacizumab combination, 
only sorafenib exposures were available to assess the impact on toxicity, results of which 
are shown in Fig 6-2. With increased exposures from the lower quartile to the upper 
quartile, the incidence of fatigue decreased, and there was no major change in the 
frequency of rash, diarrhea and hypertension. Incidence rates of HFSR increased 
significantly from below the median to above the median exposures (p=0.0039). From 
Fig 6-2 and Table 6-1, we observe that, although sorafenib exposures for patients 
enrolled in the ST trial were comparatively low, the percent incidences of HFSR and 
hypertension toxicities were same or higher. 
 
Note that the use of bevacizumab monotyherapy has not been associated with HFSR, but 
the addition of bevacizumab to sorafenib reduced the dose at which highest-grades of 
HFSR toxicity appeared (60). Hypertension is a common toxicity for both sorafenib and 
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bevacizumab, and for all the agents with activity against VEGF pathway; hence, the 
increase in the frequency of hypertension with combination therapy is not unexpected.  
 
These results suggest that addition of bevacizumab intensifies the sorafenib treatment-
associated HFSR; it shifts the occurrence of HFSR to a lower dose level, and also 
following addition of bevacizumab incidences of HFSR appear to increase with increase 
in sorafenib exposure. We observed an exposure-toxicity relationship for sorafenib / 
bevacizuamb combination, but not for sorafenib monotherapy. 
 
6-2.2.3 Phase II trial in patients with colorectal cancer treated with sorafenib and 
cetuximab combination 
The number of patients in the CRC trial was limited; hence it was not possible to evaluate 
(sorafenib) exposure-toxicity analysis for fatigue, HFSR and hypertension (Fig 6-3). 
Rash and diarrhea are common toxicities for both sorafenib and cetuximab (49, 147). 
Therefore, the frequency of these side-effects was relatively higher in patients on this 
combination than in other patients (Table 6-1). The incidence of rash was not altered 
significantly, but the incidence of diarrhea appeared to decrease with increased exposures 
from below median to above median. One possible explanation is that, if sorafenib 
systemic exposures are high, it would suggest a low concentration of unabsorbed drug in 
the GI tract and, hence, lower the incidence of diarrhea. However, for the combination of 
drugs with common toxicities it is less likely to see a positive correlation between 
toxicities and exposure (pharmacokinetics) of only one drug, when both are administered 
together. Alternative metrics or markers, integrating plasma concentrations for all the 
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drugs in combination would be a better measure to assess the relationship with treatment-
associated toxicities. 
 
The sample size for this trial is small, and further evaluation with larger sample size is 
required to draw conclusions about impact of sorafenib exposure on toxicity. This trial is 
currently (at the time of analysis) enrolling the patients with targeted cohort size of 50. 
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    Table 6-1 Summary of toxicities in sorafenib clinical trials 
Trial Fatigue 
% (N) 
Rash: 
desquamation 
% (N) 
Hand-foot skin 
reaction 
% (N) 
Diarrhea, 
% (N) 
Hypertension 
% (N) 
 Gr1 Gr2 Gr≥3 Gr1 Gr2 Gr≥3 Gr1 Gr2 Gr≥3 Gr1 Gr2 Gr≥3 Gr1 Gr2 Gr≥3 
mCRPC 
(N=46) 
24 
(11) 
9 
 (4) 
0  
(0) 
4  
(2) 
20 
(9) 
9  
(4) 
41 
(19) 
13 
(6) 
2  
(1) 
9  
(4) 
13 
(6) 
2  
(1) 
33 
(15) 
15 
(7) 
4  
(2) 
NSCLC 
(N=18) 
22 
(4) 
6  
(1) 
0  
(0) 
33 
(6) 
28 
(5) 
0  
(0) 
11 
(2) 
39 
(7) 
11 
(2) 
28 
(5) 
11 
(2) 
0  
(0) 
11 
(2) 
28 
(5) 
6  
(1) 
CRC 
(N=18) 
44  
(8) 
6  
(1) 
0 
(0) 
11 
(2) 
22 
(4) 
17 
(3) 
22 
(4) 
11 
(2) 
0 
(0) 
17 
(3) 
28 
(5) 
17 
(3) 
6 
(1) 
6 
(1) 
0  
(0) 
ST 
(N=28) 
33 
(9) 
30 
(8) 
7  
(2) 
33 
(9) 
22 
(6) 
0  
(0) 
26 
(7) 
48 
(13) 
0  
(0) 
41 
(11) 
4  
(1) 
15 
(4) 
11 
(3) 
26 
(7) 
30 
(8) 
KS† 
(N=8) 
12.5 
(1) 
12.5 
(1) 
12.5 
(1) 
12.5 
(1) 
0 
(0) 
0 
(0) 
0 
(0) 
0 
(0) 
25 
(2) 
25 
(2) 
0 
(0) 
0 
(0) 
0 
(0) 
0 
(0) 
37.5 
(3) 
† Data from only 2 of these patients on sorafenib without ritonavir were included in exposure-toxicity analysis. 
Gr: toxicity grade based on NCI CTC version 3, mCRPC: Phase II trial of sorafenib in metastatic castrate resistant prostate cancer, 
NSCLC: Phase II trial of sorafenib in non-small cell lung cancer, CRC: Phase II trial of sorafenib and cetuximab combination in 
patients with colorectal cancer, ST: Phase I trial of sorafenib and bevacizumab combination in patients with solid tumors. KS: Phase I 
trial of sorafenib (with or without ritonavir) in patients with Kaposi’s sarcoma. 
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Fig 6-1 Evaluation of exposure-toxicity relationship for clinical trials involving administration of only sorafenib  
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Fig 6-2 Evaluation of exposure-toxicity relationship for ST trial involving administration of sorafenib in combination with 
bevacizumab 
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Fig 6-3 Evaluation of exposure-toxicity relationship for CRC trial involving administration of sorafenib in combination with 
cetuximab 
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6-2.3 Discussion  
The majority of treatment-related toxicities associated with oral sorafenib administration 
were mild to moderate in severity. These toxicities were constitutional (such as fatigue), 
dermatological (such as rash, desquamation and HFSR), gastrointestinal (such as 
diarrhea) and cardiovascular (such as hypertension) in nature. Sorafenib monotherapy at a 
standard dose of 400 mg BID was well tolerated, and treatment-associated toxicities were 
manageable with the supportive therapies (91). However, even lower grades of these 
toxicities are of concern because sorafenib is a cytostatic agent and requires long-term 
administration for therapeutic benefit; recurrence of even lower grades of toxicities for a 
long time could adversely affect patient’s quality of life and/or lead to treatment 
disruption/discontinuation.  
 
Co-administration of bevacizumab, another anti-angiogenic agent, increased the 
incidence and severity of selected treatment-associated side effects. There is some 
overlap in toxicity profiles of these drugs; for example, both sorafenib and bevacizumab 
can cause hypertension, diarrhea and gastrointestinal perforation (49, 120). However, 
skin rash and HFSR are not common toxicities of bevacizumab (60, 120). Many patients 
on this dual-drug trial required reduction in sorafenib dose to 200 mg QD (one fourth of 
the clinically approved dose) because of treatment-associated toxicities (115). Similarly, 
administration of sorafenib in combination with cetuximab increased the incidence of 
their common toxicities, rash and diarrhea. 
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The incidence rate of rash increased with increased exposures following administration of 
sorafenib monotherapy.  A pooled analysis of four phase I trials also found an increase in 
the severity of rash with a higher starting dose of single-agent sorafenib (91). The 
exposures for erlotinib, a tyrosine kinase inhibitor which belongs to the same class of 
drug as sorafenib, have also been shown to be related with incidence of skin rash (88, 
148) 
  
The frequency and severity of HFSR were reported to be significantly associated with a 
sorafenib dose in the range of 300-600 mg BID (91). However, no significant correlation 
was found between sorafenib exposures (pharmacokinetics) and HFSR, for single agent 
sorafenib trials. These results suggest that with cytostatic agents metrics which relates to 
extended exposures, such as cumulative dose, might be more useful for assessment of 
exposure-response relationship than the single dose exposures. Earlier, a report based on 
(part of) patients involved in current analysis has shown rise in incidences of HFSR with 
increasing cumulative sorafenib dose in single-agent sorafenib studies (60). The 
incidence of diarrhea and fatigue was determined not to be associated with dose based on 
pooled analysis of phase I studies (91), and we did not find any significant correlation 
with sorafenib exposures, too. 
 
The incidence of HFSR increased significantly with increased sorafenib exposures, when 
administered in combination with bevacizumab. Sorafenib exposures at which HFSR was 
seen appeared to be lower for combination therapy compared with single agent therapy. 
Earlier investigations based on patients involved in current analysis have shown an 
increased frequency of high-grade HFSR for combined sorafenib and bevacizumab 
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therapy compared to treatment with sorafenib monotherapy (p=0.0006), as well as a 
lower dose was required for onset of highest grades of HFSR (60). Cumulative median 
dose of sorafenib for HFSR toxicity in combination therapy was 21,117 mg, while that 
dose level was not reached for treatment with single-agent sorafenib (60). The incidence 
and severity of HFSR were higher with combined sorafenib and bevacizumab therapy 
compared with single agent sorafenib at any given cumulative dose of sorafenib (60). 
Together, these results indicate higher incidences of HFSR with increased sorafenib 
exposure and cumulative sorafenib dose in the sorafenib/bevacizumab combination study, 
suggesting that the anti-VEGF effects of bevacizumab potentiates the sorafenib 
treatment-associated HFSR. The role of VEGF pathway in induction of HFSR has also 
been supported by several other observations reported by Azad et al (60). The risk of 
HFSR was not found to be related with other factors such as the number and type of prior 
therapies, including exposure to pegylated liposomal doxorubicin, previous toxicities, 
baseline neuropathy, or dermatological toxicities from prior treatments (60).  
 
No significant correlations were found between the incidence of hypertension/fatigue and 
sorafenib exposures in single-agent or combination sorafenib trials, which was in 
agreement with results from pooled analysis for phase I studies (91).  
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6-3 Sweat concentrations of sorafenib as a marker of HFSR 
6-3.1 Introduction 
In Table 6-1 it is reported that HFSR is a common toxicity associated with sorafenib and 
combined vascular endothelial growth factor therapy. . Pain and disability associated with 
HFSR caused by sorafenib and sunitinib affects up to 62% of patients and can limit 
treatment dose and duration (53, 54, 60, 149). In phase III clinical trials of sorafenib in 
renal cell carcinoma and hepatocellular carcinoma, 10-38% patients required treatment 
discontinuation and 13-44% patients required dose reductions or interruptions because of 
treatment-related toxicities, which may compromise efficacy (53, 54).  In phase II 
studies, patients treated with sorafenib for prostate cancer and lung cancer experienced 
dose reductions for HFSR toxicity (10% and 31%, respectively) (60). However, the 
mechanism underlying HFSR is not clearly understood. 
 
Traditional chemotherapeutics such as cytarabine and liposomal doxorubicin, also cause 
acral erythematous plaques and dysesthesia, also known as hand-foot syndrome/HFS, 
acral erythema, or palmar-plantar erythrodysesthesia (150, 151). Based on anatomical 
distribution and eccrine histological changes of traditional HFS, others have postulated 
and studied sweat excretion of these toxic drugs as the etiology of traditional HFS (146). 
Similarly, we hypothesized that excretion of sorafenib in sweat might be a causal factor 
for HFSR. We sought to investigate this hypothesis to understand the mechanism of 
HFSR, which would also provide the basis for its prevention and effective treatment. 
 
6-3.2 Methods 
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6-3.2.1 Patients and study design 
Sweat was collected from hands of two patients with HFSR: a) a 62 year old female with 
ovarian cancer and active grade 1 HFSR on day 30 of sorafenib 200mg twice daily and 
bevacizumab 5mg/kg and b) a 62 year old male with prostate cancer, who had prior grade 
2 HFSR, which improved after treatment was held for grade 3 hypophosphatemia, and 
had active grade 1 HFSR on day 197 of sorafenib 400mg twice daily at time of sweat 
collection. In addition, sweat samples were collected from two healthy volunteers, which 
were used to set-up the quantitation method using plasma samples as calibrators. 
 
6-3.2.2 Sweat collection 
Sweat excretion was stimulated with pilocarpine iontophoresis and was collected using a 
capillary macroduct collector (Wescor Macroduct® kit, Wescor, Inc., Logan, Utah). 
Immediately after collection sweat was transferred to a small sealable container, which 
was stored at -80 ˚C till the time of analysis. 
 
6-3.2.3 Quantitation of sorafenib in sweat 
A LC/MS)/MS method, originally developed and validated for plasma matrix (152) was 
used for analysis of sweat samples. For this analysis, sweat samples were measured 
against plasma calibrators. Precipitation agent was added to sweat in a 1:10 ratio. Sweat 
samples from healthy volunteers were spiked with known concentrations of sorafenib and 
were analyzed to determine the lower limits of quantitation (LOQ).  
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6-3.3 Results 
The chromatograms of sweat samples from healthy subjects with externally spiked 2, 5 
and 10 ng/mL concentrations are shown in Fig 6-4. The LOQ was determined to be 5 
ng/mL. The sorafenib in sweat samples was found to be stable for at least 3 months, when 
stored at -80 ˚C. 
 
Chromatograms for sweat samples collected from patients are shown in Fig 6-5. No 
sorafenib was detected in sweat collected from the hands of two patients with HFSR. The 
plasma concentrations for both the patients were at steady-state given that sorafenib’s 
half-life is 25-48 h (49) and samples were collected on day 30 and 197. The plasma 
concentration for patient with prostate cancer during sweat collection was 7468.6 ng/mL. 
No pharmacokinetic blood samples were collected from the patient with ovarian cancer. 
Neither patient received prior HFS-associated chemotherapeutics. These results suggest 
that HFSR may not be associated with excretion of sorafenib in sweat, at least in 
concentrations of 5ng/mL and above. 
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Fig 6-4 Chromatograms for sorafenib concentrations of (A) 2 ng/mL (B) 5 ng/mL and 
(C) 10 ng/mL when drug was spiked externally in sweat samples collected from healthy 
subjects. 
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Fig 6-5 Chromatograms for sweat samples from; (A) collected from patient with active 
HFSR grade 1 on day 30 of phase II trial of sorafenib and bevacizumab in patients with 
epithelial ovarian, fallopian, and peritoneal cancer, (B) collected from patient with active 
HFSR grade 1 on day 197 of phase II trial of sorafenib in patients with androgen-
independent prostate cancer. 
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6-3.4 Discussion 
Sorafenib is a lipophilic compound with experimentally determined lipophilicity (logP) 
value of 3.8 (153). The sweat secreted from eccrine sweat glands, which are abundant on 
the palms of the hands and soles of the feet - the sites of HFSR, is mainly composed of 
water, various salts, and minute amounts of fatty material, urea and other waste.  Based 
on the sweat composition sorafenib, being lipophilic, is less likely to be excreted via 
eccrine sweat glands. Sunitinib, another agent associated with HFSR, is also relatively 
lipophilic (logP: 2.5) (153). Conversely, most other HFS-causing drugs are relatively 
hydrophilic; the logP values for these drugs are -0.5: doxorubicin, -0.8: fluorouracil, -2.8: 
cytarabine, -1.6: hydroxyurea and capecitabine, 0.4 (153). Of note, sweat excretion has 
been shown to act as a carrier of doxorubicin to skin surfaces, which would then possibly 
be stored in stratum corneum and react with epidermal cells, resulting in HFSR (146).  
 
Histologic examination of HFSR lesions has demonstrated focal horizontal zones of 
necrotic keratinocytes, dilated blood vessels, mild perivascular lymphohistiocytic 
inflammation, and eccrine gland abnormalities including dilatation and dysmorphic 
eccrine cells.(154, 155) The multi-kinase inhibitors target platelet-derived growth factor 
receptor (PDGFR) and c-KIT, which are both expressed on eccrine glands. Our findings 
demonstrate no association of HFSR with sorafenib sweat excretion ≥5 ng/mL. An 
alternative hypothesis is that the leakage of drug from blood capillaries damaged by 
subclinical trauma may cause HFSR, which is partly supported by the worsening severity 
of HFSR with increased activity and friction. However, to the best of our knowledge, 
there are no published studies which confirm this mechanism. Sorafenib and sunitinib 
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target tyrosine kinase receptors expressed on endothelial cells (PDGFR, c-KIT, and 
vascular endothelial growth factor receptor). Furthermore, combined anti-vascular 
endothelial growth factor therapy of sorafenib and bevacizumab is associated with a 
higher incidence of HFSR.(60) 
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CHAPTER SEVEN 
EVALUATION OF VEGFR2 POLYMORPHISMS AS A 
MARKER OF THE RISK OF PROSTATE CANCER, AND 
SURVIVAL AND TOXICITY IN SOLID TUMOR PATIENTS 
RECEIVING ANTI-VEGF/VEGFR2 THERAPY 
 
 
7-1 Introduction 
The process of new blood vessel formation from the pre-existing blood vessels, or 
angiogenesis, is crucial for development of tumor, invasiveness and metastasis (156). 
This process is governed by an array of growth factors favoring or opposing the new 
blood vessel formation; however, vascular endothelial growth factor (VEGF) is the major 
regulator of this process (156). Angiogenesis has been implicated in several tumor types 
including the prostate cancer, NSCLC, CRC and other solid tumors. Raising interest in 
angiogenic modulators have led to the design and synthesis of several new molecules that 
target VEGF signaling pathway. These agents have shown promising anticancer activity 
and some of them, such as sorafenib, bevacizumab and sunitinib, are currently used 
clinically for various solid tumors. 
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So far, three VEGF receptors have been identified, namely VEGFR1 (or the fms-like 
tyrosine kinase (Flt-1)), VEGFR2 (or Kinase domain receptor (KDR)/ the murine fetal 
liver kinase (Flk-1)) and VEGFR3 (157). The VEGFR1 and 3 receptors are expressed in 
selected vascular beds, whereas the VEGFR2 receptor is expressed on almost all 
endothelial cells (158). Among these, VEGFR2 has the strongest kinase activity (157) 
and its interaction with VEGF is believed to be of utmost importance for angiogenesis 
during tumor development. Independent expression of only VEGF or VEGFRs does not 
always relate to increased tumor-angiogenesis, but the expression of their 
VEGF/VEGFR2 complex appears to be a better predictor of VEGF angiogenic activity 
(159). The VEGF/VEGFR2 complex was prominently localized in cancer cells and intra-
tumoral vasculature in non-small cell lung and endometrial carcinomas (159, 160). The 
expression of this complex was related with poor prognosis and increased vascularization 
at the invading tumor-front regardless of VEGF levels (159), and appeared to be a strong 
prognostic factor than VEGF expression alone. These findings suggest that VEGFR2 
plays a major role in VEGF signaling pathways by mediating the biological effects of 
VEGF. VGEF has shown to play an important role in both localized and metastatic 
prostate cancer (161-163) and its over-expression was shown to be associated with poor 
disease outcomes (164, 165). Microvessel density (MVD), a marker of angiogenic 
activity, and VEGFR2 expression was higher in prostate tumor cells compared to normal 
prostatic glands (166, 167).  
 
Functional SNPs affecting the expression of genes or function of coded proteins may 
result in differences in an individual’s susceptibility and severity of disease. These effects 
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might be caused by a single SNP or by coinheritance of multiple SNPs (also known as 
haplotypes) in a signaling pathway. Compared to the introduction of new 
VEGF/VEGFR2 targeted therapies, only few studies have investigated the impact of 
VEGFR2 SNPs on risk and prognosis of disease and drug response. The new targeted 
therapies are not equally tolerated by all patients, and some side-effects do not appear to 
be related with administered dose; suggesting that exploration of factors other than dose 
will be important to predict the occurrence of these side-effects. The etiology of common 
side-effects associated with anti-angiogenic class of compounds, such as hypertension 
and proteinuria, is not well understood (168). However, in-vitro and in-vivo evidence 
supports that these side-effects most probably result from inhibition of the VEGF 
pathway (168). 
 
There is a critical need to identify molecular and pharmacogenetic markers to recognize 
patients who will likely benefit or develop toxicities from anti-angiogenic therapies. In 
the current study we evaluated the possible association between two SNPs in the 
VEGFR2 gene, namely rs2305948 (C/T) and rs1870377 (T/A), and (i) risk of prostate 
cancer, (ii) toxicities related with anti-VEGF/VEGFR2- inhibitor therapies, (iii) survival 
in solid tumor patients treated with anti-VEGF/VEGFR2- inhibitor therapies. These SNPs 
are located on exon 7 and 11 and result in nonsynonymous amino acid changes at residue 
297 Val>Ile and 472 His>Gln, respectively. 
 
7-2 Methods 
7-2.1 Patients and controls 
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The analyses were performed on genomic DNA from 184 patients (144 males and 40 
females) with solid tumors who received sorafenib (VEGFR2 inhibitor) and/or 
bevacizumab (anti-VEGF) with or without other agents. These patients were enrolled in 
six phase I/II clinical trials and their characteristics are summarized in Table 7-1. Sixty-
one patients with castrate resistant prostate cancer not treated with anti-angiogenic 
therapies (i.e., bevacizumab or sorafenib) were used as controls for survival analysis. 
DNA samples from 292 control subjects with no known diagnosis of prostate cancer, 
obtained from Valley Biomedical (Winchester, VA, USA), were used as controls for risk 
analysis. Characteristics for survival and risk controls are also summarized in Table 7-1. 
This retrospective analysis was approved by the NCI Institutional Review Board. 
Information about survival and treatment-associated toxicities were collected from all 
patients treated with sorafenib and/or bevacizumab. Toxicities were graded based on NCI 
common toxicity criteria version 3.0.  
 
7-2.2 Genotyping 
DNA was extracted from plasma or whole blood samples using a QiaBlood extraction kit 
(Qiagen, Valencia, CA) and stored at 4◦C. The primers were obtained from Invitrogen 
Corp (Carlsbad, CA). Genotyping for two VEGFR2 loci, VEGR2 H472Q and VEGFR2 
V297I, was performed by single/nested PCR using the PCR primers shown in Table 4-3. 
The single PCR samples were subjected to an initial 40-cycle reaction with the following 
temperature cycle: 5 minutes at 94 ºC, 30 seconds(s) at 94 ºC, 30 s at annealing 
temperature (Table 4-3), 30 s at 72 ºC, and 7 minutes at 72 ºC. The nested PCR reaction 
consisted of a primary 20-cycle round of amplification using F1, R1 primers followed by 
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a second round of amplification for 40 cycles using F2, R2 primers with the same 
conditions as above. All samples were checked via 2% agarose gel electrophoresis for the 
presence of products.  
 
PCR products were cleaned by treatment with Shrimp Alkaline Phosphatase (SAP) and 
Exonuclease I (Exo I) (USB Corporation, Cleveland, OH). These enzymes were 
deactivated by PCR cycle run for 90 minutes at 37 ºC and 20 minutes at 70 ºC, in 
preparation for sequencing. Sequencing PCR was carried out with big dye under the 
following cycle sequence: 5 minutes at 94 ºC, 10 s at 96 ºC, 5 s at 50 ºC, and 4 minutes at 
60 ºC. The PCR products were then sequenced on an ABI Prism 310 Genetic Analyzer 
(Applied BioSystems, Foster City, CA) as per the instructions from manufacturer.  
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Table 7-1 Summary of patients and control subjects included in analysis 
Tumor type Treatment (s) N Ethnicity Gender Information collected 
   C: AA: others Male:Female Survival Toxicity 
Cases       
mCRPC Sorafenib 46 38 : 6 : 2 46 : 0 Yes Yes 
NSCLC Sorafenib 22 16 : 2 : 4 13 : 9 Yes Yes 
CRC Sorafenib + Cetuximab 18 13 : 1 : 4 9 : 9 Yes Yes 
KS Sorafenib +/- Ritonavir 8 7 : 1 : 0 8 : 0 Yes Yes 
ST Sorafenib + Bevacizumab 33 31 : 1 : 1 11 : 22 Yes Yes 
mCRPC Bevacizuamb + Thalidomide 
+ Docetaxel 
60 50 : 8 : 2 60 : 0 Yes  Hypertension and 
HFSR 
Survival controls      
mCRPC Docetaxel 25 19 : 3 : 2 25 : 0 Yes No 
 Docetaxel + Ketoconazole 37 28 : 3 : 1 37 : 0  Yes No 
Risk controls      
No tumor No cancer treatment received 292 143 :149 292 : 0 NA NA 
 C: Caucasian, AA: African-American, Others: Hispanic or Asians, mCRPC: metastatic castrate resistant prostate cancer, NSCLC: 
non-small cell lung cancer, CRC: colorectal cancer, KS: Kaposi’s sarcoma, ST: solid tumors, HFSR: hand-foot skin reaction 
syndrome, NA: not applicable    
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7-2.3 Statistical considerations 
Hardy-Weinberg equilibrium was tested for only Caucasian patients and both Caucasian 
and African-American controls for both VEGFR2 SNPs using Chi-square test. The 
genotype and allele frequencies between Caucasian and African-American controls and 
patient and control groups were compared by Fisher’s exact test or Chi-square test. Odds 
ratios and their 95% confidence intervals, estimated using logistic regression models, 
were used to compare the probability of genotypes between prostate cancer and control 
groups. Fisher’s exact test was used to measure the strength of association between 
VEGFR2 genotypes and prostate cancer risk. The impact of genotypes on treatment-
associated toxicities and association between toxicities were assessed by Fisher’s exact 
test. Survival curves based on genotype or toxicity groups (grade ≤ 1/grade ≥ 2) were 
compared by the Kaplan-Meier method using a log-rank and stratified log-rank test. The 
latter test was used to adjust for trial-associated variation in PFS and frequency of 
toxicities, and from these tests only the less significant, more conservative, p-values were 
reported. All statistical analysis were two-tailed at a pre-specified significance level of 
<0.05. In view of the exploratory nature of analysis, p-values were not formally corrected 
for multiple testing. 
 
7-3 Results 
7-3.1 Genotyping 
The genotype and allele frequencies of studied VEGFR2 SNPs in patients with solid 
tumor and male Caucasian and African-American controls are shown in Table 7-2 and 7-
3. Both VEGFR2 SNPs were in Hardy-Weinberg equilibrium (p<0.05), when evaluated 
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individually for Caucasian patients, Caucasian controls and African-American controls. 
These frequencies are in close agreement with previous reports by Schneider et al (169, 
170) and Försti et al (79). The genotype data were consistent with healthy Swedish 
Caucasians females (p>0.14), but did not match the data obtained in healthy Polish 
Caucasians females (p≤0.0204) (79). 
 
7-3.2 Are VEGFR2 H472Q and V297I genotype/allele frequencies different 
between Caucasian and African-American male controls?  
As shown in Table 7-3 the variant allele frequency for VEGFR2 H472Q was 
significantly greater in Caucasian male controls than African-Americans (p=0.0137), 
while for VEGFR2 V297I, the frequency of the variant allele was significantly higher for 
African-Americans (p=0.003) than Caucasian controls. Schneider et al. reported similar 
ethnicity-based differences in allele frequencies in patients with breast cancer with 
following variant allele frequencies respectively for Caucasian and African-American 
patients: H472Q, 0.25 and 0.10, and V297I 0.09 and 0.20 (169, 170). 
 
7-3.3 Are VEGFR2 H472Q and V297I genotypes associated with risk of prostate 
cancer? 
Genotype frequencies in the subgroup of Caucasian patients with prostate cancer and 
Caucasian male controls were compared to assess the impact of studied VEGFR2 SNPs 
on prostate cancer risk. Studied VEGFR2 SNPs had no significant association with the 
risk of prostate cancer (Table 7-4). Confidence intervals on odds ratios for heterozygous 
and variant genotypes compared to reference wild-type group included 1, suggesting that 
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the probability of observed genotype frequencies were not different between cancer 
patients and controls. However, these confidence intervals also included 2, suggesting 
that the true odds of disease in patients with variant alleles could be double the odds in 
other patients. This needs to be confirmed in a large prospective epidemiological study. 
The number of African-American prostate cancer patients on these trials was too low to 
assess the impact of VEGFR2 genotype on disease risk. 
 
7-3.4 Are VEGFR2 H472Q and V297I genotypes associated with treatment 
associated toxicities for sorafenib and/or bevacizumab therapy? 
All patients included in the current analyses were treated with either sorafenib and/or 
bevacizumab as one of the treatment modalities. There is some overlap in toxicity 
profiles of these drugs, for example both sorafenib and bevacizumab causes hypertension, 
diarrhea, gastrointestinal perforation etc (49, 120). However, dermatological toxicities 
such as skin rash and hand-foot skin reaction (HFSR) were only associated with sorafenib 
treatment. Combined therapy with bevacizumab and sorafenib has reported to result in 
increased incidences and severity of side-effects (60, 115).  
 
Frequencies for most severe grades of five common sorafenib treatment associated 
toxicities, namely rash: desquamation, diarrhea, HFSR, hypertension and fatigue were 
compared between wild-type and variant allele groups for studied VEGFR2 SNPs. 
Toxicity data were available from all trials involving treatment with sorafenib, but only 
hypertension and HFSR toxicity data were available for patients treated with 
bevacizumab with thalidomide and docetaxel.  
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Only the associations of hypertension and HFSR with VEGFR2 H472Q SNP were 
significant (p<0.016; Fig 7-1 and Table 7-5). The frequency of hypertension and HFSR 
was almost double for patients carrying the variant VEGFR2 H472Q polymorphism than 
for carriers of wild-type allele while on therapies against VEGF pathway (hypertension: 
variants, 39% vs. wild-type, 21%, p=0.0154; HFSR: 33% vs. 16%, p=0.0136). Similar 
results were obtained for following subgroups: patients treated with sorafenib 
monotherapy (hypertension: 37% vs. 18%, p=0.1051; HFSR: 40% vs. 16%, p=0.0302) 
and patients treated with sorafenib as at least one of the therapy (with or without 
bevacizumab; hypertension: 42% vs. 21%, p=0.0210; HFSR: 44% vs. 20%, p=0.0063). 
Analysis of the association between toxicities revealed that hypertension was associated 
with development of HFSR, with 19 of 126 patients (15.1%) with hypertension grades ≤ 
1 developing HFSR (grades ≥ 2) compared to 19 of 52 (36.5%) who developed or 
worsened hypertension to grades ≥ 2 (p=0.0024). Earlier, an analysis based on a subgroup 
of patients receiving sorafenib and bevacizumab combination demonstrated association 
between hypertension and HFSR (60). Genotype-toxicity relationships for other toxicities 
and studied SNPs were non-significant (Table 7-5).  
 
7-3.5 Are VEGFR2 H472Q and V297I genotypes associated with survival in 
patients treated with sorafenib and/or bevacizumab, with or without other agents? 
The progression free survival (PFS) and overall survival (OS) was compared for the 
studied VEGFR2 SNPs across patients or patient subgroups using Kaplan survival 
analysis. The PFS was significantly different with respect to the VEGFR2 H472Q 
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polymorphism for patients with solid tumors receiving sorafenib as single agent or in 
combination therapy (5.7 months for heterozygotes, N=40, vs. 3.2 or 3.7 months for 
homozygous wild-type, N=76 or variants, N=6, p=0.044), with an apparent heterozygous 
advantage, as shown in Fig 7-2. Similar, but non-significant differences with tendency of 
heterozygous advantage was seen for following patient subgroups: patients treated with 
sorafenib monotherapy (p=0.25), patients treated with sorafenib and bevacizumab 
combination (p=0.48), patients treated with bevacizumab, docetaxel and thalidomide 
combination (p=0.57), and patients treated with bevacizumab with other agents 
(sorafenib/docetaxel and thalidomide, p=0.26. The observed heterozygous advantage was 
thought to be influenced by small sample size in homozygous variant group (N=6). 
Alternatively, it could be an outcome of overdominance or haplotype association of 
H472Q SNP with other functionally important SNPs conferring heterozygous advantage. 
It is important to note that patients with variant allele for VEGFR2 H472Q appeared to 
have longer PFS and were also more susceptible to hypertension and HFSR. The 
difference in OS based on VEGFR2 H472Q genotype was not statistically significant. 
The VEGFR2 V297I SNP was not related with either PFS or OS in studied patients. 
Earlier, a study in breast cancer patients reported no significant effect of these VEGFR2 
SNPs on survival (170). 
 
7-3.6 Are hypertension and HFSR phenotypic markers for effect of VEGFR2 
H472Q SNP on PFS? 
 262
VEGFR2 Polymorphisms as Markers of Risk, Survival and Toxicity                     Chapter 7 
Because VEGFR2 H472Q SNP was related with both the PFS and toxicities 
(hypertension and HFSR), we evaluated whether these toxicities were also predictive of 
PFS (Fig 7-3). 
 
 
 
Fig 7-1 Comparison of incidence of hypertension and hand-foot skin reaction (HFSR) 
toxicities between VEGFR2 genotype groups 
 
 263
VEGFR2 Polymorphisms as Markers of Risk, Survival and Toxicity                     Chapter 7 
-0.1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
P
ro
po
rti
on
 s
ur
vi
vi
ng
0 5 10 15 20 25 30 35
Months from on-study date
 
Fig 7-2 Kaplan-Meier survival curves following treatment with sorafenib (as a single 
agent or in combination therapy) versus VEGFR2 H472Q genotypes. Red: wild-type 
genotype (N=76), Green: heterozygous genotype (N=40) and Blue: variant genotype 
(N=6). P=0.0440 by a two-tailed log-rank test. 
 
 
     Fig 7-3 Diagram of possible association between VEGFR2 H472Q SNP, toxicities 
and PFS 
 
The PFS and OS were compared between hypertension and HFSR toxicity groups (grades 
≤ 1 and ≥ 2) using Kaplan Meier survival analysis. Hypertension (in patients receiving 
bevacizumab as one of the therapy) and HFSR (in patients receiving sorafenib as single 
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agent or in combination therapy) were predictive of longer PFS or slower disease 
progression. Patients who developed hypertension following treatment with bevacizumab 
in combination with sorafenib or docetaxel and thalidomide were also the patients who 
had relatively longer PFS or slower disease progression (p=0.0051; Fig 7-4). While 
patients who developed HFSR following treatment with sorafenib, either as single agent 
or in combination with ritonavir, bevacizumab or cetuximab, had longer PFS than 
patients without these toxicities (p=0.0011; Fig 7-5). Association of these toxicities with 
OS was not significant. These results suggest that treatment associated hypertension and 
HFSR act as phenotypic markers for effect of VEGFR2 H472Q on PFS in patients with 
solid tumor treated with therapies against VEGF pathway. Earlier, a study involving 
patients with breast cancer determined significantly longer OS for patients who 
developed hypertension on bevacizuamb and paclitaxel combination than patients 
without toxicity (170). Associations between other toxicities and PFS or OS were not 
significant. 
 
7-3.7 The impact of VEGFR2 H472Q SNP in patients not treated with drugs 
against the VEGF pathway 
To determine whether the effect of VEGFR2 Q472 SNP on PFS was restricted to use of 
drugs against the VEGF pathway or was common for other categories of drugs as well, 
we genotyped 62 patients who were on docetaxel therapy, as single agent (N=25) or in 
combination with ketoconazole (N=37). Kaplan-Meier curve of survival for these patients 
is shown in Fig 7-6; there was no significant difference in survival based on genotype 
(p=0.5703), and also no trend of survival advantage was observed for heterozygous 
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genotype. These results indicate that delay in disease progression (or longer PFS) based 
on VEGFR2 H472Q genotype was only limited to treatments with activity against VEGF 
pathway. 
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Table 7-2 Genotype and allele frequencies for SNP in VEGFR loci for solid tumor patients treated with sorafenib and/or 
bevacizumab, with or without other agents 
Allelic variant N Gender (N) Ethnicity (N) Genotype frequencies, N (%) Allelic freqencies
  Male : Female C : AA : Others Wt Het Var p q 
VEGFR2 H472Q 176 139:37 145:18:13 108 (61.4) 60 (34.1) 8 (4.5) 0.78 0.22 
VEGFR2 V297I 176 138:38 145:18:13 135 (76.7) 38 (21.6) 3 (1.7) 0.87 0.13 
C: Caucasians; AA: African-Americans; Others: Hispanic or Asians; Wt: wild-type genotype; Het: heterozygous genotype; Var: 
homozygous variant genotype; p and q are standard Hardy-Weinberg nomenclature for allele frequencies. 
 
Table 7-3 Comparison of genotype and allele frequencies for two VEGFR2 SNPs between Caucasian and African-American male 
controls 
Allelic variant Ethnicity N Genotype frequencies, N (%) Allelic frequencies 
   Wt Het Var p-value† p q p-value† 
   TT TA AA  T A  
VEGFR2 H472Q Caucasian 138 93 (67.4) 36 (26.1) 9 (6.5) 0.0724 0.80 0.20 0.0137 
 African-American 149 117 (78.5) 28 (18.8) 4 (2.7)  0.88 0.12  
   CC CT TT  C T  
VEGFR2 V297I Caucasian 143 117 (81.8) 22 (15.4) 4 (2.8) 0.0038 0.90 0.10 0.0030 
 African-American 148 96 (64.9) 47 (31.8) 5 (3.4)  0.81 0.19  
†Chi-squares test was used to compare the genotype and allele frequencies between Caucasian and African-American controls 
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Table 7-4 Assessment of risk of prostate cancer based on VEGFR2 genotype 
VEGFR2 SNP Genotype frequency, N (%)   
 Prostate Cancer Cases Controls Odds ratio [95%CI] p-value† 
VEGFR2 H472Q     
TT 62 (62.6) 93 (67.4) 1  
TA 33 (33.3) 36 (26.1) 1.4 [0.8-2.4] 0.3066 
AA 4 (4.0) 9 (6.5) 0.7 [0.2-2.3] 0.5705 
(TA+AA) vs. TT 35 (37.4) 45 (32.6) 1.2 [0.7-2.1] 0.5798 
VEGFR2 V297I     
CC 76 (77.6) 117 (81.8) 1  
CT 20 (20.4) 22 (15.4) 1.4 [0.7-2.7] 0.3870 
TT 2 (2.0) 4 (2.8) 0.8 [0.1-4.3] 1.000 
(CT+TT) vs. CC 22 (22.4) 26 (18.2) 1.3 [0.7-2.5] 0.4175 
†p-values are based on Fisher’s exact test 
 
Table 7-5 Comparison of toxicities between wild type and variant allele groups for VEGFR2 SNPs 
VEGFR2 H472Q VEGFR2 V297I Toxicity grade ≥2  
N (%*) wt allele var allele p-value† wt allele var allele p-value† 
Hypertension 22 (21.4) 26 (38.8) 0.0154 38 (29.0) 12 (30.8) 0.8431 
HFSR 16 (15.5) 22 (32.8) 0.0136 28 (21.4) 10 (25.6) 0.6618 
Rash:desquamation 17 (25.0) 13 (28.9) 0.6686 23 (27.7) 9 (30.0) 0.8165 
Diarrhea 14 (20.6) 7 (15.6) 0.6236 19 (22.9) 3 (10.0) 0.1795 
Fatigue 12 (17.7) 6 (13.3) 0.6080 14 (16.9) 4 (13.3) 0.7766 
*% of total patients in that group, †p-values are based on Fisher’s exact test. wt: wild-type, var: variant 
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Fig 7-4 Kaplan-Meier survival curves following treatment with bevacizumab (in 
combination with sorafenib (N=27) or docetaxel and thalidomide (N=60)) versus 
hypertension grades (≤1 or ≥2). Red: hypertension grade ≤1 (N=57) and Blue: 
hypertension grade ≥2 (N=30). P=0.0051 by a two-tailed log-rank test. 
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Fig 7-5 Kaplan-Meier survival curves following treatment with sorafenib (as single agent 
(N=76) or in combination with bevacizumab (N=27) or cetuximab (N=18)) versus HFSR 
grades (≤1 or ≥2). Red: HFSR grade ≤1 (N=87) and Blue: HFSR grade ≥2 (N=34). 
P=0.0011 by a two-tailed log-rank test. 
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Fig 7-6 Kaplan-Meier survival curves following treatment with docetaxel (as a single 
agent (N=25) or in combination with ketoconazole (N=31)) versus VEGFR2 H472Q 
genotypes. Red: wild-type genotype (N=35), Green: heterozygous genotype (N=17) and 
Blue: variant genotype (N=4). P=0.5703 by a two-tailed log-rank test. 
 
 
7-4 Discussion 
Only a few studies have evaluated the role of VEGFR2 SNPs as a predictive or 
prognostic disease marker. Försti and colleagues assessed the impact of VEGF and 
VEGFR2 SNPs on the risk of breast cancer (79). Two studies by Schneider and 
colleagues investigated SNPs in VEGF and VEGFR2 gene as potential markers for breast 
cancer risk (169) and for the prediction of toxicity/treatment outcomes following 
treatment with paclitaxel with or without bevacizuamb (170). These studies were focused 
on a single tumor type. Additionally, two small studies evaluated the impact of 
VEGF/VEGFR2 SNPs on recurrence of colon cancer (171) and on the prediction of 
efficacy or toxicity in patients treated with anti-angiogenic therapy (172).  
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This is the first report evaluating the impact of two functionally important VEGFR2 
SNPs on the risk of prostate cancer, and also investigating their role as prognostic and 
predictive markers in a diverse solid tumor patient population undergoing treatment with 
drugs having activity against VEGF pathway. For the first time, genotype and allele 
frequencies of VEGFR2 H472Q and V297I SNPs have been characterized and compared 
between Caucasian and African-American male subjects with no known diagnosis of 
cancer (i.e., controls) of U.S. origin. 
 
The frequencies of these SNPs between male controls and patients with prostate cancer 
were not statistically different, suggesting that these SNPs would not act as predictive 
markers for risk of prostate cancer. Earlier, these polymorphisms were reported also not 
to be related with risk of breast cancer as well (79, 169). 
 
The VEGFR2 H472Q SNP was related with better prognosis and risk of hypertension and 
HFSR. Few subjects carried the variant genotype; hence only joint toxicities in 
heterozygous and homozygous variant genotypes could be compared against wild-type 
carriers. Carriers of the variant allele for H472Q were more susceptible to both 
hypertension and HFSR, and these toxicities were associated with each other. These 
toxicities appeared to be the phenotypic markers for the effect of VEGFR2 H472Q SNP 
on disease progression in patients with solid tumor, treated with sorafenib and/or 
bevacizumab with or without other agents. Patients who developed these toxicities had 
longer PFS than others while on therapies against VEGF pathway. These findings suggest 
that patients who develop these toxicities are more likely to also achieve a therapeutic 
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benefit. Hence, these side effects should be effectively managed to avoid or delay the 
treatment disruption or discontinuation. 
 
We observed a better prognosis for the heterozygous genotype compared to both wild-
type or variant genotype. The difference in PFS for wild-type and variant genotypes 
appeared to be non-significant. The discrepant order of PFS for patients who carry two 
copies of the variant allele was thought to be biased by a small sample size in that group 
(N=6). The overdominance hypothesis may also explain the heterozygous allele 
superiority relative to homozygous alleles (173). The VEGFR2 H472Q (rs1870377; exon 
11) SNP is linked with rs3816584 (intron 16), rs6838752 (intron 17), rs10016064 (intron 
13), rs17085262 (intron 21), rs17085265 (intron 21), rs 2219471 (intron 20), rs13136007 
(intron 13), rs1870378 (intron 15) and rs1870379 (intron15) based on CEU data from 
HapMap project. It is possible that H472Q acts as tag SNP for other functionally 
important SNPs. The VEGFR2 V297I (rs2305948; exon7) was not linked to any other 
SNPs; and was not related with progression free survival, overall survival or 
susceptibility to hypertension and HFSR. These results suggest a prognostic and 
predictive role for VEGFR2 H472Q SNP, but not for V297I SNP. The lack of impact on 
OS by these SNPs suggests that tumor biology was not altered based on their genotypes.  
 
The exonic VEGFR2 V297I and H472Q SNPs are located in the third and fifth 
immunoglobulin like (Ig-like) domains of VEGFR2 receptor. The Ig-like domain 3 is 
critical for binding of VEGF (174), while domains 4-7 contain structural features that 
inhibit VEGFR2 signaling in the absence of VEGF (175). Wang et al studied the effect of 
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these SNPs on VEGF binding by transfecting the HEK293s cells with variant allele for 
one or both of these SNPs (176). As expected, transfects with variant VEGFR2 V297I 
SNP had significantly low VEGF binding efficiency regardless of VEGFR2 H472Q 
allele; while variant VEGFR2 H472Q allele had minimal effect on VEGF binding 
efficiency (176). 
 
The non-synonymous amino acid change by VEGFR2 H472Q SNP may result in a loss 
of inhibition of VEGFR2 signaling in the absence of VEGF leading to a constitutively 
active VEGFR2 receptor. These patients with seemingly constitutive signaling appear to 
have a pronounced effect, following treatment with sorafenib and bevacizumab. 
Sorafenib acts intracellularly on VEGFR2 receptors to inhibit the auto-phosphorylation 
and receptor activation. Bevacizumab acts extracellularly to inhibit the binding of VEGF 
protein to VEGFR2 receptor. The site of VEGFR2 H472Q is downstream to the 
bevacizumab’s target site in VEGF signaling pathway, even than it appears to be related 
with progression free survival and frequency of toxicities, suggesting that VEGFR2 
H472Q receptor polymorphism may be important even in patients with reduced VEGF 
levels. 
 
Hypertension is a common side effect associated with agents that block signaling through 
VEGF pathway, which is not unexpected given that VEGF receptors are present on 
endothelial cells on blood vessels. Hypertension has been reported in all studies involving 
bevacizumab (177). Azad and colleagues has presented several lines of evidence to 
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support the role of VEGF pathway in development of HFSR (115). These data also 
explain the effect of VEGFR2 SNP on susceptibility to hypertension and HFSR. 
 
In conclusion, VEGFR2 H472Q SNP appears to play an important role in prediction of 
toxicities and treatment outcome following treatment with drugs having activity against 
the VEGF pathway. Treatment associated toxicities on these therapies should be 
aggressively treated, as opposed to taking patients off the trial after the first sign of 
toxicities, to achieve the optimal therapeutic benefit.  
 
 
 
 
 
 
 
 
 
 
 
Summary & Overall Conclusions                      Chapter 8 
 
 
CHAPTER EIGHT 
SUMMARY AND OVERALL CONCLUSIONS 
 
 
A collaboration between Bayer and Onyx pharmaceuticals in the discovery of novel 
therapies targeting the Ras-Raf-MEK-ERK pathway using high-throughput screening and 
a combinatorial chemistry approach led to the identification of sorafenib as a potential 
anticancer agent (1).  Sorafenib was found to be a potent inhibitor of wild-type b-raf, 
oncogenic b-rafV6600E serine/threonine kinases, c-raf, pro-angiogenic RTKs (VEGFR1, 
2, 3, PDGFRβ, FGFR1) and other RTKs involved in tumorigenesis (c-Kit, Flt-3 and 
RET)(1). It has been tested as a potential treatment for patients with solid tumors in 
several clinical trials since year 2000 (1). In 2005, it was first approved by the FDA for 
the treatment of advanced renal cell carcinoma, and later in 2007, the original approval 
was extended to unresectable hepatocellular carcinoma (9). Currently, it is used in more 
than 70 countries worldwide for these indications (9). In general, sorafenib is well 
tolerated with a manageable side-effects profile (1). Therefore, it has also been (is being) 
evaluated in combination with other anticancer therapies, including the cytotoxic 
chemotherapies, immunological agents and anti-angiogenic agents (1).  
 
Sorafenib’s pharmacokinetics and toxicity profiles are well characterized in patients with 
solid tumors and normal organ functions (38-40, 63) and more recently, in special patient 
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populations, such as with hepatic or renal impairment (94). All published clinical studies 
reported high inter-patient variability in its systemic exposure, clinical efficacy and 
toxicities (chapter 1), suggesting that clinical outcomes are highly variable in patients 
treated with sorafenib. Hence, there was/is a critical need for identification of predictive 
markers for efficacy and toxicity to improve the clinical utility of sorafenib. To determine 
such markers, we designed several correlative studies for clinical trials being conducted 
at NCI involving administration of sorafenib. A total of five phase I/II clinical trials 
evaluated the safe dose or efficacy (response rate) of sorafenib in patients with mCRPC, 
CRC, NSCLC, KS and various ST following administration as a single agent or in 
combination with other chemotherapies. Sorafenib was orally administered at 200/400 
mg BID dose levels. From patients enrolled into these trials, pharmacokinetic, 
pharmacodynamic and pharmacogenomic data were collected along with information 
about their demographic characteristics and organ functions. Analysis of pharmacokinetic 
characteristics, Pharmacokinetic-Pharmacodynamic-Pharmacogenomic correlative 
studies and ex-vivo cell line experiments were conducted to explore the potentially 
predictive markers based on available data. 
 
For quantitation of sorafenib in plasma samples from patients enrolled in the above-
mentioned trials, a LC-MS/MS bioanalytical method was required. Published 
bioanalytical methods were limited by complex extraction procedures, long run-times, 
poor sensitivity and requirement of large plasma volume. Hence, a simple, rapid, 
sensitive and efficient method was developed and validated. This method was based on a 
simple protein precipitation, required only 50 μL of plasma volume, and had short run 
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time of 4 minutes with a lower quantifiable limit of 5 ng/mL (152). Plasma samples from 
all patients enrolled in the above mentioned trials were analyzed using this method, and 
plasma concentration-time profiles were generated. 
 
Exposure metrics and pharmacokinetic parameters were determined by non-
compartmental analysis-general linear modeling (NCA-GLM; two-stage approach) and 
population pharmacokinetic modeling: 
 
Sorafenib exposures after the first dose (AUC0-12), maximum plasma concentration (Cmax) 
and time to maximum plasma concentration (tmax) were estimated by non-compartmental 
analysis, using single-dose plasma concentration – time profiles over 12 hrs. The %CV 
on AUC0-12 and Cmax for 400 mg BID dose ranged from 45 to 79% and 46 to 87%, 
respectively, and for the 200 mg BID dose %CV on both of these parameters were 
approximately 65%. To explain this variability, demographic (age, weight, height, BSA, 
gender, ethnicity), clinical (serum albumin, alkaline phosphatase, ALT, AST, bilirubin 
total, total protein, serum creatinine and estimated creatinine clearance) and 
pharmacogenetic (CYP3A4*1B, CYP3A5*3C, UGT1A9*3, UGT1A9*5, VEGFR2 
H472Q and VEGFR2 V297I) factors were explored using general linear modeling of the 
ln-transformed exposure metrics. Body weight, BSA, serum albumin and UGT1A9*3 
were statistically significant and mechanistically plausible covariates for both of these 
pharmacokinetic metrics. However, their contribution to the overall variability in 
systemic sorafenib exposure was small, making these effects clinically irrelevant and 
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would not justify any dose adjustments. Only one patient carried the UGT1A9*3*3 
genotype; hence, its potential effects need to be evaluated in future studies. 
 
The plasma concentration –time profiles from both single dose and steady-state were 
used together to perform the population pharmacokinetic modeling. A mechanism-based 
pharmacokinetic model was successfully developed; taking into account sorafenib’s 
known pharmacokinetic properties. A one-compartmental body model with first-order 
absorption, discontinuous entero-hepatic recycling, serial GI transit absorption 
compartments (n=4) and first-order elimination best described the sorafenib 
pharmacokinetics. Only body weight was found to be a significant covariate for apparent 
volume of distribution (V/F), which reduced inter-patient variability in log-transformed 
plasma concentrations from 72% to 69%. Because the contribution of body weight to the 
variance on V/F was small, and a large proportion of the overall variability remains 
unexplained, this effect was clinically irrelevant and would not necessitate any dose 
adjustments. For a patient with a body weight of 81.5 kg, the typical population value for 
clearance (CL/F) was 8.0 L/h, V/F 217 L and GI absorption transit time 1.98 h. The 
model-predicted plasma concentrations were in reasonable agreement with observed 
concentrations, and the estimated typical population mean values were in accordance 
with sorafenib’s known pharmacokinetic characteristics. Both NCA-GLM and population 
pharmacokinetic analysis appeared to agree on role of body weight as a statistically 
significant covariate; albeit, not clinically important. 
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In NCA-GLM analysis, serum albumin appeared to be an important covariate for Cmax/D 
and AUC0-12/D, but its contribution to overall variance in these exposure metrics was 
minimal. Serum albumin was also a significant covariate for V/F during stepwise-forward 
regression stages of covariate model building, but was not significant in the final 
population pharmacokinetic model. These effects were mechanistically plausible, but had 
minimal clinical relevance because of their small contribution to overall varianbility in 
pharmacokinetic/exposure parameters. Genetic variations in metabolic enzymes for 
sorafenib (i.e., CYP3A4 and CYP3A5) appeared to be unimportant in describing the 
variations in disposition of sorafenib. However, the UGT1A9*3 SNP appeared to be 
statistically significant covariate by NCA-GLM and during covariate model building 
stages of population pharmacokinetic analysis. Since only one patient carried the 
homozygous variant genotype (i.e., UGT1A9*3*3), its effect may have been biased by 
small (unbalanced) sample size in genotype subgroups. Nevertheless, these effects were 
mechanistically plausible, where UGT1A9*3 would reduce the metabolic activity of 
UGT1A9 enzyme resulting in higher plasma levels for carriers of this SNP. The effect of 
UGT1A9*3 on sorafenib exposure requires further prospective investigations with a 
larger sample sizes. None of the studied patients carried UGT1A9*5 SNP, hence, its 
effect on sorafenib disposition could not be evaluated. 
 
The results of NCA-GLM and population pharmacokinetic analysis were in agreement 
with the results of published prospective clinical studies. In particular, a drug-interaction 
study investigated the effect of ketoconazole co-administration, a potent CYP3A4 
inhibitor, on sorafenib pharmacokinetics (37). The CYP3A4 inhibition by ketoconazole 
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was reported to have no significant effect on sorafenib’s systemic exposure, but reduced 
the levels of circulating N-oxide metabolites (37). Another study investigated the 
pharmacokinetics of sorafenib in patients with various degrees of liver and renal 
dysfunction (94). Sorafenib exposures were highly variable among these patients, but no 
association was apparent with extent of liver or kidney impairment. The collective 
conclusions from these studies support our findings that liver and kidney function 
parameters and genetic variation in CYP3A4 and CYP3A5 metabolic enzymes are not 
clinically important determinants of sorafenib exposure. 
 
Following exploration for sources of variability in pharmacokinetics of sorafenib, we 
investigated possible associations between sorafenib exposure and clinical outcomes. The 
hypothesis was that higher exposures of sorafenib would be be associated with better 
efficacy and/or higher incidence or severity of treatment associated side-effects, 
assuming no major inter-patient differences in responsiveness to sorafenib.  
 
Clinical efficacy and toxicities in patients treated with sorafenib were highly variable. 
Sorafenib appeared to have modest activity in patients with mCRPC. Co-administration 
with bevacizumab and cetuximab resulted in improved efficacy in patients with ST and 
CRC compared to historical response rates with single-agent therapies. Response 
evaluation in patients with NSCLC was limited by the small sample size. Up to 79% 
patients in combination therapy trials had partial response (PR) or stable disease (SD) 
compared to less than 50% patients in single agent trials. The combination of targeted 
therapies appears to improve on the modest activity of these drugs as single agents. 
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However, these combinations may also result in higher than expected toxicities; hence, 
they necessitate careful adjustments of doses and development of strategies for 
management of side-effects. We observed higher incidence and severity of treatment-
associated side effects in patients treated with combination therapy than single agent 
alone. The incidence of treatment-associated toxicities, such as hypertension, hand-foot 
skin reaction (HFSR), rash: desquamation, fatigue and diarrhea, were normally less than 
50% in single-agent sorafenib trials, which increased to 74% in trials involving 
combination therapies. 
 
Exposure-efficacy relationship appeared to be non-significant for patients with mCRPC, 
CRC and ST based on sorafenib exposures alone. Clinical efficacy in patients with 
NSCLC appeared to be associated with systemic exposure of sorafenib; however, a lack 
of correlation between exposure (AUC0-12) and PFS and small number of patients on this 
trial (N=18) suggests the need of further evaluation. The exposure-efficacy relationship 
was not evaluated for patients with KS because of limited enrollment of patients in that 
trial. 
 
Assessment of exposure-toxicity relationships suggested an increase in the incidences of 
rash with increase in sorafenib exposure for single-agent sorafenib therapy. Following 
administration of sorafenib with bevacizumab, the incidence of HFSR appeared to be 
associated with sorafenib exposures, which was not significant for single-agent sorafenib 
studies. Other toxicities were not associated with sorafenib exposures, following 
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treatment as either single agent or in combination therapy. These results were also 
supported by published literature. 
 
In addition to exposure-efficacy relationships, we evaluated prostate specific antigen 
(PSA) and ex-vivo anti-angiogenic activity as markers for clinical efficacy, respectively, 
in patients with mCRPC and ST. 
 
PSA concentrations have long been used as an indicator of treatment efficacy and tumor 
progression (cancer staging) in patients with prostate cancer. Greater than 50% post-
treatment declines in serum PSA concentrations were shown to be associated with 
survival advantage. Contrary to conventional chemotherapies, serum PSA concentrations 
increased following treatment with sorafenib, which declined after treatment 
discontinuation. Also, a few patients had improvement in bone scans despite of 
continuous rise in PSA. It was hypothesized that sorafenib may influence PSA 
concentrations independent of its effect on cellular-growth. To check this hypothesis we 
treated LNCaP human prostate cancer cells with increasing concentrations of sorafenib in 
in-vitro experiments. The concentrations of secreted PSA increased with increase in 
sorafenib concentrations, and as expected, cell counts declined. These results support the 
clinical observations and indicate that PSA is not a suitable surrogate marker of efficacy 
in prostate cancer patients treated with sorafenib. These changes in PSA secretion are 
thought to be in part due to drug-induced increase in PSA transcription activity. 
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We also investigated the association of ex-vivo anti-angiogenic activity for steady-state 
serum samples from patients on sorafenib and bevacizumab combination and their best 
clinical responses. The ex-vivo anti-angiogenic activity was assumed to act as a surrogate 
of combined plasma concentrations of these drugs and was measured by rat aortic ring 
assay using steady-state serum samples. The anti-angiogenic activity was not associated 
with clinical outcome, suggesting that it may not be used as a biomarker for clinical 
response; however, these results were limited by small sample size.  
 
We also evaluated laboratory and pharmacogenetic markers for toxicities, which were 
selected based on mechanistic reasoning. HFSR, a sorafenib treatment associated side 
effect, mainly affects the palms of hands and soles of feet, causing erythema with 
swelling followed by blistering and desquamation. Eccrine sweat glands are abundant in 
these skin surfaces and are also adversely affected by HFSR, resulting in dilatation and 
dysmorphism of eccrine cells. Based on anatomical distribution of HFSR and effects on 
eccrine sweat glands, we hypothesized that its development might be associated with 
excretion of sorafenib in sweat. We collected sweat samples from patients with HFSR 
and determined sorafenib concentrations in them using a LC-MS/MS method with lower 
quantifiable limits of 5 ng/mL. Sorafenib was undetectable in these samples, suggesting 
that HFSR is not associated with leakage of sorafenib in sweat at concentrations 
measuring ≥5 ng/mL. 
 
Development of HFSR has also been shown to be associated with inhibition of the VEGF 
pathway. Supporting evidence was offered by Azad and colleagues(60), (a) increase in 
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frequency and severity of HFSR following combination of sorafenib with bevacizumab, 
(b) predilection of HFSR for traumatic foci, suggesting that inhibition of VEGF may 
retard tissue repair from minor trauma, (c) direct association of cumulative bevacizumab 
dose with incidences of HFSR, and (d) the association of HFSR and development of 
hypertension, suggesting a role of vascular effects. Another side effect, hypertension, is a 
common side effect of drugs with anti-angiogenic activity (or activity against VEGF 
pathway) including sorafenib, which is not unexpected given that VEGF receptors are 
present on endothelial cells on blood vessels. Considering the role of the VEGF pathway 
in development of these toxicities, we evaluated the impact of genetic variation (SNPs) in 
VEGFR2 (i.e., H472Q and V297I), a receptor which mediates the majority of cellular 
responses of VEGF, on incidences of these toxicities. Patients with variant alleles for 
VEGFR2 H472Q SNP were more likely to develop hypertension and HFSR than carriers 
of the wild-type allele while on anti-angiogenic therapies. Patients who developed 
hypertension on anti-angiogenic therapies were also more likely to develop HFSR. 
 
Because clinical effects of anti-angiogenic drugs used in current trials (i.e., sorafenib and 
bevacizumab) were also mediated by VEGFR2, the impact of genetic variation in 
VEGFR2 on overall and progression-free survival (OS and PFS) was also determined. 
Patients with VEGFR2 H472Q heterozygous genotype appeared to have longer PFS than 
carriers of homozygous wild-type or homozygous variant genotype while on anti-
angiogenic therapy with sorafenib and/or bevacizumab, but OS was not associated with 
genotype. The exact mechanism of this apparent heterozygous advantage is not known, 
but possible explanations include the small sample size in the variant allele group (N=6), 
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and/or the phenomenon of overdominance or proxy role of H472Q SNP for other 
functionally important SNPs (i.e., haplotype association).  It is important to note that 
variant allele for H472Q appears to be associated with both slower disease progression 
(or longer PFS) and higher incidence of HFSR and hypertension toxicities, suggesting 
that these patients are more responsive to anti-angiogenic therapies than wild-type 
carriers. Hypertension and HFSR appear to act as phenotypic markers for the effect of 
VEGFR2 H472Q SNP on PFS. The exact mechanism for this effect is not known, but 
based on the known functional roles of site where these SNPs are located, the variant 
H472Q allele appears to lead into constitutive activation of VEGFR2 receptors. Inhibition 
of constitutive signaling would result into prominent changes from baseline compared to 
inhibition of normal signaling, therefore, possibly resulting into pronounced effects on 
survival and toxicities. These findings also suggest that these side effects should be 
managed effectively to avoid or delay the discontinuation of treatment. 
 
In addition to assessment of VEGFR2 SNPs as pharmacogenetic marker for efficacy and 
toxicity, we investigated their impact on risk of prostate cancer by conducting a case-
control study. Both VEGFR2 H472Q and V297I were not associated with risk of prostate 
cancer.  
 
Results of these all correlative studies are summarized in Fig 8-1.  
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Fig 8-1 Schematic illustration of results from exploration of demographic, clinical, laboratory and pharmacogenetic markers for 
exposure, efficacy and toxicity in patients with solid tumors following treatment with sorafenib. Results from assessment of 
pharmacogenetic markers for risk of prostate cancer are also included. 
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Overall, in this research project, potential demographic, clinical, laboratory and 
pharmacogenetic factors contributing to variability in pharmacokinetics, clinical efficacy 
and toxicity for sorafenib treatment were explored. Pharmacogenetic markers for risk of 
prostate cancer were also investigated. There are several clinically important findings 
which are summarized below: 
(a) No dose adjustments for sorafenib are necessary based on patient’s demographic 
characteristics studied, namely their genotype for CYP3A4*1B, CYP3A5*3C and 
possibly UGT1A9*3 SNPs in metabolic enzymes, and liver and kidney function, at least 
based on the range of data available from the studies included in this analysis. 
(b) Higher exposures of sorafenib may not translate into better clinical efficacy, but are 
likely to result in higher incidences of dermatological toxicities. 
(c) For prostate cancer patients treated with sorafenib, markers other than PSA should be 
used to assess/predict the efficacy. The role of PSA as efficacy markers for other targeted 
therapies should also be examined before its clinical use, to avoid withdrawal of 
(clinically effective) therapies because of the possibility of a false indication of disease 
progression. 
(d) Treatment with anti-angiogenic therapies should not be discontinued merely because 
of development of toxicities such as HFSR and hypertension. These side effects may 
actually be indicative of patient’s favorable response to administered treatment. Hence, 
aggressive adjuvant therapies should be used to manage these side effects before 
discontinuation of treatment. 
(e) Genetic variations in VEGFR2 predict the survival, and frequency of selected 
toxicities, indicating that activity of the VEGF pathway is indeed important for the 
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clinical effects of anti-angiogenic drugs. Combination of targeted drugs with activity 
against multiple (upstream and downstream) proteins in the VEGF pathway might result 
in better efficacy. However, the benefit-risk ratio in the context of each individual patient 
should be assessed, because treatment with drug combination may also increase the 
incidence of toxicities. 
(f) Drugs decreasing the secretion of sweat might not be helpful in reducing the severity 
of HFSR associated with sorafenib treatment. This mechanism need to be evaluated 
further using methods with higher sensitivity, such as fluorescent labeling.  
 
These studies are a step forward towards individualization of sorafenib treatment, with an 
ultimate aim to provide the right dose of sorafenib to right patient at right time. However, 
these results need to be confirmed in prospective clinical studies. Identification of 
markers for efficacy and toxicity are not only important to increase clinical utility, but 
also to avoid the false-negative conclusions about the inefficacy of sorafenib in certain 
tumor types. The later is critical to facilitate the availability of drugs with activity in a 
selected patient population. 
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                Appendix 1-1 
Phase I single agent or combination studies of sorafenib 
 
Type of 
clinical trial 
Patient 
population 
Sorafenib 
Dose (mg) 
Dosing 
schedule 
MTD Response 
rate 
AE Remarks Ref 
Phase I, 
dose 
exploratory 
Advanced 
refractory 
solid 
tumors 
50 q5d, 50 q2d, 
(100, 200, 300, 
400, 600, 800) 
bid  
21 days 
on/7days off 
400 mg bid 50 % SD HFS, Diarrhea, 
rash, 
desquamation, 
fatigue 
Sorafenib is well 
tolerated. 
Awada et 
al, British J 
Cancer, 
2005 
Phase I, 
dose 
exploratory 
Advanced 
refractory 
solid 
tumors 
100, 200, 400, 
600, 800 bid 
7 days on / 7 
days off 
600 mg bid 26 % SD Rash, 
desquamation, 
hypertension 
Sorafenib is well 
tolerated. 
Clark et al, 
Clin Cancer 
Res, 2005 
Phase I, 
dose 
exploratory 
Advanced 
refractory 
solid 
tumors 
50 q4d, (50,100) 
qd, 
(100,200,400,600
) bid 
28 days 
on/7days off 
400 mg bid 22% SD HFS, Fatigue Sorafenib is well 
tolerated. 
Moore et 
al, Annals 
of oncology 
2005 
Phase I, 
dose 
exploratory 
Advanced 
refractory 
solid 
tumors 
(50-800) qd, bid  varying weekly 
schedule 
400 mg bi 
d 
18% SD diarrhea, nausea Sorafenib is well 
tolerated. 
Strumberg 
et al, JCO, 
2005 
Phase I, 
safety, 
efficacy 
Japanese 
HCC 
200, 400 bid 28 days 
continuous cycle 
400 mg bid 4% PR 
83% SD 
HFS, 
desquamation, 
rash, hypertension, 
elevated amylase 
and lipase 
Sorafenib is well 
tolerated. 
Furuse et 
al, Cancer 
Sci, 2007 
Phase I, 
sorafenib (S)+ 
Erlotinib(Erl) 
Advanced 
refractory 
solid 
tumors 
1. 200 bid S + 
   100 qd Erl 
2. 200 bid S +  
   150 qd Erl 
3. 400 bid S + 
   150 qd Erl  
S for 1 week 
followed by 
both S and E 
 
400 mg bid S 
+ 150 mg qd 
E ; may 
require 
modification 
on longer 
20% PR, 
60% SD 
Fatigue, Diarrhea, 
Acneiform rash, 
hypophospthatemia 
Combination well 
tolerated and has 
promising activity. 
No PK interaction. 
Duran et al, 
Clin Cancer 
Res, 2007 
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 administration 
Phase I S+ 
Gefitinib 
(Gef) 
Refractory 
or recurrent 
NSCLC 
S (200-400) bid + 
Gef 250 qd 
(21 days on one 
agent, 7 days 
off), (crossover 
to second agent 
for 21 days on, 7 
days off), 
followed by 28 
days cycles 
400 mg bid S 
+ 250 mg qd 
Gef 
1 PR,  
65% SD,  
Median 
PFS 133 
days 
Diarrhea, elevated 
ALT, rash, fatigue,  
Decreases Gef 
plasma levels, 
activation of 
CYP3A4 by S 
resulting in 
increased 
biotransformation 
of Gef 
Adjei et al, 
Clin Cancer 
Res, 2007 
Drug 
interaction 
with 
Ketoconazo
le (ket) 
Healthy 
subjects 
S 50, Ket 400 S, 10 days 
washout, 
followed by 3 
days Ket and 4th 
day S 
-  Nausea , tremor, 
hypertension 
-No clinically 
significant increase 
in sorafenib 
exposure.  
-Level of sorafenib 
N-oxide went down 
Lathia et al, 
Cancer 
Chemother 
Pharmacol, 
2006 
Safety, 
efficacy and 
PK in 
combination 
with 
irinotecan 
(Irc) 
Advanced 
refractory 
solid 
tumors 
Cohort 1-3 (100, 
200, 400) bid  S+ 
125 mg/m2 Irc 
Cohort 4 
400 bid S + 
140 mg Irc 
6 wk cycles of S 
combined with 
wkly i.v. Irc for 
4 wks followed 
by 2 wks 
without Irc 
MTD was not 
reached 
1 PR,  
60% SD in 
cohort 1-3, 
77% SD in 
cohort 4 
Diarrhea, 
decreased 
ANC/AGC, 
decreased 
leukocytes 
-Increased 
exposure of Irc 
and SN-38 
following 
concomitant S 400 
administration 
didn’t increase the 
toxicity 
-Only in S 400 bid 
+ Irc 125 mg/m2 
group; S mean 
AUC0-10 went up by 
68% and Cmax went 
up by 78%. 
-Cohort 3, Irc 
AUC0-∞ and Cmax 
increased by 26 & 
36% respectively. 
-Cohort 4, Irc 
AUC0-∞ and Cmax 
Mross et al, 
European J 
of Cancer, 
2007 
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 increased by 42 & 
73% respectively. 
-Mean AUC0-48 and 
Cmax  for SN-38 
increased by 120% 
with Irc 125 mg/m2 
and by 70% with 
Irc 140 mg. 
Phase I,  
S +  
Doxorubici
n (Dox) 
Refractory 
solid 
tumors 
Dox 60 mg/m2  + 
S (100, 200, 400) 
bid cohort 1-3 
Administer Dox 
(21 days cycle) 
1st day, from 4th 
day continuous 
S. S free period 
48 hr before and 
24 hr after 2nd 
dose of Dox 
MTD was not 
reached 
48% SD HFS, Neutropenia, 
Diarrhea, stomatitis 
-S partly increased 
AUC0-8 or Cmax but 
no effect on steady 
state S PK. 
-Dox PK no effect 
with 100, 200 mg 
bid S. 
-Contradictory 
findings for cohort 
3 based on dose 
denominations (50 
mg tablet vs. 200 
mg tablet). 
-Dox exposure may 
increase with S. 
S may reverse the 
resistance to Dox 
Richy et al, 
Annals of 
oncology, 
2006 
Phase I, S+ 
Gemcitabin
e (Gem) 
Refractory 
solid 
tumors and 
Gem 1000 mg/m2 
+ S (100, 200, 
Escalating doses 
of S bid 
S 400 bid + 
Gem 1000 
10.5% PR, 
63% SD. 
Pancreatic 
HFS, rash, 
diarrhea, 
hypertension, 
-No clinically 
relevant PK 
Siu et al, 
Clin Cancer 
Res, 2006 
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 extended 
cohort of 
Advanced 
pancreatic 
cancer  
400 w/ 50 mg 
tab, 400 w/ 200 
mg tab) bid  
continuous 
administration 
schedule + Gem 
1000 mg/m2 
wkly (initially 7 
consecutive wk, 
1 wk rest, 
followed by  3 
wk for every 4 
wks) 
mg/m2 wkly 
(initially 7 
consecutive 
wk, 1 wk rest, 
followed by  3 
wk for every 
4 wks) 
cohort 53% 
SD 
elevated hepatic 
transaminases and 
bilirubin, elevated 
pancreatic enzymes 
interaction between 
S + Gem. 
-S may reverse 
resistance to Gem 
Phase I,  
S +  
IFNα-2a  
  
Unreseceta
ble and/or 
metastatic 
RCC or 
malignant 
melanoma 
Cohort 1, S 200 
bid + s.c. IFN 6 
MIU  
Cohort 2, S 400 
bid + s.c. IFN 6 
MIU  
Cohort 3, S 400 
bid + s.c. IFN 9 
MIU  
 
S continuously, 
IFN thrice wkly 
DCE-US-to 
measure 
dynamic 
changes in 
tumor volume 
and/or tumor 
vasculature 
Biomarker, 
pERK levels in 
circulating 
PBLs   
MTD not 
reached 
1 PR RCC, 
61.5% SD 
(7 RCC + 1 
melanoma) 
HFS, Diarrhea, 
fatigue, weight 
loss, nausea,  
-No effect of S PK 
-Trend toward 
reduction in 
absolute value of 
lymphocytes. 
-No significant 
dose dependent 
inhibition of ERK 
phosphorylation 
Escudier et 
al, Clin 
Cancer 
Res, 2007 
Phase I, S+ 
Oxaliplatin 
(Oxl) 
Refractory 
solid tumor 
including 
colorectal 
cancer 
Oxl 130 mg/m2 on 
day 1 of a 3 wk cycle 
+ S from 4th day 200 
bid (cohort 1), 400 
bid (cohort 2A, 2B & 
Oxl day 1 of 3 
wk cycle + S 
from 4th day bid 
continuous 
MTD not 
reached 
(Recommended 
400 mg bid S + 
Oxl 130 mg/m2) 
78% SD Diarrhea, sensory 
neuropathy, other 
dermatological 
toxicities  
-No PK interaction  Kupsch et 
al, Clin 
Colorectal 
Cancer, 
2005 
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3) 
Phase I , S+ 
Dox 
Primary 
Liver 
cancer 
   1 PR, 1 
unconfirmed 
PR,  
61% SD 
  Richly et 
al,  Int J 
Clin 
Pharmacol 
Ther, 2004 
Phase I 
 
AML/MLD 
patients 
NR NR 
Biomarker- 
pERK in PBLs 
using PMA 
activation or 
SCF activation 
NR NR NR -No evidence of 
decrease in ERK 
activation  
Tong et al, 
Clinical 
cytometry  
Phase I, S + 
Carboplatin 
+Paclitaxel 
(Melanoma 
pts were 
analyzed for 
B-raf 
mutation) 
solid 
tumors 
S 100,200,400 
mg bid 
Paclitaxel 225 
mg/m2 day 1 
Carbolplatin, 
corresponding to 
area under the 
curve (AUC) of 6  
S, oral, days 2-
19 of 21 day 
cycle 
Paclitaxel and 
Carboplatin, i.v., 
day 1 
S, 400 mg bid 
Paclitaxel 225 
mg/2 
Carboplatin 
AUC equal to 
6 
(3% CR, 
23% PR) in 
pts of 
melanoma 
Hematologic, 
Rash:desquamation
, HFSR 
-Pts with melanoma 
respond favorably 
to this combination 
-Exposure to 
Paclitaxel was not 
altered by co-
administration of 
sorafenib 
Flaherty 
KT, CCR 
2009 
 
 
S: sorafenib, CR: complete response, PR: partial response, SD: stable disease, Gef: Gefitinib, Erl: erlotinib, ALT: Alanine amino transferase, Gem: 
Gemcitabine, Ket: Ketoconazole, Irc: Irinotecan, ANC: absolute neutrophil count, AGC: absolute granulocyte count, Dox: doxorubicin, DCE-US: 
dynamic contrast enhanced ultra sonography, Oxl: Oxaliplatin, AML: Acute myeloid leukemia, MLD: myelodysplastic syndrome, PBL: peripheral 
blood lymphocytes, PMA: phorbol myristate acetate, NR: Not reported, qd: Once-a-day, bid: Twice-a-day, i.v.: Intra-venous 
 
 
 
 
 
 
 
                Appendix 1-2 
 Phase II single agent or combination studies of sorafenib 
 
Type of 
clinical trial 
Patient 
population 
Sorafenib 
Dose (mg) 
Dosing schedule Response 
rate 
Toxicities Remarks Ref 
Phase II RDT 
Biomarker- 
B-raf, N-ras, 
K-ras status 
Advanced 
melanoma 
400 bid  a). 12 wk run-in 
phase,  
b). Assigned to S 
or placebo or 
withdrawn from 
study based on 
response 
19% SD 
62% PD 
19% 
unevaluable 
 
Overall 
median PFS 
11 wks 
Rash, 
desquamation, 
HFSR, diarrhea, 
fatigue 
No relation between 
b-rafV599E and 
disease stability 
No antitumor 
activity as a single 
agent 
Eisen T et 
al, 
BJCancer 
2006 
Phase II RDT RCC 400 bid a). 12 wk run-in 
phase,  
b). Assigned to S 
or placebo or 
withdrawn from 
study based on 
response 
Overall 
median PFS 
29 wks, 
50% SD 
 
Rash, 
desquamation, 
HFSR, pain, 
diarrhea, 
hypertension 
 S has antitumor 
activity against RCC
Ratain et 
al, JCO, 
2006 
Phase II 
Biomarker-
pERK levels 
in PreRx 
biopsies & 
blood cell 
RNA 
expression 
Patients with 
inoperable 
HCC 
400 bid 4 week continuous 
cycles 
Overall 
median 
survival 9.2 
months, 
34% SD, 8% 
PR or MR 
Fatigue, diarrhea, 
HFSR 
Modest efficacy as 
single agent 
PreRx pERK levels 
correlated with 
TTP. 
Identified panel of 
18 genes whose 
expression 
distinguished 
progressors from 
non-progressors  
Abou-alfa 
et al, 
JCO, 2006 
Phase II 
Biomarkers 
Pts with 
recurrent or 
400 bid 4 week continuous 
cycles 
Halted after 
1st stage. 
Fatigue, 
lymphopenia, HFS, 
Modest anticancer 
efficacy. 
Elser et al, 
JCO, 2007 
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 pERK-Signal 
transduction; 
Ki67-
proliferation; 
Mcl-1-
apoptosis; 
CD31 & SMA 
–angiogenesis 
metastatic 
squamous cell 
carcinoma of 
the head and 
neck or 
nasopharyngeal 
carcinoma 
1 PR (total 
21 pts) 
Overall 
median 
survival 4.2 
months 
hypertenision, 
anemia, mucositis 
Phase II  Japanese RCC 
pts, received 
nephrectomy 
and failed at 
least one 
cytokine 
therapy 
400 bid  Continuous dosing 
schedule 
12.4% PR, 
72% SD, 
Disease 
control rate 
73.6% 
Median PFS 
224 days  
HFSR, 
hypertension, 
elevated lipase, 
increased amylase, 
diarrhea, 
rash/desquamation 
S has antitumor 
efficacy 
Akaza et 
al, Jpn J 
Clin Oncol 
2007 
Phase II, S+ 
IFNα-2b 
VHL gene 
mutation 
analysis 
Advanced RCC S 400 bid + 
INFα-2b 10 
MU on 3 
nonconsecutive 
days weekly 
28 days cycles  19% PR, 
50% SD,  
Median PFS 
7 months  
OS 17 
months 
Fatigue, rigors, 
chills, fever 
leukopenia, 
hypertension, 
diarrhea 
RR is greater than 
expected with either 
S or INF alone. 
VHL mutations may 
be associated with 
longer PFS among 
patients receiving 
VEGF targeted 
therapy 
 
Ryan et al, 
JCO 2007 
Phase II, S+ 
IFNα-2b 
 
Metastatic 
RCC 
S 400 bid + 
INFα-2b 10 
MU on 3 
nonconsecutive 
days weekly 
8 wks cycle, 
followed by 2 
cycle break 
5%CR, 28% 
PR, 45% SD 
Median PFS 
10 months 
Fatigue, anorexia, 
anemia, diarrhea, 
rash, nausea, 
hypophophatemia, 
HFSR 
Combination has 
substantial activity 
in treatment naive 
and IL-2 treated 
patients with RCC 
Gollob et 
al, JCO, 
2007 
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 Phase II, 
S+Gem or 
S+Erl 
Advanced 
NSCLS in 
elderly pts or 
pts with 
performance 
status 2 
Gem 1200 
mg/m2 + S 800 
mg/m2 OR Erl 
150 mg/m2 + S 
800 mg/m2 
Gem days 1 & 8 
every 3 wks for 
max 6 cycles.  
S and Erl daily 
Currently 
ongoing 
  Gridelli et 
al, Clinical 
lung 
cancer, 
2007 
Phase II, S Pts with 
progressive 
hormone-
refractory 
prostate cancer 
S 400 mg bid Continuously 27% SD by 
PSA and 
RECIST 
criteria. 
Median PFS 
8 weeks  
Fatigue, Pain, 
Skin, Diarrhea, 
Hypertension 
S has activity in 
HRPCP when 
evaluated for 
RECIST and PSA 
based response 
Steinbild S 
et al, Br J 
Can, 2007 
Phase II, S Metastatic 
castrate 
resistant 
prostate cancer  
S 400 mg bid   28 days 
continuous cycle 
4% PR, 42% 
SD 
Median PFS 
3.7 months, 
Median OS 
18 months  
HFSR, Rash, liver 
function 
abnormalities, 
fatigue 
S has moderate 
activity as second 
line treatment for 
mCRPC 
Aragon-
Ching JB 
et al, BJUI, 
2008 
Phase II, S + 
Dacarbazine 
Advanced 
melanoma 
S 400 mg bid  21 days 
continuous cycle 
24% PR, 
47% SD, 
29% PD 
Median PFS 
21.1 weeks, 
Median OS 
51.3 weeks 
Hematologic side 
effects, 
hypertension, 
nausea, fatigue  
S was well tolerated, 
had encouraging 
improvement in PFS 
but not in OS 
McDermott 
DF et al, 
JCO, 2008 
Phase II, S Advanced 
thyroid cancer 
S 400 mg bid 28 days 
continuous cycle 
23% PR, 
53% SD 
Median PFS 
79 weeks 
Rash, HFSR, 
fatigue, weight 
loss, diarrhea, 
nausea 
S has clinical 
activity in pts with 
metastatic, iodine-
refractory thyroid 
carcinoma  
Gupta-
Abramson 
V et al, 
JCO, 2008 
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 Phase II, S Chemo-naïve 
castration-
resistant 
prostate cancer 
S 400 mg bid Continuous cycles Median PFS 
2.3 months 
HFSR, Increased 
AST, Fatigue, 
Lymphopenia, 
Anemia 
S has limited 
activity. Limitations 
of using PSA as an 
indicator of 
progression and 
response 
Chi KN et 
al, Annals 
of 
Oncology, 
2008 
Phase II, S 
 
 
 
 
Metastatic 
breast cancer, 
had received 
prior treatment 
S 400 mg bid   28 days 
continuous cycle 
No CR or 
PR 
No grade 4 and 
few grade 3 
toxicities. Fatigue, 
anorexia, diarrhea, 
nausea, skin 
reaction etc. 
Trial was stopped 
after first stage 
because of lack of 
efficacy 
Moreno-
Aspitia S et 
al, JCO 
2009 
Phase II, S or 
INF-α-2a 
untreated 
advanced renal 
cancer 
S 400 mg bid  
or 9 million U 
INF-α-2a, s.c.  
S continuously, 
INF-α-2a 3 times 
5% PR, 74% 
SD, 10% PD 
Median PFS 
5.3 months 
Fatigue, Diarrhea, 
Pain, Alopecia, 
HFSR, 
Rash:desquamation
S resulted in better 
tumor size 
reduction, better 
QOL, and better 
tolerability 
Escudier B 
et al, JCO, 
2009 
Phase II, S Metastatic 
thyroid cancer 
S 400 mg bid   21 days 
continuous cycle 
15% PR, 
56% SD 
Median PFS 
15 months 
Hand-foot skin 
reaction, 
musculoskeletal 
pain, fatigue 
S is reasonably well 
tolerated and has 
biological activity in 
metastatic PTC 
Kloos RT 
et al, JCO 
2009 
Phase II, S Advanced 
HCC in a 
Hepatitis B-
endemic Asian 
population 
S 400 mg bid  28 days 
continuous cycle 
8% PR, 18% 
SD. Median 
OS 5 months 
Diarrhea, malaise, 
HFSR 
S demonstrated 
good efficacy and 
acceptable 
tolerability 
Yau T et 
al, Cancer, 
2009 
S : Sorafenib, HFSR: Hand-foot skin reaction, Gem: Gemcitabine, Erl: Erlotinib, RCC: Renal cell carcinoma, HCC: Hepato-cellular 
carcinoma, mCRPC: metastatic castrate resistant prostate cancer, PTC: Papillary thyroide cancer, SD: Stable disease, PR: Partial 
response, CR: Complete response, PD: Progressive disease, PFS: Progression free survival, OS: Overall survival. 
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               Appendix 1-3 
Phase III trials for sorafenib as a single agent or in combination with chemotherapy 
 
Type of clinical 
trial 
Patient population Sorafenib 
Dose (mg) 
Dosing 
schedule 
Response rate AE Remarks Ref 
Phase III placebo 
controlled 
TARGET trial 
Advanced clear-cell 
RCC 
400 bid  Continuous Median PFS 5.5 
months, PR 10% 
pts 
Diarrhea, 
rash, fatigue, 
HFSR, 
hypertension 
S prolongs PFS Escudier et 
al, NEJM, 
2007 
Phase III placebo 
controlled 
SHARP trial 
Unresectable HCC 400 bid Continuous PR 2% 
Median overall 
survival 10.7 
months 
Median 
(radiologic) PFS 
5.5 months 
Hypertension, 
Fatigue, 
HFSR, rash/ 
desquamation 
S improved overall 
survival by 44 % in 
HCC patients 
S levels are low in 
patients with 
hepatic 
impairment 
compared to 
clinical trials for 
other indications 
Llovet JM et 
al, NEJM, 
2008  
Phase III 
randomized 
double blind 
placebo controlled 
trial 
Advanced HCC 
patients from Asia – 
Pacific region 
400 bid Continuous 
in 6 weeks 
cycles 
PR 3.3%, SD 54% 
Median overall 
survival 6.5 
months 
Median PFS 2.8 
months 
HFSR, 
Diarrhea, 
Fatigue, 
Rash :desqua
mation, 
Hypertension 
S is effective for 
treatment of 
advanced HCC, and 
it is well tolerated. 
Cheng AL, 
Lancet Oncol 
2009 
Phase III  
S+/-(Carboplatin+ 
Paclitaxel) 
Melanoma S, 400 bid 
Paclitaxel 225 
mg/m2 
Carboplatin 
dose equal to 
area under the 
curve of 6 
S, days 2-19 
Paclitaxel 
and 
Carboplatin 
on day 1 
Response rate 
12% S vs. 11% 
Placebo 
PFS, 17.4 weeks 
S vs. 17.9 weeks 
placebo 
 
Dermatologic
al events, 
thrombocytop
enia, 
diarrhea, 
fatigue 
S can not be 
recommended in the 
second-line setting 
for pts with 
advanced melanoma 
Hauschild A, 
JCO, 2009 
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 Phase III  
S+/-(Carboplatin+ 
Paclitaxel) 
NSCLC 400 bid Trial 
ongoing 
    
 
Phase III 
S+Cisplatin+ 
Gemcitabine 
NSCLC       
S : Sorafenib, HFSR: Hand-foot skin reaction, RCC: Renal cell carcinoma, HCC: Hepato-cellular carcinoma,NSCLC: Non small cell 
lung cancer, SD: Stable disease, PR: Partial response, CR: Complete response, PD: Progressive disease, PFS: Progression free 
survival, OS: Overall survival. 
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               Appendix 1-4 
Drug interaction studies with sorafenib 
Study Interacting drug Patient 
population 
Findings Conclusion 
Lathia C et al, 
Cancer Chemo 
Pharmaco 
(2005) 
 
Ketoconazole 
 
Healthy 
volunteers 
No increase in exposure of 
sorafenib 
 
Safe to co-administer with 
CYP3A4 inhibitors/substrates 
 
Kupsch P et al, 
Clin Colorectal 
Cancer (2005) 
 
Oxaliplatin 
 
Advanced solid 
tumors 
No detectable drug interaction Safe to administer in 
combination 
Richly et al, Int 
J Clin 
Pharmacol Ther 
(2004) 
Doxorubicin 
 
Primary hepatic 
cancer 
21% increase in AUC of 
doxorubicin. 
No apparent increase in toxicity. 
No apparent increase in the 
toxicity of these agents 
Richly et al, 
Annals of 
Oncology 
(2006) 
Doxorubicin Refractory solid 
tumors 
AUC0-8 and Cmax of sorafenib 
partly increased. 
Sorafenib may increase the levels 
of doxorubicin 
Sorafenib may reverse the 
resistance to sorafenib 
Mross K et al, 
Int J Clin 
Pharmacol Ther 
(2003) 
Irinotecan  (CPT-11) 
Solid tumors 
67-120 % increase in AUC of SN-
38; 26-42 % increase in AUC of 
irinotecan 
Caution recommended. No 
apparent increase in the toxicity 
of these agents 
Siu et al, CCR, 
2006 
Gemcitabine Refractory solid 
tumor; extended 
cohort of 
advanced 
pancreatic cancer 
No clinically relevant PK 
interaction 
Slightly decreased, but not 
significant gemcitabine exposure 
observed in pancreatic extension 
Sorafenib may reverse the 
resistance to gemcitabine 
Falherty et al, J Carboplatin/Paclitaxel Metastatic No change in PK values of Combination well tolerated, 
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 Clin Oncol 22: 
7507 (Abstract) 
melanoma paclitaxel, 6-OH paclitaxel, total 
or free platinum 
without any unexpected adverse 
events and PK interaction. 
Sorafenib 
prescribing 
information, 
revised 11/2007 
Docetaxel 
Sorafenib administration after 3 
day break around Docetaxel 
dosing 
 36-80 % increase in Docetaxel 
AUC; 16-32 % increase in 
Docetaxel Cmax 
Caution recommended. 
Figer et al, Ann 
Oncol 15:iii87 
(Abstract 327) 
Fluorouracil  Both increase (21-47 %) and 
decrease (10 %) in AUC of 
fluorouracil was observed 
Caution recommended upon 
sorafenib co-administration with 
fluorouracil or leucovorin 
Sorafenib 
prescribing 
information, 
revised 11/2007 
Rifampicin & other CYP3A4 
inducers 
 37 % reduction in sorafenib AUC 
with rifampicin 
Other CYP3A4 inducers (e.g., 
St. John’s wort, phenytoin, 
carbamazepine, phenobarbital 
and dexamethasone) might 
increase sorafenib metabolism 
In-vitro     
Sorafenib 
prescribing 
information, 
revised 11/2007 
CYP2B6 & CYP2C8 substrate  In-vitro Ki values are 6 and 1-2 
μM respectively. 
Systemic exposure of CYP2B6 
and CYP2C8 substrates is 
expected to increase upon co-
administration with sorafenib 
Sorafenib 
prescribing 
information, 
revised 11/2007 
In-vitro studies indicate sorafenib 
is a competitive inhibitor of 
CYP2C19 (Ki=17 μM), CYP2D6 
(Ki=22μM) and CYP3A4 (Ki= 29 
μM) 
 Concomitant administration of 
sorafenib didn’t alter the exposure 
of midazolam (CYP3A4 
substrate), dextromethorphan 
(CYP2D6 substrate) and 
omeprazole (CYP2C19 substrate) 
Unlikely to have in-vivo 
interaction with substrates of 
these enzymes 
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               Appendix 4-1  
Details of population pharmacokinetic model presented at ASCPT-2009 annual meeting 
 
      Table A Number of patients and sample collection time 
 
Cancer  No. of patients 
Type 
Phase  Course 
SD SS 
Sample collection time (hr) 
mCRPC Phase II C1D1 46 - 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12 & 24  
C1D1 &  NSCLC Phase II 
C1D15 
17 16 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12 & 24  
C1D1 &  ST Phase I 
C2D1 
28 12 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12 & 24  
CR Phase II C1D1 15 - 0, 1,  2, 4, 8, 12, 16 & 24  
KS Phase I C1D7 - 8 0, 1,  2, 4, 8, 12, 16 & 24   
SD: Single Dose; SS: Steady-state; mCRPC: metastatic castrate-resistant prostate cancer; NSCLC: Non-small cell lung cancer; ST: 
refractory solid tumors; CR: Colorectal cancer; KS: Kaposi’s sarcoma 
 
 
 
 
  
Table B Patient baseline characteristics 
Characteristic Value 
Number of patients 109 
Demographics Median (Range) or n(%) 
Age, years   63.9 (30-85) 
BSA, m2 1.9 (1.2-2.5) 
Weight, kg 81.3 (35-133) 
Gender (F/M) 33 (30%) / 76 (70%) 
Race (Caucasian/African-
American/Hispanic/Asian) 
89 (81%) / 13(12%) / 2(2%) / 5(5%) 
Clinical Median (Range) 
Albumin, g/dL 3.6 (2.2-4.4) 
Total protein, g/dL 6.6 (4.6-8.0) 
Alakaline phosphatase, U/L 81 (34-414) 
Bilirubin total, mg/dL 0.6 (0.1-1.7) 
SGOT, U/L 26 (13-90) 
SGPT, U/L 21 (8-75) 
Creatinine clearance, mL/min 96.5 (26-150) 
Genetic               (wt/het/var) – n(%) 
CYP3A4*1B 67(86%) / 5(6.4%) / 6(7.6%) 
CYP3A5*3C 7(8%) / 15(16%) / 69(76%) 
UGT1A9*3 87(97%) / 2(2%) / 1(1%) 
UGT1A9*5 89(100%) / 0(0%) / 0(0%) 
VEGFR2 Val297Ile 61(70%) / 24(28%) / 2(2%) 
VEGFR2 Gln472His 60(69%) / 24(28%) / 3 (3%) 
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Final Model: 
  CL/Fi = θCL/F . exp(ηCL/Fi) 
  V/Fi = θv . (weight/70) . exp(ηV/Fi)  
  Kai = θKa . exp(ηKai) 
  TK0i = θTK0 . exp(ηTK0i) 
  ALAG1i = (θALAG1+ Ethnicity*θALAG1~African-American) . exp(ηALAG1i) 
  Method = HYBRID, ZERO = (2,3,5) 
  θ: Population estimates or fixed effect parameters 
  η: Random inter-individual variability 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Covariate Model:  
• First, Body weight was identified as covariate for apparent volume of distribution (V/F).  
• Second, Ethnicity was included as covariate for tlag. African American subjects had relatively higher ALAG1 as compared to 
other subjects [which included Caucasians, Asians and Hispanics]. 
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 Table C Parameter estimates from the earlier developed population 
pharmacokinetic model  
 
Parameter Population mean %RSE 95%CI 
Population estimates (typical values) 
θCL/F, L/h 4.74 11.6 [3.7, 5.8] 
θV/F, L 156 9.8 [126, 186] 
θKa, 1/h 1.04 17 [0.7, 1.4] 
θTK0, h 1.92 16.5 [1.3, 2.5] 
θALAG1, h 0.196 11.5 [0.15, 0.24] 
θ ALAG1~African American 0.696 5.9 [0.62, 0.78] 
Between subject variability 
CL/F (%CV) 45% 27.9 [34%, 56%] 
V/F (%CV) 80% 20.9 [54%, 106%] 
ka (%CV) 136% 35.6 [7%, 266%] 
TK0 (%CV) 30% 39.4 [23%, 37%] 
tlag (%CV) 145% 55.9 [-88%, 378%] 
Residual error 
Additive (ng/mL) 68.3 44 [-3989, 4125] 
Proportional (%CV) 48% 12 [42%, 53%] 
 
Diagnostic plots 
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Conclusions 
• A population pharmacokinetic model for sorafenib in a diverse oncology 
population was developed successfully. 
• The sequential zero- and first-order absorption adequately described the 
sorafenib’s GI solubility-limited absorption, as reported in published phase I dose 
escalation studies. 
• Body weight and ethnicity were found to be statistically significant covariates for 
volume of distribution and absorption lag time; however, their contribution to 
BSV was minor.  Their ultimate clinical importance needs to be further evaluated 
by simulations. 
• The causes of the apparent ethnicity-related differences in absorption lag time are 
unclear but differences in expression of influx/efflux transporters (e.g., P-gp, 
sorafenib is a weak substrate of P-gp) between ethnic groups may be one of the 
reasons. 
• The genetic variation in selected metabolic enzymes did not explain the 
variability in sorafenib disposition, in studied population. 
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